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Abstract 
 
Classification of tumours such as gliomas, which are on a continuous spectrum of histology and 
malignancy into distinct categories is still a challenge using histopathology. There has been 
significant advances in the techniques used to fight cancer in the past two decades. A number 
of studies have looked at different approaches to improve the accuracy in diagnosis using 
histopathology. This study evaluated a number of techniques to compliment histopathology. 
One study looked at vibrational spectroscopy, Raman and attenuated total reflection-fourier 
transform infrared (ATR-FTIR) looking at brain tumour cell lines. This study investigated the 
potential application of vibrational spectroscopy in the segregation of different types of brain 
tumours using two tumour cell lines, U87MG, 1321N1 and a control, SVGP12. Another study 
looked at two approaches, elemental profiling of both tissue and serum using inductively 
coupled plasma-mass spectrometry. Trace elements increase or deficiency has been linked to 
cancer development and progression. The final study looked at the diagnostic application of 
Raman spectroscopy to distinguish between gliomas, meningiomas, medulloblastoma and 
several other brain tumours from histological normal brain tissue from brain tumour patients 
used as controls.  The three cell lines U87MG, SVGP12 and 1321N1 were cultured and grown on 
calcium fluoride slides in triplicates. Spectra from each cell line was taken using both Raman and 
ATR-FTIR. The spectra was then analysed using multivariate statistics. In the elemental profiling 
study serum and tissue samples from 55 patients with brain tumours were collected and 
analysed using ICP-MS. The elemental data was then evaluated using multivariate statistics to 
investigate significant differences. In the analysis of human brain tumours tissue blocks of both 
tumour and histological normal brain that were formalin fixed and paraffin embedded (FFPE) 
were processed and mounted on low-E slides, dewaxed using Xylene, washed with alcohol and 
water before storage at room temperature until analysis. Raman and ATR-FTIR were able to 
separate U87MG, SVGP12 and 1321N1 with very high classification accuracy. All the brain 
tumour groups investigated showed a deficiency of Mg, Fe, Cu, and Zn concentrations against 
reported levels from healthy individuals in the literature. Raman spectroscopy coupled with 
multivariate statistics was able to distinguish between normal brain tissue and normal brain 
tumour tissue used as controls. Classification of gliomas based on the degree of malignancy was 
also apparent with very high classification accuracy. Spectral panels were developed that can be 
used as biomarkers in the diagnosis of brain tumours. Raman and Infrared spectroscopy are 
types of vibrational spectroscopy which have the potential to be used as diagnostic tools in 
neuropathology. They provide an intrinsic molecular fingerprint of the sample based on the 
interaction of light. The panels can accurately identify and classify specific brain tumours 
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alleviating the need to use complex statistical models. Raman and ATR-FTIR were able to 
elucidate chemical information from the samples which was used to differentiate the three cell 
lines with very high classification accuracy. Diagnosis of a brain tumour is not always a straight 
forward process and the current techniques used lack the desired level of precision in diagnosis 
and cytoreductive surgery.  
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Chapter 1 
1  Introduction 
1.1 Cancer 
Cancer is one of the widely researched disease of modern times and is often misunderstood to 
be one disease. There are more than 100 different types of cancer [1]. Whilst cancer is a common 
disease which has been shown to affect one person in three, it is true that four out of the five 
die from other ailments. Cancer is generally more common in old age, with the five most 
common cancers1 in males and females varying considerably by age group (Figure 1) [2].  
However diseases of the heart and blood vessels are still the leading cause of death in the ageing 
population [3].  
 
Figure 1. Plot showing five most common cancers with average number of new cases per year and age specific 
incidence rates in the UK, 2009-2011 [2]).  
Cancer is a genetic disease caused by the accumulation of mutations in the genome of somatic 
cells [4]. The disorder in the cells caused by the mutations usually results in a loss of control over 
cell division [4]. The result is a swelling made up of a mass of cells commonly known as tumours. 
Whilst cancer can develop in any of the body’s tissue, each type of cancer has its own unique 
features [1]. A century and a half ago Johannes Muller made an important discovery that cancers 
                                                          
1 breast, prostate, lung, bowel and malignant melanoma 
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are made up of cells. This discovery was followed by an important breakthrough in 1914 by 
Theodor Boveri in his famous book Zur Frage der Enstehung maligner Tumoren2 that 
chromosome abnormalities were the cellular changes causing the transition from normal to 
malignant.  The basic processes that produce cancer are very similar in all forms of the disease. 
Significant advances have now been made in what we know about the disease owing to 
technological advances and the sequencing of the human genome. An understanding of the 
makeup and function of normal cells and tissue has given a lot of insight into tumour 
angiogenesis and progression. Cancer develops when a normal cell breaks free of the restraints 
on cell division and begins to proliferate uncontrollably (Figure 2).  
 
Figure 2. Schematic showing different stages of cancer development. A. Single cell’s DNA becomes altered due to 
mutation. The exact number of mutation is not yet known. B. The altered cell and its progeny grow and divide rapidly 
resulting in a condition called hyperplasia. At some point one of these cells experiences some more mutations causing 
it to further divide. C. The cells progeny divide excessively and start to look different in shape and size, a condition 
called dysplasia. After a while another cell experiences other mutation(s). D. The cell and its progeny are very different 
and very abnormal in both growth and appearance. If the tumour formed through these cells is still contained within 
its tissue of origin, it’s called carcinoma in situ. Tumours that are in situ may remain contained in their tissue of origin 
indefinitely. E. If the cells experience additional mutations that allow the tumour to invade neighbouring tissues and 
shed cells into the blood or lymphatic system, the tumour is said to be malignant. These cells may cause new tumours 
in other sites of the body, a condition called metastases or secondary tumours [1] ). 
Cancers can spread throughout the body by two mechanisms namely invasion and metastases. 
Invasion is the direct migration of cancer cells to neighbouring tissue, whilst metastases involves 
the penetration into the blood and/or lymphatic system and invasion of normal tissue elsewhere 
in the body. The term cancer refers to malignant tumours which are capable of spreading by 
invasion or metastases [1]. Our understanding of the mechanisms involved in cancer comes from 
a long line of experimental work and hypotheses shown in (Table 1), [1, 5]. 
                                                          
2 English translation of title: “On the question of the genesis of malignant tumours” 
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Table 1. Timeline diagram showing the development of theories and experiments forming the basis of our 
understanding of cancer development and aetiology [1]. 
 
The modern understanding is that cancer forms through multiple genetic changes over a period 
of time [3]. The accumulation of these genetic mutations enables precancerous cells to acquire 
some traits that allow the malignant growth of cancer cells. The normal processes that control 
the cell cycle, survival and DNA repair are altered during tumorigenesis. There are two classes 
of genes that play an important role in the formation of cancer, proto-oncogenes and tumour-
suppressor genes [1]. Proto-oncogenes in their normal state encourage cell division, whilst 
tumour- suppressor genes inhibit cell division and promote apoptosis. These two classes of 
genes regulate growth that normally ensures every tissue and organ in the body maintains a size 
and structure that meets the needs of the body [3]. Mutations in one copy of the tumour 
suppressor gene followed by part or complete loss of the other copy on the chromosome 
bearing the second version of the same gene has been shown to be the most common scenario 
for inactivation of both copies of a tumour suppressor gene.  Consistent regions of chromosomal 
loss in specific tumour types almost always suggests a tumour suppressor gene in that 
chromosomal region. These basic themes of oncogene activation and tumour suppressor gene 
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inactivation coupled with chromosomal homozygosity, underlie the current molecular 
understanding of human tumour formation [6, 7]. 
1.2 Brain Tumours 
Brain tumours are classified under tumours of the nervous system and in particular the central 
nervous system (CNS) which is made up of the brain and spinal cord. CNS tumours can be divided 
into two major groups [8]:  
 Intrinsic tumours, those arising from cells within the CNS or its coverings 
 Metastatic tumours, those which arise from a primary tumour outside the CNS, 
including locally invasive tumours.  
Metastatic tumours to the CNS commonly arise from carcinomas arising in the lung, breast, 
kidney, and malignant melanoma [9].  
Intrinsic tumours can be further divided into two subgroups: 
 Neuroepithelial tumours, arising from glial and neuronal cells or their precursors within 
brain and spinal cord  
 Non-neuroepithelial tumours, arising from cells within blood vessels, arachnoidal cells, 
cranial and spinal nerve sheath cells.  
Tumours of the nervous system are the second most common tumours in children and the sixth 
most common in adults [9]. Brain tumours can be very distressing for both carers and patients, 
affecting the brain with the onset of focal neurological signs, personality changes or raised 
intracranial pressure. The most common initial treatment given to patients with a brain tumour 
is surgical resection of the growth [10], depending on the position. Successful treatments are 
offered for certain types of tumours of the nervous system, however some of the most common 
brain tumours, such as glioblastoma, have a poor prognosis and treatment usually results in 
marginal success [9]. Improvements in imaging techniques such as computerised tomography 
(CT) and magnetic resonance imaging (MRI) has led to an increase in the demand for biopsy 
diagnosis of brain tumours [9]. Histopathology is the current gold standard for the diagnosis of 
brain tumour biopsies. The need for general awareness of the pathology of these tumours 
among pathologists, radiologists and clinicians has also increased owing to the high demand of 
histological assessments. Precise histopathological diagnosis of brain tumours has been shown 
to be subjective to some extent, whilst available diagnostic imaging techniques to delineate the 
excision border during cytoreductive surgery lack the required precision to support the surgeon 
[9, 11]. An understanding of the pathology of brain tumours plays a vital role in downstream 
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operations such as patient management, clinical and biological research. Although improved 
imaging techniques allow accurate localisation of intracranial lesions such as brain tumours, and 
often serve as good guide to the nature of the lesion, the final diagnosis of a brain tumour relies 
almost exclusively on histological evaluation of tissue taken at biopsy or autopsy.  
Histological and molecular genetic methods for the study of brain tumours have also improved 
over the years, with immunohistochemistry complementing the older tinctorial and silver stains 
technique for tissue diagnoses. However, the constant need for clinico-pathological and 
radiological correlation in the diagnosis of brain tumours remains [11]. The effective use of 
pathology in the management of patients with brain tumours requires accurate diagnostic 
criteria and an agreed classification. Universal practice is essential for accurate communication 
between pathologists and clinicians. Emerging ideas and concepts are beginning to take shape 
with the introduction of new techniques such as vibrational spectroscopy and spectrometry into 
neuropathology. Vibrational spectroscopy has the potential of becoming a bio-analytical tool in 
pathology and particularly in cancer because it can probe chemical composition and molecular 
structure of normal and neoplastic tissue [12]. Vibrational spectroscopic techniques, such as 
Raman and Infrared spectroscopy are capable of determining the fingerprint structures of 
several molecules, such as nucleic acids, proteins, lipids, carbohydrates and fatty acids. Spectral 
data from these molecules can then be processed using computational algorithms to identify 
differences between healthy and cancerous samples [12-14].   
1.2.1 Statistics of Mortality and Morbidity 
Primary brain tumours are an important cause of morbidity and mortality in both adults and 
children, representing the commonest cause of deaths from cancer in children under the age of 
15 years, females under 35 years and males under 45 years. Primary CNS tumours account for 
less than 2 % of all malignant tumours, representing the sixth commonest group in adults and 
the second in children [9].  
1.2.2 Histological Classification of Brain Tumours 
There are a number of grading systems shown in Appendix D, available to classify tumours 
affecting the CNS, however the grading system developed by the WHO is widely used which 
classifies tumours based on the cell of origin and how they behave, from the least aggressive, 
benign and most aggressive, malignant. Bailey and Cushing in 1926 formulated the accepted 
classification of brain tumours upon which subsequent methods were used for classification. 
Their classification was based on cytological and histological similarities of tumour cells in the 
adult or developing nervous system [9]. Kernohan and Sayre introduced a system of grading in 
1949 which was based mainly upon autopsy material and related histological features to clinical 
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prognosis. Their system was an attempt to rationalise the description of neuroepithelial 
tumours. The current WHO classification system (2007) is the fourth edition since the first in 
1979 by Zulch and an international team which saw revisions in 1990, and 2000.  
There was an update on the WHO grading scheme and the sections on genetic profiles [15]. The 
rhabdoid tumour predisposition syndrome was added to the list of familial tumour syndromes 
typically involving the nervous system. As in the previous, 2000 edition of the WHO ‘Blue Book’, 
the classification is accompanied by a concise commentary on clinico-pathological 
characteristics of each tumour type. The fourth edition classification is based on the consensus 
of an international Working Group of 25 pathologists and geneticists, as well as contributions 
from more than 70 international experts, and is presented as the standard for the definition of 
brain tumours to the clinical oncology and cancer research communities world-wide [15]. 
Pathological classification of primary brain tumours can be put into two groups, tumours of 
neuroepithelial tissue and non-neuroepithelial tissue as shown in Appendix A.  
Diffuse astrocytoma designated World Health Organisation (WHO grade II), Appendix D, 
tumours account for about 10-15 % of all astrocytic brain tumours, with 1.4 new cases per 
million per year.  The mean survival time after surgical intervention of an anaplastic astrocytoma 
(WHO grade III) is 6-8 years. However this tumour can progress into a glioblastoma (GBM) which 
will give it a different outcome. The mean age at biopsy is 41 years and males are affected more 
than females (M: F ratio, 1.8: 1). High grade (III and IV) brain tumours have poor prognosis and 
patient survival correlates with age and histological type [16]. In the US, 5 year survival rate for 
brain tumours for all ages was reported as 20 % with a 95 % confidence interval of 18-22 % in 
1999. These statistics have not shown any significant improvements [17]. Glioblastoma (GBM) 
patients have the poorest prognosis and survival. GBM is the most common malignant astrocytic 
tumour [6]. GBM can be both primary and secondary. The majority of GBMs are primary at 90 
% with a short clinical history and no evidence of a pre-existing lesion. Secondary GBMs arise 
from progression of a diffuse astrocytoma (WHO grade II) or an anaplastic astrocytoma (WHO 
grade III). These types of tumours are less frequent and are usually found in younger patients 
[6]. The peak incidence age of a GBM is between 45-75 years with a mean age of 63 years for 
both men and women.  
Oligodendroglioma (WHO grade II) appear more in adults with a peak incidence between 40 and 
45 years. Anaplastic Oligodendrogliomas (WHO grade III) have a peak incidence between 45-50 
years.  
Meningioma (WHO grade I) patients have good overall survival rates of 81 % at 2 years, and 69 
% at 5 years [18]. Peak incidence is between 60-70 years and possible recurrence within 20 years 
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[19]. Anaplastic meningioma (WHO grade III) is fatal with a median survival of less than 2 years 
[20, 21] and a 5 year survival rate of 54.6 % [22]. The prognosis is much worse for metastasis, 
with incidence increasing by age and survival of patients with multiple metastasis treated with 
radiotherapy is 3-6 months and those with solitary metastases may survive longer. In the UK, 
meningiomas make up 25 % of adult brain tumours with the vast majority of them grade I and 
treated with surgical resection alone [23, 24].  
Pilocytic astrocytoma (WHO grade I) belongs to astrocytic tumours, appears usually in the first 
two decades of life (20s). The tumour grows slowly with long term survival if completely resected 
[25]. Ependymoma (WHO grade II) affect all age groups, with a mean age of 6.4 years. Survival 
and prognosis depends on various factors such as age and extent resection, location and grade. 
Good prognosis has a survival of 50 % at 5 years. Choroid plexus papilloma (WHO grade I) 
tumours most appear in young adults younger than 20 years with equal incidence in males and 
females. Treatment is usually by surgery with a 5 year survival rate up to 100 %. 
Medulloblastoma (WHO grade IV) usually appears in children with a peak incidence of 7 years 
with 65 % being male. The 5 year survival rate is 60-70 % [9]. In the case of primary brain tumours 
progression free survival has been predicted by factors such as tumour location and extent of 
the resection [26].     
Metastatic brain tumours are the most frequently occurring type of tumour in adults with US 
incidence being approximately 200 000 cases per year. The majority of these type of tumours 
originate from primary cancers in lung (40-50 %) or breast (15-25 %), or from melanoma (5-20 
%) [27].   
1.3 Diagnostic Pathology of Brain Tumours 
The pathological classification of brain tumours plays a vital role in the management plan and 
treatment strategy of the disease. The pathologist defines the target which the rest of the clinical 
team focus on. Histological assessment of the tissue remains an invaluable tool in the diagnosis 
of brain tumours. The process involves cross discipline collaboration with both patient and 
clinical staff gathering as much information as possible. Slides with biopsies are interpreted in 
correlation with patient’s age and clinical presentation. Radiological findings complement the 
macroscopic description in other organs and assessment of the location (supratentorial, 
infratentorial, intra-ventricular), growth pattern (circumscribed versus infiltrative, solid versus 
cystic), enhancement pattern (non-enhancing versus enhancing), and the presence or absence 
of oedema, necrosis, calcification should be consolidated with the microscopic findings [28].  
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1.3.1 Clinical presentation of Brain Tumours 
Patients with either primary or metastatic brain tumours usually present with both generalised 
or focal signs and symptoms [29].  
Signs and Symptoms connected to Brain Tumours  
Brain tumour can present symptoms and signs by a number of ways such as local brain invasion, 
compression of adjacent structures, and increased intracranial pressure (ICP). The clinical 
manifestations apart from the histology of the tumour are determined by the function of the 
area of brain affected [30].  Headaches are common symptoms of brain tumours and present in 
about half the patients [30, 31]. Patients with bifrontal headaches report worsening of the 
condition after a change in body position, such as bending over, or manoeuvres that raise 
intrathoracic pressure, such as coughing, sneezing or the Valsalva manoeuvre which involves the 
moderate forceful exhalation against a closed airway  [32]. A generalised headache on the other 
hand can arise from increased intracranial pressure, which can arise either from a large mass or 
restriction of cerebrospinal fluid outflow causing hydrocephalus. This usually results in 
headache, nausea, and papilledema [33, 34].    
Seizures are the most common symptom of gliomas and cerebral metastases. Patients who are 
seizure free at diagnosis have been known to subsequently develop seizures [35]. Seizure 
incidence is higher in primary tumours than metastatic lesions, and among patients with primary 
tumours they are less common in high grade tumours [36]. Although seizures can be generalised 
or focal, any seizure focus can cause a generalised seizure. The clinical presentation of a focal 
seizure is dependent upon the tumour location. Frontal lobe tumours may cause focal tonic-
clonic movements involving one extremity, while seizures originating within the occipital lobe 
may cause visual disturbances [37, 38]. Temporal lobe seizures are the most difficult to diagnose 
and localise, and are associated with abrupt sudden behavioural changes occurring with or 
without typical preseizure auras, such as abnormal smell, taste, or gastrointestinal symptoms. 
Tumour related seizures are repetitive and stereotyped in a given patient, with the ictal event 
being preceded by an aura, which is itself a simple partial seizure, and followed by postictal 
sequelae. The postictal phase may appear as a period of fatigue and an urge to sleep.  
Nausea and vomiting in brain tumours are caused by increasing the ICP at the area postrema of 
the medulla. A number of characteristics suggest the possibility of tumour-associated emesis, 
such as triggering emesis by an abrupt change in body position. Neurogenic nausea and vomiting 
usually occur in the context of other neurologic deficit with subtle signs and symptoms. Syncope 
a condition which leads to temporary loss of consciousness in brain tumour patients can result 
from a temporary cut off of cerebral perfusion resulting from a significant rise in ICP. Brain 
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tumour patients are susceptible to syncope in association with normal plateau waves. Plateau 
waves are sustained pressure waves that normally occur within the brain and are caused by 
activities that transiently raise the ICP. Coughing, sneezing or other Valsalva manoeuvres that 
increase intrathoracic pressure can impede jugular venous drainage, leading to a transient 
increase in ICP [32, 39].  
Memory problems and mood or personality change is common among patients with brain 
tumours. Most of the neurocognitive deficit associated with brain tumours are subtle, with 
patients complaining of having low energy, fatigue, an urge to sleep and loss of interest in 
everyday activities. Muscle pain is another common complaint experienced by brain tumour 
patients. In upper motor neuron lesions, weakness is generally more pronounced in the flexor 
of the lower extremities than in the extensors, and more pronounced in the extensors than the 
flexors in the upper extremities [40, 41]. Cortical sensory deficit can develop in patients whose 
tumours invade the primary sensory cortex resulting in sensory loss. The sensory deficits usually 
do not respect a dermatomal or peripheral nerve distribution. The deficit varies with respect to 
tumour location. Some sensory deficit include loss of spatial orientation, tingling, and lack of 
coordination. Some brain tumour patients may experience aphasia which is a disorder of 
language function. It is a specific sign of a lesion in the dominant hemisphere usually left frontal 
or parietal. Non-dominant hemispheres may produce apraxia which refers to an inability to 
perform purposeful movements. Visual spatial dysfunction can result from having a brain 
tumour in the visual pathway courses through the brain from the retina and optic chiasm to the 
occipital poles of the cerebral cortex. Tumour related compression of the optic chiasm usually 
manifests as a bitemporal hemianopsia [42, 43].             
1.3.2 Imaging of Brain Tumours 
Adults presenting with signs and symptoms suggesting brain tumours generally go through 
differential diagnosis which may include both neoplastic and non-neoplastic conditions. 
Neoplastic conditions are those conditions which arise from abnormal growth of tissue such as 
a tumour. There have been significant developments in the number of techniques that are used 
to detect the location and physiological properties of brain tumours [9]. These techniques 
include, CT scans, MRI, positron emission tomography (PET) and the use of cerebral and spinal 
angiography for the localisation of arteriovenous malformations and other lesions of vascular 
tissue. Despite these advances none of the techniques allow the diagnosis of a tumour with 
absolute certainty. Biopsies still undergo diagnostic tests such as histopathology and molecular 
evaluations.  
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Computerised Tomography Scanning (CT) 
CT scans are visualised as horizontal or coronal sections of the skull, the brain and its surrounding 
structures or as horizontal sections of the spinal column. This information is based on 
computerised integration of tomographic X-ray data. The distortion of brain and spinal cord 
anatomy and variations in attenuation of the X-rays allows localisation of intracranial and 
intraspinal lesions to be pathologically assessed. Lesions appear less dense (black), astrocytoma 
or oedema around a GBM are hyperdense (white) in the case of fresh haemorrhage or 
calcification. Injections of iodine-containing contrast media are given intravenously, which do 
not cross the normal blood brain barrier (BBB), to locate areas or regions of BBB breakdown. 
These areas appear as white contrast enhancing regions such as those seen in GBM, metastatic 
carcinoma and meningiomas. Contrast enhancement occurs normally in the choroid plexus and 
in the pineal as these regions lack a BBB [9].     
Magnetic Resonance Imaging (MRI) 
MRI images are derived from magnetically induced changes in the orientation of water 
molecules [9] and offers a variety of modes and is used either alone or in various combinations 
with CT scanning to localise cerebral tumours and investigate their physiology. Gadolinium-
enhanced MRI is usually the only test needed to suggest a brain tumour [16, 44]. The use of T1-
and T2- weighted images, different characteristics of pathological lesions and normal structures 
can be depicted [9]. Malignant gliomas are typically hypointense on T1-weighted images, they 
enhance heterogeneously following contrast infusion. An enhancing tumour can be 
distinguished from the surrounding hypointense signal of oedema on T1 weighted sequences 
regardless of the histological grade. Astrocytomas generally show increased T2 and FLAIR signal 
intensity; however, some astrocytomas do not manifest contrast enhancement. Low grade 
gliomas generally present as an infiltrating hemispheric lesion that produce little mass effect 
[31].  
 
Positron Emission Tomography (PET) 
 
PET imaging technique uses intravenous injection of radioisotopes and detects their differential 
uptake by different regions of the brain. This technique is mainly used for stroke and dementia 
patients by measuring glucose uptake capacity in different regions of the brain. In brain tumours 
it has been used to investigate physiological function of brain tumour tissue and for differential 
diagnosis of recurring tumour versus radiation damage of tissue [9]. A combination of PET with 
fluorodeoxyglucose (FDG) is able to detect malignant tumours with high metabolic rates. These 
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types of lesions take up a greater amount of glucose than surrounding tissue or tumours with 
slower metabolic rates [44]. FDG-PET is an ideal tool to guide surgeons: 
 To localise the area of maximum glucose utilisation within the tumour during the extraction 
of a biopsy [45].  
 Mapping of functional areas of the brain prior surgery or radiation in conjunction with 
functional MRI minimises injury to eloquent areas [46].    
 Differentiate recurrent tumour from radiation necrosis [21] 
 Differentiate high grade (glucose hypermetabolising) from low-grade (glucose 
hypometabolising) brain tumours [47] 
1.3.3 Histological Diagnosis 
The histological classification and diagnosis of brain tumours is performed on sections cut from 
formalin-fixed paraffin-embedded (FFPE) tissue blocks.  A range of staining techniques and 
immunohistochemistry is carried out on the tissue sections. Haematoxylin and Eosin (H and E) 
is the routine stain of choice used in most laboratories and provides excellent nuclear and 
cytoplasmic details [48]. H and E staining can confirm a diagnosis on its own, however further 
investigations are routinely employed that include specific stains, immunohistochemistry and in 
some cases electron microscopy. The special stains are used to show a wide range of structures 
or cell products in brain tumours. A reticulin stain can show the abnormal vascular proliferation 
in GBM, or a periodic acid/Schiff (PAS) stain is useful for the demonstration of mucins in 
myxopapillary ependymoma [49].  
Immunohistochemical staining on tissue sections binds an antibody to a specific epitope in a 
protein of interest, allowing the visualisation of the antibody epitope complex in the tissue 
section. This processes allows the localisation of the protein in the tumour cells to be 
determined [9]. Stains also aide diagnosis in complex cases and some of them have become 
routine in most laboratories; 
 Glial fibrillary acidic protein (GFAP) is expressed in glial cells. Staining for GFAP is 
characteristically positive in astrocytic tumours, but can also be positive in most 
ependymomas and some oligodendrogliomas. The higher the grade of the glioma, the 
more variable the intensity of GFAP staining can become as shown in a GBM (Figure 3). 
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Figure 3. Image of immunohistochemistry analysis of GFAP showing staining in the cytoplasm of paraffin 
embedded human cerebellum tissue, (A) negative control compared to (B) GFAP positive (brown) [50].  
 Neurofilament protein (NFP) and synaptophysin (SYN) (Figure 4), are neuronal proteins 
that are detected by immunohistochemistry in neuronal and ganglion cell tumours and 
in pre-existing brain tissue (neuropil) that is invaded by a tumour. 
 
Figure 4. Image showing (A) NFP positive staining in about 10 % of tumours cells and some of the positive 
stains are in the form of a large cytoplasmic dot. Nuclear wrapping shown by arrows is also seen in the slide. 
Slide (B) shows SYN positive in most tumour cells [9]. 
   S-100 protein is present in Schwann cells (Figure 5), glial cells and melanocytes and is 
used to stain nerve sheath tumours such as Schwannomas and neurofibromas, 
ependymomas and melanomas. 
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Figure 5. Image of S100 beta Antibody showing staining in the cytoplasm and nucleus of paraffin embedded 
human melanoma (B) compared to a negative control without primary antibody (A) [9].  
 Cytokeratins are expressed in cells showing epithelial differentiation, and are found in 
metastatic carcinomas but not in gliomas. This test can help to establish site of origin in 
metastatic carcinomas in brain tumours where primary site is unknown. Metastatic 
carcinomas of the breast and lung express cytokeratin 7, but not cytokeratin 20, whilst 
metastatic carcinoma of the bowel expresses cytokeratin 20 and not 7.  
 Cell proliferation-associated protein are present in the nuclei of cells, (Figure 6). Tumour 
cells that have entered the proliferative phase of the cell cycle can have their nuclei 
stained with Ki67 antibody, which can allow a proliferative index to be calculated. This 
index is often expressed as a percentage of the total number of tumour cell nuclei [49]. 
High cell proliferation indices indicate high grade intrinsic tumours such as glioblastoma 
and in metastatic carcinoma.        
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Figure 6. Image of Ki-67 immunostaining of a brain tumour with a high proliferative rate. Ki-67 marker 
determines the growth fraction of a given cell population. The fraction of Ki-67 positive tumour cells (Ki-67 
labelling index) is often correlated with the clinical course of cancer [9].  
1.4 Vibrational Spectroscopy 
All matter contains molecules and these molecules have bonds that are continually vibrating. 
These bonds can vibrate with stretch motions or bend motions. Stretching can either be 
symmetric or asymmetric. A molecule with more than two atoms can experience a bending 
vibration [51]. Vibrational spectroscopy uses molecular vibrations to obtain information relating 
to the structure of different systems as large as animal and plant tissues or the molecular 
structure of inorganic samples in different states, solid, gases and liquid. It is concerned with 
how matter interacts with electromagnetic radiation. Spectroscopic methods can be classified 
according to how these techniques are used. The use of spectroscopy to identify a sample or 
measure chemicals is called spectrochemical analysis, and its use to measure a spectrum is 
known as spectrometry. Spectroscopic methods can also be grouped into two groups based on 
the type of analytes under investigation or the type of light they employ. In order to understand 
vibrational spectroscopy there is a need to first understand the concept of molecular vibrations. 
1.4.1 Molecular vibrations 
If we imagined atoms in a molecule as balls and their chemical bonds holding them together as 
springs with no mass, such ball and spring model can be represented as shown in (Figure 7). 
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Figure 7. Schematic of a ball and spring model for a diatomic molecule. The model shows two atoms m1 
and m2 being pulled apart with a spring from an equilibrium position. 
 We can assume that the masses of the two atoms are m1 and m2 respectively, and the restoring 
force F of the spring is proportional to the displacement x of the atoms from their equilibrium 
position. 
𝐹 = −𝑘𝑥(𝐻𝑜𝑜𝑘𝑒𝑠 𝐿𝑎𝑤) (1) 
Where k is the force constant of the spring in N m-1, which is a measure of the strength of the 
bond between the two atoms. The resulting motion is simple harmonic. Based on these 
assumptions the ball and spring model is a harmonic oscillator. The vibrational frequency V0, in 
Hz, of the harmonic oscillator in terms of classical mechanics is given by the equation; 
V0 = 
1
2𝜋
√
𝑘
𝑚
   (2)  
Where m is the reduced mass in Kg: 
𝑚 =
𝑚1𝑚2
𝑚1+𝑚2
   (3) 
The wavenumber unit Ṽ, is often used in vibrational spectroscopy and is expressed in cm-1. This 
is the number of waves in a length of one centimetre; the reciprocal wavelength is given by the 
following relationship; 
Ṽ =
1
𝜆
=
𝑣
𝑐
   (4) 
Where λ is the wavelength and c is the velocity of light in vacuum (2.997925 x 108 m s-1). 
Frequency and wavelength can be used to describe energy as a wave. The wavenumber unit has 
the advantage of being linear with energy. The force constant k and the reduced mass of the 
chemical bond m are the two molecular properties that determine the frequency at which a 
molecule will absorb infrared radiation. This means the vibrational frequency is higher when the 
force constant is higher. Conversely the heavier the vibrating masses the lower the frequency or 
wavenumber respectively. A vibrational state is reached when a molecule is exposed to a specific 
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frequency. A bond is promoted to an excited state through exposing it to radiation of the exact 
same frequency as the energy difference between ground and excited state. These frequencies 
all lie within the Infrared region of the electromagnetic region, which is a region of lower 
wavelength than visible light.  
Light can interact with matter through various ways which can occur when light is either released 
by or taken up by matter. The release of light by matter is known as emission. The emission of 
light occurs when matter such as an atom, ion or molecule goes from an excited state to a lower 
energy state [52]. An excited state in a chemical can also be created by other means such as the 
uptake of light as in what occurs in fluorescence or through the input of energy from a chemical 
reaction which occurs in chemiluminescence. When the excited state of this chemical relaxes to 
a lower energy state it must release its extra energy. One way this energy is released is by giving 
off a photon of light. The photon that is released will have the energy exactly equal to the 
difference in energy between the initial excited state of the chemical and its final lower energy 
state. A plot of intensity of light that is emitted by matter at various wavelengths, frequencies, 
or energies is known as an emission spectrum. The difference in energy of a chemical as it goes 
from an excited state to a lower energy state is often a unique value for that chemical. This is 
the basis in which the identity of a chemical or material can be investigated. The amount of 
released light will be directly related to the amount of chemical that emitted that light. The 
intensity of this light can be used to determine how much of this chemical is present in a sample 
if we compare this emission to that obtained with standard samples. 
A second way in which matter can interact with light is through absorption. Absorption can be 
defined as the transfer of energy from an electromagnetic field (light) to a chemical entity such 
as an atom, ion or molecule. The difference between emission and absorption is that we start 
with a chemical species that is in a low energy state and move this species to a higher energy 
state by having the chemical absorb a photon of light. This process again requires that the 
photon have an energy that is exactly or equal to the difference in energy of the chemical in its 
original low energy state and its final excited state. The result of the absorption of light is that 
the intensity of this light will be lower than the original value of the energy or wavelength that 
was absorbed by the sample. The remaining light that passes through the sample is said to have 
undergone transmission, which is defined as the passage of electromagnetic radiation through 
matter with no change in energy taking place. The amount of light transmitted by a sample and 
that absorbed by the same sample should be equal to the total amount of light that entered the 
sample. A plot of the intensity of light that is absorbed or transmitted by a sample at various 
wavelength, frequencies or energies is called an absorption spectrum [53]. 
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There are other interactions in which light can have with matter, which include reflection, the 
process that occurs when light encounters a boundary between two regions that have different 
refractive indices where at least part of the light changes its direction of travel and returns to 
the medium in which it was originally travelling. Diffraction which is a process that refers to the 
spreading of a wave such as light around an object. Refraction is when light can be affected by 
matter when it changes direction of travel as it passes through a boundary between two media 
having different refractive indices. Another way is scattering which results in a change of travel 
by one particle such as a photon due to its collision with another particle such as an atom, ion 
or molecule. 
Raman and infrared (IR) spectroscopy are excellent methods for the analysis of biological 
materials. These techniques are non-destructive, quick, cost effective and easy to carry out. The 
human body in the simplest form is composed of water, proteins, nucleic acids, lipids and 
carbohydrates, and any changes in the body leading to diseases such as cancer are known to 
result in biochemical changes in one or more these components [31]. These biochemical changes 
can be investigated using vibrational spectroscopy and used to draw information which can be 
vital in the diagnosis, treatment and management of diseases.  
1.4.2 Raman Spectroscopy 
The interaction of monochromatic light with a sample results in the scattering of light at the 
same wavelength as that of the incident light in a process known as Rayleigh scattering (Figure 
8). A small proportion of the incoming light, approximately one photon out of a million is 
scattered at a wavelength that is shifted from the original wavelength, known as Anti-Stokes 
Raman scattering. A more detailed explanation of the Raman Effect can be explained by the 
classic theory of electrodynamics shown in (Appendix H).  
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Figure 8. Schematic diagram showing the Raman Effect when a light source such as a laser interacts with a sample 
resulting in different types of light scattering, Rayleigh, Stokes Raman and Anti-Stokes Raman. 
Several Raman spectroscopic studies have been carried out to investigate different types of 
biological specimens to determine differences between normal and disease state. Lorincz et al. 
[54] looked at the ability of Raman spectroscopy to detect changes which take place during the 
transformation of normal tissue to neoplastic tissue. Their study investigated normal kidney, 
lung, and liver samples from pigs, and rats. They also analysed a human neuroblastoma and 
hepatoblastoma in vitro. The Raman spectra of the animal samples of kidney, liver, and lung 
were significantly different in the intensity distribution of the Raman peaks. The spectra from 
pigs and rat specimens, although similar were different enough to distinguish between the two 
animals. The human specimens from normal liver, viable tumour and fibrotic hepatoblastoma 
were very different. The fibrotic tissue had increased proteins and nucleic acids. A study by 
Rabah et al. [55] looked at the diagnosis of neuroblastoma and ganglioneuroma in children using 
Raman spectroscopy.  Their study looked at fresh tissue samples from normal adrenal glands, 
neuroblastomas, ganglioneuromas, nerve sheath tumours, and pheochromocytoma. At least 12 
spectra were collected from different regions of each specimen, processed for noise reduction, 
fluorescence, and analysed using principal component analysis (PCA) and discriminant function 
analysis (DFA). Raman spectroscopy was able to differentiate between normal adrenal gland, 
neuroblastoma, and ganglioneuroma with 100% sensitivity and 100% specificity. The study 
reported differentiating neuroblastoma from nerve sheath tumours and pheochromocytoma 
with 94% sensitivity and 92% specificity. Devpura et al. diagnosed head and neck squamous 
carcinomas using Raman spectroscopy [56]. Their study investigated 17 different paraffin 
embedded tissue blocks from eight patients where 7 were normal, 4 with carcinoma in situ, and 
6 invasive squamous cell carcinoma (SCC). Some of the tissue was obtained from different parts 
of the tongue from the same patient. The Raman spectra were pre-processed for noise reduction 
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using adaptive minmax/wavelets method and then normalised with respect to the peak with the 
highest Raman intensity in the spectrum. Spectral differences of various groups present in the 
data were investigated using PCA and DFA. Their study reported increases in Raman bands 
assigned to tryptophan, protein keratin and decreases when tissue changes from normal to 
carcinoma in situ and then invasive SCC. The results suggested that tryptophan and keratin play 
an important role in SCC of the tongue. Professor Martin’s group in Lancaster investigated the 
diagnostic segregation of human brain tumours using fourier-transform infrared and Raman 
spectroscopy [11]. The study looked at 52 formalin fixed paraffin embedded (FFPE) tissue blocks 
which included, 7 normal brain, 15 meningiomas, 15 gliomas, and 15 metastatic brain tumours. 
The gliomas were further subdivided into three pathological subtypes with each category having 
five tissue blocks, low grade astrocytoma (LA), anaplastic astrocytoma (AA), and glioblastoma 
multiforme (GBM). Parallel tissue sections were stained with H&E followed by confirmation of 
histology for all specimens by a neuropathologist. Additional glioma tissue sections went 
through Immunohistochemical staining with IDH1 or p53. Raman spectroscopy was performed 
and a total of 2600 spectra obtained from independent locations with 50 spectra acquired from 
each sample. Subtraction of background fluorescence was done using a 5th order polynomial fit, 
de-noised and vector normalised. Residual paraffin peaks from the wax were excluded from LDA 
and PCA-LDA computational analysis. Their study reported an overlap of IR spectra for normal 
brain and brain tumours in the fingerprint region making it difficult to distinguish subtle but 
significant changes in the tissue. The application of multivariate analysis of IR and Raman spectra 
allowed the identification of diagnostic spectral patterns which enabled the classification of the 
specimens. The study was able to distinguish between normal brain and tumour tissue as well 
as between various subtypes.  
1.4.3 Infrared Spectroscopy 
The vibrational states probed by Raman spectroscopy are similar to those involved in infrared 
spectroscopy. However these two vibrational spectroscopic techniques are complimentary in 
that vibrations that are strong in an infrared spectrum (those involving strong dipole moments) 
are typically weak in a Raman spectrum.  
When infrared radiation of successive frequencies or wavelength is incident on a molecule, some 
of the radiation frequencies correspond to characteristic frequencies of the molecule and under 
such natural resonant conditions energy can be exchanged from one system to another if 
coupling mechanism is available. The coupling mechanism in this case is the change in electric 
dipole moment caused by the vibration bond. In an infrared spectrum the amount of radiation 
absorbed or transmitted is plotted as a function of the wavelength. The intensity of radiation of 
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one wavelength transmitted by the same sample (I) is related to the intensity of the incident 
light of this sample (I0), to the path length in the sample (b) and to the concentration of the 
sample (c) by the equation (23) 
𝐿𝑜𝑔10 (
𝐼0𝐼
𝐼
) = 𝑎𝑏𝑐  (5) 
Where, a is a constant for a particular substance at a given wavelength. This equation is a form 
of the Beer-Lambert or Beer-Bouguer law. Two commonly used terms derived from this law are 
transmittance (T) and absorbance (A) which can be expressed as shown in (24 and 25). 
Transmittance (T)  
𝑇 = 𝐼/𝐼𝑜   (6) 
Absorbance (A) 
𝐴 = 𝑙𝑜𝑔 (
𝐼
𝑇
) = 𝑙𝑜𝑔10 (
𝐼0
𝐼
) (7) 
An infrared spectrum can either be a plot of absorbance or transmittance against intensity. A lot 
of studies have looked at both IR and Raman spectroscopy for use with biological samples. 
Raman spectroscopy has been preferred for use with hydrated biological samples because water 
has a weak Raman signal compared to IR. However for samples that do not require hydration, 
IR has equally emerged a powerful tool for the analysis of biological specimens, such as tissue 
and serum.  
Watanabe investigated clinical applications of near-infrared spectroscopic (NIRS) mapping in 
neurosurgery [57]. NIRS is a non-invasive mapping technique for studying brain activity. It uses 
infrared light to detect the regional blood volume change, which is reflective of the regional 
activation of the cortical neurons. The method was evaluated as a potential alternative to Wada 
test to determine the language dominant hemisphere. The Wada test provides information 
regarding both cerebral dominance for speech and memory function in each hemisphere [58]. 
Their study demonstrated the feasibility of NIRS in the diagnosis of hemispheric language 
dominance. The study showed a 90 % agreement of the results with the Wada test.  
The simplest way to measure solids in IR is by using transmission techniques. A sample such as 
tissue can be placed on an IR transparent substrate and the thickness of the sample kept 
between 1 and 20 µm to avoid blocking all the light [59]. Early studies on biological materials 
such as tissue frozen or fixed done using a substrate but alternatively the sample can be mixed 
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with an insert KBr matrix to form what is known as a KBr pellet. Some studies utilised a diamond 
anvil cell and pressure tuning [60]. The technique uses two diamond anvil cells with very flat 
faces mounted parallel to each other with the sample placed on one diamond and the other 
brought into contact with first flattening the sample. Reflection sampling technique involves 
reflecting the IR beam off the surface of the sample instead of passing through the sample as is 
done in transmission. There are a number of reflection techniques, and these are defined based 
on the angle of incidence and angle of reflection. The angle of incidence, is the angle the 
incoming light makes with the surface normal, where surface normal is a line perpendicular to 
the surface of the sample. The angle of reflection is defined as the angle the outgoing light makes 
with the surface normal. There are two different types of reflection, specular and diffuse. 
Specular reflection occurs when the angle of incidence equals the angle of reflection. Diffuse 
reflection occurs when the angle of incidence is fixed, but the angle of reflection is variable. 
Transflection or double-transmission is a form of specular reflection and is often used in tissue 
studies. This type of technique requires a smooth surface such as a mirror which has a coating 
that is strongly reflective of IR radiation. Typically gold or MirrIR substrates are used with thin 
slices of tissue, 1-10 µm mounted on the surface of the substrate. The light beam passes through 
the tissue to the substrate, reflects off the surface of the substrate, and passes through the 
sample a second time.  Tissue and cells can also be studied on a glass slide with the use of an 
attenuated total reflection (ATR) accessory. For a single-reflection IRE, the spot size is around 
100-200 µm. The technique is easy to use and fast for single spot on the sample but does not 
allow for tissue mapping because they are no motorised xy-stages [61, 62]. 
Studies by Li et al. have shown Fourier transform infrared (FTIR) spectroscopy to have the 
potential as an in vivo real-time surgical tool through the application of FTIR fibre-optic ATR 
spectroscopy to freshly resected thyroid tissue [63]. Their study looked at a total of five patients 
with large intestine cancer detected in situ. Three cases of colon cancer and one case of cecum 
cancer were detected intraoperatively and in vivo by using FTIR spectrometer during surgical 
operation, and one case of rectum cancer was explored non-invasively and in vivo before the 
surgical operation. The study showed significant differences between FTIR spectra of normal and 
malignant colorectal tissues detected in vivo and in situ. They also reported spectral 
characteristics of normal and malignant tissues found in vivo and in situ to be similar to those 
obtained from in vitro measurements in their previous study. Bergner et al. used Raman and 
FTIR to investigate brain metastasis [64]. The study looked at brain sections from patients 
undergoing surgery. Replicates of sections used for spectroscopy were stained and histologically 
assessed by a neuropathologist. A total of 42 FTIR samples from 20 patients were investigated 
with medical records of brain tissue with regular cell density, necrosis and six kinds of brain 
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metastasis with primary originating sites from bladder carcinoma (BC), colon carcinoma (CC), 
lung carcinoma (LC), mammary carcinoma (MC), renal cell carcinoma (RCC) and prostate 
carcinoma (PC). The data were analysed using PCA and SVM and their classification of tumour 
groups was in agreement with histopathological results with a classification accuracy of 99 % for 
brain metastasis. Bambery  et al. [65] used FTIR images to investigate GBM in an animal model 
using UHCA analysis. The study looked at adult male Wistar rats, in which one rat served as host 
for brain tumour and another as an aged matched healthy control. The brain tumour was 
generated by C6 cultured cells injected in the rat into the anterior part of the right brain 
hemisphere.  Both animals were sacrificed after 2 weeks and a resection carried out on the 
tumour mass area. The tissue was histologically processed and thin sections mounted on 
superfrost® slides and MirrIR slides. IR spectra were recorded in reflection/absorption mode 
over the region 4000-900 cm-1. The spectra contained in each image were quality tested and 
processed to generate chemical images and UHCA maps. Chemical images are a plot of 
intensities as a function of the integrated area under a chosen spectral band. These were 
baseline corrected using CytoSpec. The study was able to distinguish the tumour growth shown 
by FTIR imaging as chemically different from surrounding brain tissue through UHCA clustering. 
The tumour and surrounding tissue were immediately separated at the first pair of clusters. The 
invasive portion of the tumour in the FTIR chem-images was clearly apparent than the visible 
light micrograph. The study showed that FTIR imaging technique coupled with UHCA analysis 
provided more information to the extent of showing differences within regions of the brain such 
as layers in the cortex which correspond well with the six anatomical Brodmann layers of the 
neocortex. 
There has been heated debate regarding electric field standing wave (EFSW) artefacts in FTIR 
microspectroscopy of biological materials. An EFSW is produced with reflective metallic surfaces 
such as the ones used in IR spectroscopy as substrates, due to the interference of incident and 
reflected light. This wave can be detected by looking at its period which is dependent on the 
wavelength of the radiation which produces a non-linear change in absorbance with increasing 
sample thickness (non-Beer-Lambert like behaviour).  Fillik et al. investigated the artefacts 
produced by FTIR in reflection-absorption (transflection) spectroscopy [66]. Their study used a 
protein micro-structure as a model for a biological cell and evaluated the differences between 
FTIR spectra collected in transmission and transflection. Through varying the sample thickness 
of the protein structure the relationship between the absorbance and sample thickness in 
transflection was determined and shown to be consistent with optical interference due to the 
EFSW resulting from the internal reflection from the sample top surface. Their experiment 
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confirmed that EFSW artefacts have profound effects on transflection spectra which resulted in 
spectral variations being due to sample thickness rather than biochemical differences.   
1.5 Inductively Coupled Mass Spectrometry 
The number of elements routinely used for the diagnosis and monitoring of different types of 
diseases has increased over the years. As a result sensitive analytical techniques with capability 
of multi-element analysis such as Inductively Coupled Plasma-Mass Spectrometry (ICP-MS) have 
become increasingly popular in the diagnosis and monitoring of diseases. The human body 
continuously absorbs a wide variety of elements from the environment whose concentration in 
the blood is regulated by homeostatic mechanisms. These elements are known as essential 
elements and their increase or decrease correlates with human diseases resulting in 
physiological changes. Minute amount of some of these elements are responsible for the 
initiation of important biochemical changes in the human body. Inductively coupled plasma-
mass spectrometry is a highly sensitive system capable of measuring these trace elements in 
body fluids and tissue. The analysis of the distribution of major and trace elements in drugs, 
body fluids and biological tissue using ICP- MS can provide vital information which can be used 
as a tool for diagnostic tests and the monitoring of diseases.  
Samples are a representative part of the object to be analysed, which is selected in such a way 
that it possesses the desired properties of the object under investigation [67]. The types of 
samples used for analysis in health studies can be divided into two groups, solids or liquids [68]. 
Samples for ICP-MS are always in aqueous form and solid samples such as plants and animal 
tissue are solubilised by an appropriate dissolution method [69]. Consideration should be given 
to the possible behaviour of both main matrix and trace elements [68]. Particle size is used to 
differentiate between dissolved and suspended solids. In chemistry and other disciplines it is 
accepted that constituents of a sample are dissolved if they pass through a 0.45-µm filter and 
anything not passing through the filter is considered particulate [70]. The preparation step 
should decompose and eliminate the organic part of the solid sample leaving the residue in the 
form of mineral compounds only with varying content. The matrix is usually formed by the main 
elements and are present at concentrations above 0.1%, in environmental samples usually Ca, 
K, Mg, Na and P, minor elements <0.1% such as Fe and Al with trace elements in µg/g  and ultra-
trace elements below ng/g or lower [71].  
Platinum complexes have been used for the treatment of several types of cancer since their 
discovery in the late 60s [72]. Laser ablation inductively coupled plasma mass spectrometry (LA-
ICP-MS) can perform two dimensional imaging of platinum distribution in tissue in the 50 μm 
range [73]. The technique has the ability to perform rapid multi-element screening of a relatively 
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large analysed area, depending on the size of the ablation chamber without any need for sample 
preparation steps. Zoriy et al. showed that platinum distribution can be mapped throughout 
multiple organs or even whole body sections in their mice model [73]. The model shows the 
potential of LA-ICP-MS in the development of new platinum complexes for the treatment of 
various cancers. 
Recent cancer studies have shown that the density of A1 adenosine receptor (A1AR) is increased 
in zones surrounding experimental tumours and human glioblastoma multiforme (GBM) [74]. 
This activity is thought to be related to local tumour infiltration. Following A1AR changes imaging 
techniques such as radioprobes and positron emission tomography (PET) have the potential to 
provide a new way to study tumour invasion non-invasively [44]. In order to evaluate the 
method, an understanding of the pathophysiological background of the A1AR changes is 
essential.  
Elemental distribution provides a more stable and direct insight into cellular function and 
dysfunction. Metal ions play an essential role as important cofactors of enzymes and in signal 
transduction mediated by second messengers [75, 76]. Zinc is known to be a neuronal co-
transmitter [77, 78], and copper functions as a co-factor in the respiratory chain and also an 
important factor in tumour growth [79] and angiogenesis [80]. Dehnhardt et al. using LA-ICP-MS 
showed an increase in copper and zinc levels in an area surrounding human brain tumours [81]. 
This area is identical with a peritumoral region of elevated A1AR density. The use of LA-ICP-MS 
to study these metals could enhance our understanding of different types of diseases which 
could provide a more detailed background for emerging new diagnostic techniques such as 
radioprobes and PET.  
1.5.1 Certified Reference Materials (CRMs) 
The use of certified reference materials is applied in many analytical techniques including ICP-
MS. These have been used in different types of investigations ranging from drug monitoring to 
pesticide analysis [82]. CRMs consist of a broad range of materials used to ensure the quality of 
the analyses by simplifying the internal quality control; providing long term internal 
comparability, inter-laboratory comparability, traceability, validation and evaluation of 
analytical methods and calculation of the measurement uncertainty [83]. These CRMs as shown 
in (Table 2) are produced in a controlled environment and their content measured by a number 
of specially selected and qualified laboratories following validated methods and techniques. The 
elements in the reference sample needs to have similar values to the certified values as close as 
possible after analysis [84].  
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Table 2. Certified Reference Material BRC-185R Certificate of Analysis by BCR (Community Bureau Reference). The 
elements are analysed by more than one technique. Table taken from the Institute for Reference Materials and 
Measurement, Belgium. 
 
This is usually difficult to achieve in practice as environmental and biological samples have 
concentrations and compositions that may vary considerably. It is important to have several 
reference materials to choose from as well as control samples to monitor the experiment. The 
selection of the quality control sample is important in judging the validity of the analytical 
procedure. The control sample can be used to detect systematic errors when they are related 
to instrumental calibration. In ICP-MS the control samples should be elements which are 
representative of the real test material and should be stable over time [83, 84].  The acceptable 
range of concentrations of the analytes in a quantitative analysis is established at ± 𝑋 % in 
agreement with the criterion of accepted accuracy of the known concentration assigned to the 
object. The preparation of internal control samples involves composition validation. The best 
approach to obtaining the true value of each single analyte is to use a commonly agreed value 
produced by a group of qualified reference laboratories. Natural samples make the best control 
samples although it may be difficult to obtain large amounts of materials at suitable analyte 
concentrations [84].   
1.6 Aims and Objectives 
The aims of this study is to explore alternative methods to histopathology for the diagnosis of 
primary brain tumours. The objectives will be met by; 
1. The use of ICP-MS on fresh human brain tumour tissue and serum to identify elemental 
thresholds, gender and age differences that can be used as diagnostic tools aided by 
multivariate statistics. 
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2. Separation of brain tumour cell lines, U87MG and 1321N1 with a control SVGP12 using 
Raman and IR spectroscopy coupled with multivariate statistics. 
3. Segregation of paraffin embedded human brain tumour tissue from brain tumour 
patients and normal brain tissue into various subgroups using Raman spectroscopy 
coupled with multivariate statistics. 
4. Development of spectral panels to be used as diagnostic tools for the separation of 
various brain tumours and their subtypes from normal brain tissue using multivariate 
statistics.  
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Chapter 2 
2 Tissue and Substrate Effect Study 
2.1 Introduction 
Vibrational spectroscopy, Raman and infrared (IR) have been shown to be powerful 
techniques in the biomedical field with a wide range of applications ranging from cancer 
diagnosis to the characterisation of proteins involved in neurodegenerative diseases and 
stem cell research on disease aetiology [13, 85]. Raman and IR have both been used in 
a number of studies with different modalities to interrogate the molecular structures of 
different materials. Raman’s inelastic scattering of incident light by molecular vibrations 
of bonds generates Stokes-shifted photons at distinct wavelengths that correspond to 
unique bond vibrations [86]. This property of Raman to produce unique bond vibrations 
to create what can be thought of as a “molecular fingerprint” of that sample or material. 
This “molecular fingerprint” can be used for the biochemical analysis of different types 
of biological materials such as serum, whole blood, cells and tissue. On the other hand 
Raman spectra is complimentary to that of IR, which represents the absorption of 
incident light at the resonant frequency of the bond or group, exciting vibrational 
modes, and the two techniques can be used in the biochemical analysis of biological 
samples.  
Recent developments have shown that samples such as individual cells can be analysed 
using Raman modalities like laser tweezers Raman spectroscopy (LTRS) without the need 
for sample preparations or substrates [86]. Techniques such as optical trapping, which 
immobilizes moving objects within the laser focus allow the interrogation of individual 
cells in a simplified manner which is less time consuming especially when analysing a 
large number of cells. Lau et al. in their proof of principle study for the identification and 
sorting of two leukaemia cell lines reported an integrated optofluidic Raman-activated 
cell sorter (RACS) which they combined with LTRS providing the potential for automated 
sampling and sorting of many cells [87].  
There are number of factors that have been shown to affect results from vibrational 
spectroscopic analyses. Substrates, chemicals or sample preparation methods for 
spectral analysis can affect the biochemical composition of the sample. The use of live 
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cells and fresh tissue for spectroscopic analyses can potentially reduce these problems. 
However, tissue has been historically preserved in hospitals using formalin fixed paraffin 
preserved (FFPP) blocks which are subsequently cut into sections for histological 
processing. It is to this end many studies have been conducted to investigate the optimal 
methods for spectroscopic analysis, which are reproducible and accurate [88-93].  
Sample processing techniques have been shown to affect the results and these effects 
vary from changes in the biological composition of the sample, such as the amount of 
ratio of proteins and lipids when using fixation products or artefacts that may result 
from residue of clearing agents used during the dewaxing process of paraffin embedded 
tissue, or an increased signal to noise ratio from substrates used to support the samples 
during analysis such as MirrIR slides (low-E), CaF2 or normal glass.  Early literature [94] 
on the application of IR to cell analysis for diagnosis revealed that cells were prepared 
by direct culture on infrared transparent substrates, followed by removal of culture 
medium and air-drying. Subsequent studies investigated the effects of air-drying and 
discovered that this process caused delocalization of biomolecules as a result of large 
surface tension forces associated with passing the water-air interface.   
Other studies looked at the influence of fixation products used in the histological 
processing of samples for both Raman and IR [86, 95], a process that is used to preserve 
the structural integrity of biochemical constituents of cells in as close to in vivo 
conditions for long periods of time. The use of methods or products that alter the 
structure or biochemical constituents of the sample can lead to results that are 
misleading during spectroscopic analysis. Pereira et al. [95] investigating the influence 
of fixation products in the IR spectra of lung cells looked at four commonly used 
products, PBS, formalin 5 %, Alcohol 70 % and Methacarn, (Figure 9). Their study showed 
that 5 % formalin and methacarn fixation protocols changed the IR spectra in the mid 
infrared region (800-1800 cm-1) when compared to unfixed cells in PBS which were used 
as controls for the experiment. Chan et al. [86] conducted a similar experiment to 
investigate the effects of cell fixation on the discrimination of normal and leukaemia 
cells with LTRS. The fixatives used in their study consisted of PBS, 4 % paraformaldehyde 
and cold methanol solution.  
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Figure 9. (a) shows infrared spectra of unfixed cells which are used as a control, (b) and (d) shows that 5% formalin 
and Methacarn fixation protocols change the spectra in the mid infrared region (800-1800 cm-1) after 48 hrs. (c) 
Shows minimal change to the spectra after the cells were fixed using 70% alcohol [86]. 
The Raman spectra of both unfixed and fixed healthy and cancer cells from the Chan et 
al. study were analysed using PCA. Their investigation showed that there was no 
significant difference between the healthy and cancer cells from both fixed and unfixed 
cells. They concluded that paraformaldehyde fixation does not adversely affect the 
identification and discrimination of cancer cells from healthy cells by Raman 
spectroscopy.  Gazi et al. compared three chemical fixation methods for the mapping of 
prostate cancer cells with synchrotron (SR) based FTIR microspectroscopy [91]. In their 
study cells were cultured directly onto MirrIR slides for transflection mode analysis. The 
first method showed no significant difference in the peaks across the frequency range 
3000-1100 cm-1 with 4 % formalin. The second method which involved formalin fixation 
and critical point drying (CPD) showed significant changes in structure with the loss of 
the lipid ester vs(C=O) peak which was thought to be due to lipid-leaching reagents 
(ethanol and acetone). The third fixation method involved glutaraldehyde and osmium 
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tetroxide (OsO4) prior to CPD. This method did not give rise to any spectral bands in the 
region of interest. The cells were found to be negative to trypan blue, indicating good 
preservation of plasma membrane lipid molecules [96].  
Formalin fixed paraffin preserved tissue goes through a dewaxing process prior to 
histological and/or spectral analysis. The dewaxing process allows histological staining 
of the tissue for pathological examination as well as reduce paraffin contributions in 
spectroscopic analysis by returning the tissue into as near an in vivo state as possible 
[97]. A number of studies looked at the efficacy of dewaxing procedures on FFPP tissue 
on different types of substrates.  Ó Faoláin et al. investigated the effects of dewaxing 
FFPP cervical tissue on glass slides. Their study reported that xylene and HistoClear 
clearing agents do not completely remove all the paraffin wax [97]. Hexane another 
clearing agent not commonly used in hospitals produced better results in their study but 
required 18 hours of tissue submersion. The study also showed that Raman 
spectroscopy was much more sensitive to detect paraffin residue than FTIR, after 
comparing identical deparaffinised tissue sections in which paraffin wax peaks were 
clearly resolved with Raman compared with FTIR.  
The use of substrates in spectroscopic studies is inevitable. Substrates support samples 
during analysis. Samples used in biomedical investigations may vary from solids to 
liquids, often some samples are relatively thin allowing incident light to interact with the 
substrate supporting it. This interaction affects the spectral analysis in a number of ways 
which may include an increased noise to signal ratio or contribute peaks in the spectral 
region of interest. A number of studies [59, 66, 98] have reported spectral artefacts 
known as the “electric field standing wave” (EFSW) using FTIR transflection analysis with 
MirrIR slides. Miljokvic et al. showed that problems of the EFSW with MirrIR can be 
overcome by utilising a 2nd derivative spectra during pre-processing which minimises the 
artefact contributions to a negligible level making it possible to carryout spectral 
histopathology [99]. Fullwood et al. investigated the effects of substrate choice and 
tissue preparation methods using Raman. Their study looked at three substrates, MirrIR, 
Spectrosil and CaF2 using HistoClear and showed the influence that substrates have on 
resulting spectra from Raman analysis. Spectral backgrounds of the three substrates 
showed that MirrIR had the highest background and CaF2 the lowest. Their study 
reported that CaF2 and Spectrosil substrates retained paraffin wax after the dewaxing 
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process whilst MirrIR showed no paraffin residue under the same conditions. The reason 
for this was suggested to be the differences in surface roughness and chemistry between 
the substrates. Atomic force microscopy was used to assess the surfaces of the three 
substrates and showed that MirrIR substrates are smoother than CaF2 or Spectrosil with 
an average roughness of 1.10 nm compared to 4.76 and 3.88 nm respectively [100]. One 
of the most interesting suggestions through their investigations was that there seemed 
to be a correlation between paraffin retention and tissue type. They observed from 
averaged spectra of normal tissue that the paraffin peaks were not fully removed by the 
dewaxing process from metastatic and GBM tissue, with metastatic tissue retaining the 
most paraffin. Fullwood et al. reported paraffin residue on tissue mounted on CaF2 and 
Spectrosil during their study of the effects and efficiency of the dewaxing process using 
HistoClear under a 5 min bath regime [100]. Their study compared spectra, (Figure 10) of 
dewaxed tissue samples on three substrates, MirrIR, Spectrosil and CaF2 using 
HistoClear. Spectra from dewaxed paraffin samples on CaF2 and Spectrosil also showed 
paraffin residue, which is consistent with this study. The reason for this could be due to 
differences in the surface chemistry of the substrates or their morphology [100].  
Fullwood et al. investigated whether tissue type mounted on MirrIR, Spectrosil and CaF2 
contributed to the residual signal. Their study showed that paraffin residue is retained 
by normal brain tissue after dewaxing and that the characteristic features of the spectra 
are of a much lower intensity than those of metastatic and GBM tissue. Their study 
concluded that the inconsistences in the tissue dewaxing efficiency could be due 
differences in the morphology of the tissue based on tissue density resulting in paraffin 
peak intensity variation between normal brain and cancerous brain tissue spectra [100].   
[53] 
 
 
Figure 10. Averaged spectra of tissue on CaF2, MirrIR and Spectrosil and paraffin wax (Reference spectra). The asterisk 
above the peaks correspond to paraffin contributions. Plot taken from [100].  
This study investigates the difference between three substrates commonly used in 
Raman and IR spectroscopy, MirrIR, CaF2 and normal glass, on the resultant spectral data 
of identical samples. The study also investigates a potential relationship between tissue 
type and paraffin retention as reported in a study by Fullwood et al. [100] using two 
different clearing agents, xylene and HistoClear under three different dewaxing bath 
conditions, 5 min, 10 min and 15 min with nitrocellulose membranes of different pore 
sizes, 1.2 µM, 5.0 µM and 8.0 µM to replicate different tissue types.    
2.2 Materials and Methods 
2.2.1 Tissue type and paraffin retention 
Histological processing 
Three replicates from 20 nitrocellulose membrane filters of varying pore sizes, 1.2 µM, 5.0 µM 
and 8.0 µM (Merck Millipore, UK) were taken for each pore size and immersed in 15 mL tubes 
with 10% formalin solution (Fisher Scientific, UK) for 24 hrs. The membrane filters were placed 
in cassettes processed in a Citadel 2000 tissue processor (Thermo Scientific, USA) using a routine 
overnight tissue processing protocol shown in (Table 3). 
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Table 3. Hospital routine program for overnight tissue processing of biopsies for histological examination used to 
process 20 nitrocellulose membrane filters. 
Position/Step Reagent Immersion Period  
Hrs /Mins 
Period Entered 
Hrs /Mins 
Position 1 Formalin 2:00 2:00 
Position 2 Formalin  2:00 2:00 
Position 3 Alcohol 70 % 1:00 1:00 
Position 4 Alcohol 90 % 1:00 1:00 
Position 5 Alcohol 100 % 1:00 1:00 
Position 6 Alcohol 100 % 2:00 2:00 
Position 7 Alcohol 100 % 2:00 2:00 
Position 8 HistoClear 1:00 1:00 
Position 9 HistoClear 1:30 1:30 
Position 10 HistoClear 1:30 1:30 
Wax Bath 1 (11) Wax 2:00 2:00 
Wax Bath 2 (12) Wax 3:00 3:00 
 
                                            End of Cycle 
Total processing time = 20 hrs 
Full program time = 20 hrs 11 mins, allowing one minute for every change of position 
 
Following processing with the Citadel 2000, the membrane filters were left to dry at room 
temperature, removed from the cassettes and embedded by positioning them in a metal 
mould and adding molten wax which is immediately cooled on a cold plate to form wax blocks. 
Membrane Sectioning 
Thin sections (10 µM) of the embedded membranes were cut using a microtome (Leica RM2235 
Leica Biosystems, UK) and placed on CaF2 (Crystan Ltd, UK), MirrIR (Kevley Technologies, USA) 
and normal microscope glass (Fisher Scientific, UK) in triplicate for each of the three bath times, 
5 min, 10 min and 15 min used during dewaxing. This was done for both HistoClear and Xylene 
clearing agents. The samples were left to dry at room temperature in petri dishes and stored in 
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a desiccator until Raman analysis. Paraffin wax sections were cut at 10 µM and mounted on each 
of the three substrates and profiles generated for paraffin reference peaks. The wax mounted 
substrates were dewaxed under the same conditions as the nitrocellulose membranes.   
2.2.2 SEM Images 
In order to assess the surface differences between the three nitrocellulose membrane filter, 1.2 
µM, 5.0 µM and 8.0 µM, based on their pore sizes images were taken (Figure 11) using the 
scanning electron microscope (SEM) (FEI Quanta 200, USA).  
 
Figure 11. SEM images of (A) 1.2 µM, (B) 5.0 µM and (C) 8.0 µM, nitrocellulose membrane filters taken at 2619X 
magnification to assess surface    differences based on their pore sizes. The images show density decreasing from 1.2 
µM, 5.0 µM to 8.0 µM. These pore sizes are intended to mimic changes in human tissue as it changes from normal 
(8.0 µM) to different disease states (1.2 and 5.0 µM). These changes are intended to represent changes in the degree 
of malignancy.  
2.2.3 Raman spectroscopy 
Raman spectral measurements were carried out using a Horiba-Yvon LabRam HR800 (Horiba 
Scientific, France) spectrometer with an air cooled CLDS point mode diode, 785 nm laser with a 
single edge filter (cut off to 100 cm-1) and an output power of 300 mW. Spectra was acquired 
with a grating of 300 gr/mm and blazed at 1000 nm and a 50 LWD X objective. The confocal hole 
was set at 100 µM for 785 nm, spectral collection with 2 accumulations at 150 seconds 
acquisition time. The instrument was calibrated before spectral acquisition to silicon at spectral 
line 520 cm-1. 30 spectral points for each replicate was taken, averaged and offset for better 
visualisation.  
2.2.4 Substrate effect 
To assess the effects of substrates on the dewaxing process and background contribution, three 
replicates of CaF2, MirrIR and normal glass were analysed using Raman under similar conditions. 
Raman profiles of the three substrates from each group were generated using the 785 nm laser 
in the spectral region of 400-1900 cm-1.  
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2.2.5 Data processing 
Data pre-processing was carried out using LabSpec 6 spectroscopy software (Horiba Scientific, 
France) and MatLab™ version 7.11.0 (R2010b) (The MathWorks Inc, USA) using in-house written 
software. Pre-processing methods were kept to a minimal to enable reproducibility. Baseline 
correction was carried out through the application of a 6th order polynomial fit using LabSpec 6 
and vector normalisation in MatLab using an in-house code written by Dr A Henderson with 
CytoSpec 64-bit. 
2.3 Results and Discussion 
2.3.1 Substrate effects 
A comparison of background spectra between CaF2, MirrIR and normal glass showed that normal 
glass had the highest intensity baseline with a number of broad peaks spanning the entire 
spectral region (400-1900 cm-1) under investigation, (Figure 12(A)). MirrIR and CaF2 showed 
relatively low baseline intensity with CaF2 having the least, however CaF2 had relatively high 
background noise (Figure 12 (B and C)). 
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Figure 12. Raman background spectra of (A) normal microscope glass, (B) MirrIR, and CaF2 substrates taken using 
the 785 nm laser in the region 400-1900 cm-1. CaF2 (c) had the lowest intensity baseline compared to (A) and (B), 
however the spectra had the most background noise comparatively. Each spectra A, B and C is the mean of 30 
spectra.  
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Most biological samples are relatively thin and allow incident light to pass through the sample 
and interact with the substrate. A major concern regarding the use of normal glass for analysis 
would be if the constituents of the sample under investigation have peaks that are of low 
intensities falling under the spectral region were the substrate has major broad peaks. CaF2 had 
the lowest intensity background, (Figure 12C), however its spectral profile was very similar to 
MirrIR, (Figure 12B), with a distinctive broad peak at 1400 cm-1. Spectra taken from CaF2 
substrates is expected to show background peaks of lower intensities compared with MirrIR 
because of its low intensity baseline shown in previous plot (Figure 12C).  
The right choice of substrate for spectroscopic analysis is important for reducing background 
noise, spectral artefacts and optimising the quality of the spectral data [101]. Normal 
microscope glass substrates are very cheap but exhibit a very large fluorescent background as 
seen in (Figure 12) and therefore not suitable for spectroscopic analyses. MirrIR substrates are 
relatively cheap compared to CaF2 and have been shown to produce artefacts when using FTIR 
transflection mode due to EFSW. However the problem of EFSW related to substrates does not 
affect other infrared modalities such as attenuated total reflection-fourier transform infrared 
(ATR-FTIR). Whilst artefacts caused by EFSW are of serious concern, Miljkovic et al. showed that 
the problem could be overcome by the use of a 2nd derivative spectral data treatment [102]. 
Therefore MirrIR slides can be used in place of CaF2 for spectroscopic analysis but special care 
needs to be taken to take into account the potential sources of spectral artefacts. MirrIR slides 
are cheap and robust compared to other substrates and comparable to CaF2 substrates.  
2.3.2 Tissue type and paraffin retention 
Paraffin profiles on substrates 
Spectral profiles from paraffin wax mounted substrates were taken from the three substrates, 
normal glass, (Figure 13), MirrIR, (Figure 15) and CaF2, (Figure 14), to generate paraffin wax 
reference peaks to be used for comparison after the dewaxing process.  
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Figure 13. Raman spectra of paraffin wax on normal glass substrate taken using a 785 nm laser in the 
spectral region 400-1900 cm-1. The profile shows the major paraffin peaks and their wavenumbers given as 
references for subsequent paraffin profiles.  
 
 
Figure 14. Raman spectra of paraffin wax on CaF2 substrate taken using a 785 nm laser in the spectral region 
400-1900 cm-1. The profile shows the major paraffin peaks and their wavenumbers are the same as those 
in Figure 13.  
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Figure 15. Raman spectra of paraffin wax on MirrIR substrate taken using a 785 nm laser in the spectral 
region 400-1900 cm-1. The profile shows the major paraffin peaks and their wavenumbers similar to those 
in Figure 13. 
The three substrates produced similar paraffin wax profiles as shown in the combined Raman 
spectra, (Figure 16) which shows all the major paraffin peaks falling under the same 
wavenumbers.  
 
Figure 16. Raman combined spectra of paraffin wax on CaF2 (blue), normal glass (green) and MirrIR (red). All major 
paraffin peaks fall under the same wavenumbers. 
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Substrate dewaxing 
The three substrates were dewaxed using the same conditions as the nitrocellulose membrane 
filters. The procedure is supposed to remove paraffin wax leaving only the sample under 
investigation.  
CaF2 substrates showed residual paraffin peaks using HistoClear under the 5 min bath regime 
(Figure 17). There were no paraffin residue on normal glass and MirrIR on all the bath regime 
time, 5, 10 and 15 min. using both HistoClear and xylene.  
 
Figure 17. Plot showing CaF2 substrate (blue) with residual paraffin peaks after dewaxing with HistoClear at 5 
minutes bath intervals. MirrIR (green) and normal glass (red) showed no paraffin residue under the same 
conditions. All the substrates showed no paraffin residue with other bath regimes and clearing agents under 
investigation. Each spectra is the mean of 30 spectra from the same sample.  
Membrane dewaxing 
Nitrocellulose membrane filters of varying pore sizes ranging from 1.2, 5.0 and 8.0 µM were 
used to mimic tissue. The 8.0 µM membrane filters represented normal brain tissue in this study, 
whilst the 5.0 and 1.2 µM represented tumours with increased density as shown in (Figure 11).  
In order to assess dewaxing efficiency, spectra of normal nitrocellulose membrane without 
paraffin wax were taken as reference after the dewaxing process. The membranes were 
dewaxed using both HistoClear and xylene on the three substrates under three bath regimes, 5, 
10 and 15 min. Nitrocellulose membranes dewaxed with HistoClear under the 5 min bath regime 
showed residual paraffin peaks (Figure 18) at positions, 1062 cm-1, 1132 cm-1, 1296 cm-1, 1419 
cm-1, 1440 cm-1 and 1463 cm-1 which can be tentatively assigned to C-C stretches, CH2 and CH3 
deformations. The effects of using CaF2 with HistoClear at 5 minutes bath intervals can be seen 
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in (Figure 19). The plot shows the offset profile of the combined spectra of the dewaxed 
nitrocellulose membrane at 5 min, normal membrane (control) and paraffin wax on CaF2 as 
reference for paraffin residue with the paraffin peaks circled on both the paraffin reference 
profile and the dewaxed spectra of the nitrocellulose membrane.  
This study showed no correlation between paraffin retention and membrane density and 
therefore suggests that the variation of paraffin peak intensity between normal brain and 
cancerous tissue observed in the study by Fullwood et al. could be due to the dewaxing process 
and choice of clearing agent. Our study showed CaF2 substrates consistently produced 
incomplete dewaxing and retention of paraffin with HistoClear at 5 min bath intervals as well as 
on the nitrocellulose membrane filters dewaxed using the same protocol across all pore sizes. 
There was no paraffin residue on CaF2 with HistoClear using 10 and 15 min bath times. Samples 
cleared with xylene on all the three substrates and bath regimes did not show any paraffin 
residues as shown in (Figure 20).     
 
Figure 18. Combined Raman spectra of dewaxed 5.0 µM nitrocellulose membrane (red) on CaF2 at 5 min 
bath intervals, 5.0. µM normal nitrocellulose membrane (green) used as reference and paraffin wax profile 
(blue) used as reference.  
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Figure 19. Combined offset Raman spectra of dewaxed 5.0 µM nitrocellulose membrane (red), 5.0 µM 
normal nitrocellulose membrane (green) used as reference and paraffin wax profile (blue) used as 
reference. 
 
 
Figure 20. Plot showing complete xylene dewaxing with no paraffin residue on CaF2 (blue), MirrIR (red) and 
normal glass (green) substrates using 5 min bath intervals. The results were similar for both 10 and 15 min 
bath intervals for all the three substrates. 
2.4 Conclusion 
This study shows the potential areas which can influence spectral analysis due to the choice of 
substrate and dewaxing protocol. Whilst CaF2 substrates are ideal, with a very low baseline 
intensity care must be taken when dewaxing tissue using 5 min bath intervals. Normal glass is 
not ideal for spectroscopic analysis due to its high fluorescence with broad peaks covering the 
entire spectral region of 400-1900 cm-1. MirrIR has a number of advantages, although it’s 
spectral background is higher compared to CaF2, spectral peaks that are detected using CaF2 
were present. Other studies have also shown that spectral peaks shown by other substrates are 
present when using MirrIR [100]. Although other studies suggested a correlation between 
[64] 
 
paraffin retention during dewaxing due to tissue density, this study found no evidence of that 
correlation based on nitrocellulose membrane filters of different densities.  
The results indicate that tissue processing still remains a challenge in spectral histopathology, 
using both Raman and IR. Whilst techniques to analyse samples without adding any 
preservatives have been developed and look promising, issues still remain with traditional 
samples that have been preserved in biobanks using different preservative methods. Current 
methods used in histology to preserve tissue and cells do not significantly change the 
morphology of these samples but when dealing with disease such as cancer, structural integrity 
of the sample is of paramount importance especially for spectral histopathology which tries to 
discriminate samples based on their structure and constituents. Xylene is a better clearing agent, 
which did not leave any paraffin residue across all three substrates, but has been reported to be 
highly carcinogenic in animal models at high concentrations [103]. Safety precautions need to 
be taken when handling xylene including the right class of fume hoods or downdraft benches 
face masks and protective wear.  
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Chapter 3 
3 Instrumentation and Data Processing 
3.1. Raman Spectroscopy 
The sources of monochromatic light used in modern Raman spectroscopy are lasers, due to their 
high intensities which produce Raman scattering of sufficient intensities that can be measured 
with a reasonable signal-to-noise ratio.  Raman spectrometers are classified into two groups, 
dispersive and Fourier transformation, based on how the scattered light is analysed [104]. The 
dispersion of optical gratings resolve light according to the wavelength, whereas Fourier 
transformed signal is obtained in a Michelson-type optical interferometer. 
3.1.1 Horiba Jobin Yvon 
The Horiba Jobin Yvon LabRam 800 instrument operates with laser sources emitting 
visible or invisible continuous laser radiation typically bellow 300 mW. The class of the 
laser product is 3B or 1 with the microscope and external laser sources housings. 
𝜆 = 325 − 1064 𝑛𝑚, 𝑃 = 300 𝑚𝑊 
The laser beam is emitted during operation inside the machine through the aperture on 
the main cover of the spectrometer and microscope. Exposure to the beam should be 
avoided, lasers are high intensity light sources producing visible or invisible light at 
specific wavelengths. This concentrated energy in a narrow laser beam may cause 
damage to biological tissues, especially to eyes. To use lasers safely, it is important to 
understand that lasers require final product safety classification which is determined by 
essentially three elements: the laser’s power, wavelength and housing. Class 3B laser 
system have Laser beams and reflected beams that can be dangerous. Diffused reflected 
beams in most cases do not present any problem [105]. 
The LabRam is equipped with standard white light illumination of the sample, by 
reflection and/or transmission. A colour camera linked to the software allows the 
sample to be visualised, and the image captured on the computer and saved. 
The LabSpec software allows the user to control the instrument and set up parameters 
used for the analysis of samples. There are different versions of the software and 
LabSpec 6 was used in this study. The instrument Setup section on LabSpec 6 under the 
Acquisition tab allows selection of key system hardware such as objective, filter, grating, 
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slit, hole, laser, stage etc. The schematic in (Figure 21) shows a typical Raman instrument 
set up [105].  
Typical Raman Instrument set up 
 
 
Figure 21. Schematic diagram showing typical set up of a Raman instrument system from the light source to the 
spectra or numerical data displayed on the computer captured via the CCD [57]. 
3.1.2 Spectra acquisition 
The LabSpec 6 software provides the user with a number of methods for acquiring a single 
spectrum, Real time spectrum adjustment or real time display (RTD) and spectrum acquisition. 
Other methods include Multiwindow spectrum and Maps. 
RTD method is primarily designed for a fast display of the spectrum on screen corresponding to 
a single shot window. The update is continuous, providing a useful way of adjusting the focus 
position to maximise the Raman signal, and quickly monitoring the stability of the spectrum. 
Each spectrum displayed replaces the previously displayed spectrum – there is no averaging or 
accumulation of the spectra, and no extended coverage possible [105].  
Spectrum acquisition method allows spectra to be acquired with multiple accumulations and 
averaging, and/or with coverage over extended regions. The method allows a single shot 
spectrum to be acquired, with user defined integration time and averaging. Multiwindow 
method allows a spectrum to be acquired over an extended range, with a defined integration 
time and averaging. The extended range is covered by taking a number of individual single shot 
windows and ‘gluing’ these together. This procedure is fully automated through the software. 
With suitable accessories on the LabRam, it is possible to acquire XY mapped images, and line (X 
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or Y), depth (Z), time and temperature profiles. The principal of these measurements involves 
acquiring an array (2D or 1D) of spectra, with each spectrum acquired with a particular varied 
parameter [105]. 
3.1.3 Processing 
The processing tab in LabSpec 6 has a number of drop down options which include; Correction, 
Smoothing and filtering, Maths, Baseline correction, Create spectral profile and Scripts.  This 
feature is to allow the user to manipulate the spectral data as part of pre-processing before any 
statistical analysis.  
Correction 
The Correction feature allows the user to apply spectral normalisation to both single and 
multidimensional spectral arrays. There are various options available under the Correction tab. 
This feature is useful as a pre-processing tool before statistical tests are employed. The spectra 
can be normalised through a number of different options, Sum, Maximum, Area, Unit Vector 
and Normal Variate.   
 Sum:  Normalise so that the sum of the spectrum intensity is 100 
 Maximum: Normalise to the maximum intensity in the spectrum 
 Area: Normalise so that the area of the spectrum is 100 
 Unit Vector: This treats a spectrum as a multidimensional vector, the intensity at nth 
spectral point being the nth element of the vector. It is normalised so that the norm is 
1 (inner product between itself).   
 Normal Variate: This treats a spectrum a collection of n (intensity) values. The spectrum 
is normalised so that the standard variation over n values is 1 [105].  
3.1.4 Baseline Correction 
The Baseline Correction feature under the Smoothing and Filtering tab allows the removal of a 
background such as fluorescence or a high background from the spectrum. The operation can 
produce a flat or zero baseline on all the spectra. The correction can be applied to both single 
and multidimensional spectrum (Figure 22). 
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Figure 22. Image of Raman multidimensional spectra A) before baseline correction and B) after baseline correction 
using the Baseline Correction feature in LabSpec 6 software. 
 Degree: Select the degree of polynomial equation used to create the baseline curve-
when the baseline type is set to Poly. 
 Type: This allows you to select the algorithm used to define the baseline curve.  
 Attach to curve: This allows manual selection of baseline points used to define the 
baseline curve [105].   
3.2 Fourier Transform Infrared (FTIR) 
FTIR spectroscopy helped overcome problems faced by dispersive instruments, with the main 
difficulty being the slow scanning process. This technique measures all frequencies 
simultaneously rather than individually as with dispersive instruments [85].  
3.2.1 JASCO FTIR-ATR 410 
Operating principle: 
Light made up of different wavelengths emitted from an infrared light source is collimated by a 
collimator and introduced to a Michelson interferometer. The interferometer consists of a beam 
splitter with a fixed mirror and moving mirror. The light is first incident on the beam splitter, 
where it is split into two beams: one beam is reflected at the fixed mirror; and the other is 
reflected at the moving mirror and returned to the beam splitter. If the peak (trough) of one 
wave meets the trough (peak) of another of equal amplitude, the waves interfere destructively 
resulting in a wave with zero amplitude at this point. Whereas, if the peak (trough) of one wave 
meets the peak (trough) of another of equal amplitude, the waves interfere constructively 
resulting in a wave with twice the original amplitude at this point. In this way, light of varying 
intensity is produced. Schematic in (Figure 23) shows the optical system of the instrument. The 
movement of the moving mirror in the Michelson interferometer produces a phase difference 
according to optical path length. These phase differences result in high and low intensity light. 
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Figure 23. FTIR Optical system used by a JASCO 410 FTIR-ATR system. The interference pattern of light is converted 
into an electrical signal by the detector and amplified by the main amplifier before being converted into a digital 
signal. [85]  
The interference pattern is converted into an electrical signal by the detector and, after being 
amplified by the main amplifier, converted into a digital signal. An interferogram is a diagram in 
which the horizontal axis represents the light path difference between the moving mirror and 
fixed mirror and the vertical axis represents light intensity. The intensity distribution with 
respect to wavenumber (i.e., infrared spectrum), can be obtained by subjecting this 
interferogram to Fourier transformation. Therefore, the digital signal is then subjected to 
Fourier transformation and the resulting spectrum is displayed on the PC monitor screen (and 
sent to the printer). A schematic diagram outlining the flow of the overall system is shown in 
(Figure 23) the spectrum obtained by Fourier transform is a single beam spectrum. Therefore, it 
is necessary to perform background measurement. The instrument automatically divides the 
sample measurement data by background data and displays a transmittance spectrum (%T). 
3.3 Multivariate analysis (MVA) 
Vibrational spectroscopic data is usually analysed using multivariate statistical models. 
Multivariate Data Analysis refers to any statistical method used to analyse data that arises from 
more than one variable. This particularly works well with spectral data from Raman or IR where 
spectral data involve more than a one variable. Despite the quantum of data available, the ability 
to obtain a clear picture of what is going on and make intelligent decisions is a challenge 
especially with biological samples where the changes are subtle. When available information is 
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stored in database tables containing rows and columns, multivariate analysis can be used to 
process the information in a meaningful fashion. There are a number of models that can be used 
to perform multivariate analysis. However, these models can be put into two major categories, 
supervised and unsupervised classification models.  
3.3.1 Principal Component Analysis (PCA) 
PCA is a method of exploring data by summarising data into ordered and non-trivial components 
which are represented by the axes. The first component describes the non-trivial variation. The 
components are independent and uncorrelated. PCA cluster analysis tool, is thought to form the 
basis of many multivariate analysis methods [106]. The model is a mathematical procedure 
recognises subtle relationships in spectroscopic data that may be used to characterise specific 
spectra to a particular disease state.  
The origins of PCA can be traced back to 1901, when Pearson formulated a statistical analysis to 
find the lines and planes of closest fit to systems of points in space[107]. However, the technique 
was first described in its modern form using principal components by Hotelling in 1933 [82].  
Principal components are a result of an orthogonal linear transformation of a data set. Given a 
set of observable variables (such as spectra),𝑚, and latent variables (such as wavenumbers), 𝑛, 
a data matrix can be formed of  𝑚 × 𝑛 dimensions. PCA plots the m variables in a 𝑛 -dimensional 
space. Any correlations in the 𝑚 set of variables would hypothetically result in the correlated 
variables clustering closely together. Since the 𝑛 -dimensional space cannot be visualised, a new 
set of coordinates are assigned. PCA identifies a new set of orthogonal axes through the data, 
by finding the direction of the maximal variance of the data through the coordinates in the 𝑛 -
dimensional space, the first principal component (PC) is obtained. The coordinates of the data 
points can then be mapped onto this new axis using orthogonal projection, obtaining a scores 
plot [83]. Further principal components are then calculated on the condition that they are on an 
orthogonal axis to the previous component, accounting for the maximal variance in the 𝑚 
variables that have not been described by any previous PCs, and that they are uncorrelated with 
all preceding PCs. With a second principal component and orthogonal axis, the coordinates can 
again be projected, but this time into a 2D-space. Each new computed PC accounts for less and 
less amounts of variance in the data set, and the cumulative percentage explained variance 
(summed over all PCs) will always equal 1. Thus, there can never be more PCs than variables. 
Usually the first 5-10 PCs of a typical spectral data set obtained in this thesis will explain the 
majority of the variance in the data (≈99%), which is why normally only the first handful of PCs 
are of any use for data analysis and interpretation. 
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The correlation between a PC and a variable estimates the information they share, and is known 
as a loading [83]. Loadings can help to determine what the variables are separating in a 
multidimensional scores plot.  
3.3.2 Discriminant function analysis (DFA)  
DFA can also be referred to as linear discriminant analysis (LDA) which is a similar technique to 
PCA, looking for linear combinations of variables that best explain a data set. However, where 
PCA aims to find a subspace whose basis vectors correspond to the direction of the maximal 
variance of the variables in the data set, LDA instead searches for those vectors in the underlying 
space that best discriminate among classes of data [84]. It is a supervised projection method 
used for classifying a set of variables into predefined classes. Information about sample grouping 
in the data set is used to produce measures of within-group variance and between-group 
variance [108]. This information is used to define a set of discriminant functions that optimally 
separate the predefined groups. A training set of the data is used to predict where data from a 
blind data set should fall, using a determined number of principal component scores as its basis. 
A test data set can then be projected into the system, with the hope of correctly discriminating 
the data into the predefined groups. 
LDA cannot be performed on raw spectral data. This is because neither co-linear variables nor 
too many variables can be fed into the LDA algorithm. PCA must be performed on data prior to 
attempting LDA because it removes co-linearities from a set of data as well as reducing the 
number of spectra [109]. If too many PCs are used in the LDA, clusters may seem very tightly 
packed and artificial, but if too few are used then no clusters may be evident that relate to the 
predefined groups. 
3.3.3 Support Vector Machines (SVM) 
Support vector machines (SVM) are supervised learning models which can infinitely find complex 
hyperplane boundaries in multidimensional space when classifying two different classes of data. 
Typically SVMs are used to find binary problems i.e. diseased (+), or not diseased (-), but they 
can also be employed to classify multiple groups using “One vs. All”. For “One vs. All” the model 
is trained to distinguish the differences between one class against the rest, this is repeated for 
all classes in the data set. For any new data being inputted into the model, the model is run 
again, each class against all, and whichever class gives the greatest positive result for the new 
data inputted is chosen as the class that the new data belongs to [110].  
To find a simple linear boundary, SVM is analogous to both PLS-DA and LDA but the boundary is 
found in a different manner. SVMs use an optimal linear separating hyperplane which maximises 
the margin between the two classes. Linear decision boundaries are found by pointing each data 
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point (𝑥) such that 𝑤𝑇𝑥 + 𝑏 = 0. This divides the plane into two sets depending on the sign 
of 𝑤𝑇𝑥 + 𝑏. With (𝑤) being known as the weight vector and (𝑏) the bias, Eq. 26 [104]. The 
discriminant function 𝑓(𝑥) describes which side of the hyperplane a data point may sit (positive 
(+), or negative (-). 
 
𝑓(𝑥) =  𝑤𝑇𝑥 + 𝑏  = 0     (8) Optimal hyperplane boundary   
𝑓(𝑥) =  𝑤𝑇𝑥 + 𝑏 ≥ 1   𝑐𝑙𝑎𝑠𝑠 = + 1  (9)                    
𝑓(𝑥) =  𝑤𝑇𝑥 + 𝑏 ≤ 1   𝑐𝑙𝑎𝑠𝑠 = − 1  (10)                     
The boundary should be equidistant from the two extreme samples from each class. If the two 
classes of data are completely linearly separable the hyperplane should split the two classes with 
no data points being projected into a data space not equal to its respective class membership, 
or at least on the boundary, (Figure 24) [104].  
 
 
 
 
Figure 24. Schematic showing the separation of two class of data H1 and H2 by an optimal hyperplane in a SVM.  
To find the best linear boundary for a data set a decision on what type of hyperplane margin 
needed to separate the data must be made. SVM’s are normally divided into two very different 
categories, hard and soft margin classifiers. The penalty error (𝑐), or cost value, can determine 
what type of margin hyperplane best separates the data. For very high values of 𝑐 hard margins 
are found, for low, soft margins. Hard margins, aim is to find the perfect hyperplane boundary 
to completely separate the two classes of data. However, these can be susceptible to outliers. 
Soft margins, have more toleration towards data points being misclassified, thus relaxing the 
hard margin boundary rule that all data from a class must be the same [104]. In order to find the 
best linear boundary cross validation is needed to find the best 𝑐 value for the data. To do this, 
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the data is firstly partitioned into both training and test data sets. The SVM uses the training set 
to find the best linear boundary which separates the two classes using different values of 𝑐. The 
test set is then used to validate the SVM model created using the optimum 𝑐 value. 
However, not all data can be separated by a linear boundary, Figure 25 shows an example of 4 
data points from two different classes; each data point consists of two variables and therefore 
can be plotted in two dimensions. From the data shown in Figure 25b it is impossible to find a 
linear boundary which will completely separate the two classes of data. To achieve this, a more 
complex non-linear boundary is needed in order to completely separate the classes of data.  
 
Figure 25. Schematic plots showing differences between two classification methods used by SVM, linear boundary 
and non-linear boundary [104]. 
SVMs are capable of constructing non-linear hyperplane boundaries by using Kernels. The radial 
basis function (RBF) is one such kernel that is a commonly used to find complex non-linear 
boundaries between two classes of data. To use the RBF kernel, support vectors define the 
boundary, however, each support vector can now be considered as a Gaussian peak. This results 
in extra parameter value, in addition to 𝑐  being needed for the SVM classifier, which is known 
as gamma(𝛾). The 𝛾 value represents radius and is used to set the size of the Gaussians support 
vectors. This gives the RBF kernel another dimension of flexibility. Low values of 𝛾 create a 
decision boundary which can almost be linear. However, with increasing 𝛾 values the boundary 
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can get more and more complex. The broader a Gaussian gets, the more likely a data point will 
be able to touch another giving more flexibility to the hyperplane boundary. This ultimately 
leads to over-fitting of the training data. Care must be taken when choosing the value of penalty 
error (𝑐) when using the RBF kernel. This is due to the fact that hard margin boundaries are 
found with increasing values of 𝑐. Hard margin boundaries try to not misclassify any data points 
due to there being a large penalty error for misclassification [104]. Ultimately with greater values 
of 𝑐, the boundary of separation will get more and more complex until perfect separation will 
be achieved from the SVM model of the training set. However, this will lead to the over-fitting 
of the training data and can be recognised by poor test set %CC from the cross validation. Cross 
validation is therefore essential when trying to find the best 𝛾 and 𝑐 values which best separate 
your data without over-fitting. 
3.4 Inductively Coupled Plasma Mass Spectrometry (ICP-MS) 
ICP-MS instruments are made up of four main systems, inductively coupled plasma, mass 
spectrometer, Plasma sampling interface and Sample injection system. The ICP-MS instrument 
is capable of measuring trace elements with very high precision. It can measure most of the 
elements on the periodic table. The ICP-MS can only detect positively charged elemental ions 
and can determine the individual isotopes of each element. The system can analyse challenging 
samples [111] with complex matrices such as serum, whole blood, tissue etc. which normally 
have low concentrations of the analyte [101]. The measurement of these analytes require 
instruments which are highly sensitive and robust capable of accurately quantifying the analyte 
of interest with very high precision. ICP-MS is a powerful analytical technique [6] for high 
precision trace element and ultra-trace element determination.  
3.4.1 Thermo Scientific X-Series 2 
The Thermo Scientific ICP-MS X-Series 2 instrument is used for the measurements of trace 
elements with high throughput. The instrument consists of a maintenance-free Infinity Lens, 
quadrupole and detector systems which ensure maximum between scheduled preventive 
maintenance visits. Figure 26, shows the schematic diagram of the ICP-MS and its major systems.  
Peristaltic pump - The peristaltic pump is located along the side of the machine and is 
responsible for the delivery of aqueous analyte solution to the nebulizer. 
Nebulizer - Creates a fine aerosol from the analyte solution which passes through a spray 
chamber before being introduced into the ICP torch. The nebulizer is capable of handling 50 % 
(v/v) solutions of hydrochloric, nitric and phosphoric acid on a regular basis. Rising temperatures 
dehydrate the analyte solution, forming a solid which then sublimates into a gas before entering 
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the ICP. Once the gas enters the plasma, high temperatures of 6 000 ⁰C singly ionize the solution 
components, which continue on through skimmer cones and enter vacuum pressures. The ion 
beam then passes through ion lenses which pass only ionized species into the universal cell, 
which may run in collision or reaction mode to reduce sample interferences. The ion beam then 
enters the mass analyser (a quadrupole) whereupon ions not on the selected mass to charge 
(m/z) ratio collide with the rods and do not pass through to the dynode detector. 
Spray chamber - The spray chamber removes larger particles from the analyte mist prior to 
injection.  
Injector - The injector delivers analyte mist to the ICP torch. There are various sizes of injectors 
depending on the type of solvent. A 0.85 mm in diameter (I.D) injector is recommended for use 
with organic solvents and the 1.5 mm or standard 2.0 mm I.D injectors will suit most needs. 
Detector - The detector is an advanced simultaneous, discrete dynode electron multiplier with 
nine orders of linear dynamic range. It accurately measures major and minor concentrations in 
a single analytical run. Intelligent over range protection and fully-automated detector cross-
calibration for superior linearity which leads to long term signal and cross-calibration stability 
between detector modes. When analyte strikes the detector a series of dynodes multiplies the 
signal which is then read and interpreted with the appropriate software such as PlasmaLab 
which runs on a Windows operating system. 
 
Figure 26. Schematic of the ICP-MS system similar to the Thermo Scientific X-Series 2 Instrument, showing the major 
systems and their components. Image taken from [22] 
 
Sampler and Skimmer cones - The interface (in reference to the depressurized region between 
the ionization scheme and the mass spectrometer) contains two cones responsible for 
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narrowing the ion beam: a sampler and a skimmer cone. The sampler cone is blunt shaped with 
a central orifice of 1.1 mm diameter and is responsible for letting only the central portion of the 
ion beam to pass. Past the sampler cone, the pressure drops to approximately 4 torr and the ion 
beam then enters the skimmer cone. This sharp-angled cone has a central orifice of 0.9 mm 
diameter and is responsible for further narrowing of the inbound ion beam, (Figure 26).  
 
Figure 27. Schematic diagram of the Sampler and Skimmer cones with their components. Image taken from [22] 
Vacuum System - This pump provides vacuum pressure of approximately 4 torr Figure 27 and 
is responsible for pumping away the majority of the gas stream from the plasma torch. The pump 
depressurizes the region behind the skimmer cone. This holds the ion optics region at a pressure 
of 8 x 10^-4 torr and the mass filter region to 1 x 10^-5 torr. 
Mass Spectrometer and Ion Optics - The mass spectrometer used by the X-Series 2 is a 
quadrupole, and it is responsible for m/z selection of the analyte ion. Before entering the 
quadrupole for mass analysis, however, the ion beam is focused into a narrower beam via a 
single cylinder ion lens. This cylinder lens operates within a voltage range of -24 V to +20 V as 
set by digital-to-analog converters controlled by the computer software. The X-Series 2 utilizes 
a collision/reaction cell for interference removal, consisting of a non-consumable hexapole and 
chicane ion deflector, which takes the ion beam off-axis and leads to low instrument 
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backgrounds of <0.5 integrated counts per second (icps) at vacant masses such as 5 and 220. 
This hexapole is inherently part of the Thermo lens system and is present in the ion path, 
regardless of the use of the collision cell. The collision/reaction gas mixtures can be 1 % NH3 in 
He, 7 % H2 in He and 100 % H2, where the NH3 and H2 are reactive gasses and the He is a collisional 
gas. The 3rd generation cell utilizes kinetic energy discrimination, which employs running the 
quadrupole bias slightly less negative (more positive) than the hexapole bias. Polyatomic ions 
generated within the plasma can have larger atomic radii than analyte ions of similar mass, i.e. 
the interferent NaAr+ (mass 63) is larger than the analyte Cu+ (mass 63). Thus, when using a 
collisional/reactive gas mixture, these larger species undergo more collisions/reactions in the 
cell, in which they lose increasingly more energy, and are then excluded from the quadrupole 
mass filter by the kinetic energy barrier. ICP-MS has a very low limit of detection less than 0.001 
parts per billion (ppb) and can detect analytes at parts per trillion (ppt) for some samples. 
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Chapter 4 
4 Analysis of Human brain tissue and serum using ICP-MS 
4.1 Introduction 
The human body contains proteinaceous substances known as enzymes and enzyme inhibitors 
which catalyse various biochemical reactions and other processes that occur in the body. 
Enzyme inhibitors however, block, modulate and control the actions of enzymes [112]. These 
inhibitors are nonselective and can affect more than one enzyme.  They can be generated 
internally inside the body or may also come from external sources such as biochemical 
substances which are either natural or synthetic [112]. The human body continuously absorbs a 
wide variety of elements from the environment whose concentration in the blood is regulated 
by homeostatic mechanisms [113]. These elements are known as essential elements and their 
increase or decrease correlates with human diseases resulting in physiological changes [114, 
115].  
Trace elements are required in small quantities as essential compounds of biological enzyme 
systems or structural portions of biologically active constituents. They constitute less than 0.01% 
by body weight of total body composition [116, 117. The solution to the cancer problem 
amongst others can be seen as that of inhibiting, blocking, poisoning, controlling, regulating, or 
modulating cancer cell metabolism. This effort involves enzymes and enzyme inhibitors to 
selectively starve cancer cells to death {Hoffman, 2007 #653]. The role played by trace elements 
in the formation and progression of cancer has been a subject of conjecture over the years with 
many conflicting reports from different authors. However carcinogenesis is considered to occur 
in four stages: initiation, promotion, progression and metastasis. Metal induced carcinogenesis 
is believed to be involved in all the stages of development [115]. Metal compounds have diverse 
physiochemical properties and have been shown to have three main predominant mechanisms 
related to metal genotoxicity; 
1) Interference with cellular redox regulation and production of oxidative stress which 
cause oxidative DNA damage or trigger signalling cascades that may lead to stimulation 
of malignant growth [118] 
2) Ability to inhibit DNA repair mechanisms which may result in genomic instability and 
accumulation of critical mutations 
3) The deregulation of cell proliferation by induction of signalling pathways or ability to 
inactivate the growth controls such as tumour suppressor genes [119]         
4) Essential trace metals on the other hand have four main functions which include; 
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 Stabilisers  
 Elements of structure 
 Essential elements for hormonal function 
 Cofactors in enzymes 
The inadequacy or lack of trace elements in biological systems affects the structure alone or 
structural function as a result of lack of stabilisation, change of charge properties and allosteric 
configuration [120]. The number of elements routinely used for the diagnosis and monitoring of 
different types of diseases has increased over the years. The improvements in sensitive 
analytical techniques with capabilities of multi-elementary analysis such as Inductively Coupled 
Plasma-Mass Spectrometry (ICP-MS) have become increasingly popular in the diagnosis and 
monitoring of diseases [71]. A number of studies have been undertaken to monitor and diagnose 
disease through elementary profiling using different types of analytical techniques.  
Studies have shown that the deficiency of trace elements as enzyme cofactors will expose the 
individual to carcinogenic stress [114, 115, 121]. Superoxide dismutase (SOD) are a group of 
metalloenzymes containing Fe, Mn, Cu and Zn with trace metals forming their core structure. 
These SODs simultaneously catalyse superoxide free radicals to form hydrogen peroxide and 
dioxide resulting in the breakdown of toxic reactive oxygen species (ROS) radical. They form the 
defence mechanism against the cytotoxic superoxide free radical. Metalloenzymes, Cu, Zn-SOD 
which is a prototypical dinuclear metalloproteinase which is an important antioxidant enzyme 
for cellular protection from ROS and several proteins involved in DNA repair [115]. Copper is 
found in many enzymes involved in oxidation such as tyrosinase, ceruloplasmin, amine oxidase, 
cytochrome oxidase. Manganese is part of enzymes involved in the formation of urea, pyruvate 
metabolism and galactotransferase of connective tissue biosynthesis. Cobalt plays an important 
role in vitamin B12 and is also a cofactor of enzymes involved in DNA biosynthesis and amino acid 
metabolism.  
Several studies have been carried out to investigate the differences in concentrations of trace 
elements in different types of biological materials. These studies have been aimed at enhancing 
our understanding of different types of diseases and potential diagnostic applications. Zinc 
values in biological fluids of cancer patients have been variable, with serum yielding higher zinc 
levels to plasma. This has been thought to be due to platelet breakdown. The levels of zinc 
concentration in serum have been found to change 2 to 3 hours after the ingestion of food. 
There has been a correlation between a decrease of zinc levels and increase in age, with women 
having lower levels than men [116]. Some studies [122, 123] observed low serum zinc levels of 
patients with cancer of the bronchus, colon, and carcinoma of oesophagus but not in other types 
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of cancer. Patients with cancer excreted more zinc than those without at a rate which was three 
times higher. Some of the known mechanisms [124] in which zinc plays in the development of 
disease includes the following: 
1. Zinc is involved in the normal development and maintenance of the thymus. 
2. Interference with T-lymphocytes helper function is associated with zinc deficiency.  
3. Zinc acts as a mitogen for animal and human lymphocytes by promoting B-cell 
function. 
4. Zinc is important and essential for bactericidal and phagocytic function of 
granulocytes. 
5. The role played by zinc in protein synthesis makes it essential for normal complement 
production. 
6. Inborn metabolic disease such as acrodermatitis enteropathica, which is failure to 
absorb zinc is marked by the defects of the above mechanisms. 
7. Zinc deficiency prevents the growth of experimentally induced cancers in animal 
models. 
8. Zinc deficiency depresses killer cell activity and promotes cancer by inhibiting normal 
vitamin A and lipid metabolism and DNA repair. 
In a study of breast tissue [125] concentrations of the elements Ca, Cr, Fe, Zn, As, Se, BR, Sr, Ca 
and Cu were found to be significantly higher in cancerous tissue than normal tissue whilst Ni, Ti 
and K had no Significant difference compared to normal tissue. Despite the use of other 
analytical techniques these levels were found to be consistent with other studies [115] whose 
results are shown in (Table 4).  
Table 4. Trace metal levels reported in the literature for cancerous and noncancerous human tissue using PIXE. 
The values are in µg/ g. Table taken from [10]. 
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Challenges in the analysis of trace elements have been demonstrated by the various 
contradicting reports in the literature to establish reference concentrations for metals in 
different types of biological materials. Investigations in the determination of total metal 
concentrations in cerebrospinal fluid (CSF) using different methods such as atomic absorption 
spectrometry (AAS), inductively coupled plasma-mass spectrometry (ICP-MS), atomic emission 
spectrometry (AES), neutron activation analysis (NAA), proton induced X-ray emission (PIXE) and 
voltammetry have been used and the results shown in Table 5, [126]. A typical concentration 
range has been reported for most elements, however reports in other papers are considerably 
higher than the bulk of values. This is typically observed for elements with a higher risk of 
contamination during sampling. Most of the papers do not provide enough information to allow 
the evaluation of proper quality assurance procedures for the analytical technique [127, 128]. 
These problems require standardised methods of analysing samples and sample handling 
techniques. An important aspect to consider may be differences in environmental and 
nutritional metal concentrations of people living in different geographical locations. This aspect 
may present a very difficult problem to get round when considering reference levels of metal 
concentrations in normal biological materials. However an investigation into individual 
differences between serum and tissue samples of patients with the same type of cancer may 
perhaps provide insights on thresholds if any that can be used for diagnostic purposes. 
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Table 5. Overview of four elemental concentrations in human CSF samples using different techniques [126, 129]. 
 
Inductively coupled plasma-mass spectrometry (ICP-MS) is a highly sensitive system capable of 
measuring trace elements in body fluids and tissue. The analysis of the distribution of major and 
trace elements in drugs, body fluids and biological tissue using ICP- MS can provide vital 
information which can be used as a tool for diagnostic tests and the monitoring of diseases. The 
aim of this study was to investigate differences between elemental concentrations in serum and 
tissue from the same patient with brain tumours and differences between elemental 
concentrations in serum and tissue samples between different groups of brain tumours from 
different patients. Medical history of the patients regarding comorbidities if any was not 
Element Concentration 
Control/Normal 
Concentration 
Diseased 
Method Remarks 
 
 
 
Cu (µg/L) 
 
21.7 ± 8.5 
22.5 ± 4.8 
34 ± 14 
 
 
 
23 ± 6 
 
ICP-DRC-MS 
HR- ICP-MS 
HR-ICP-MS 
 
Multiple 
Sclerosis 
Control 
 
Fe (µg/L) 
 
22 ± 13 
73 ± 73 
30.5  
 
 
 
19.8 ± 2.6 
 
ICP-DRC-MS 
HR-ICP-MS 
HR-ICP-MS 
 
Multiple 
Sclerosis 
 
Control 
 
 
Mg (mg/L) 
 
22.1 ± 1.0 
21.2 ± 3.2 
36.5 ± 0.5 
 
 
 
36.5 ± 0.5 
 
 
HR-ICP-MS 
HR-ICP-MS 
 
Control 
Multiple 
Sclerosis 
 
Zn (µM) 13.3 ± 0.6 
 
 
12.4 ± 0.4 
HR-ICP-MS 
HR-ICP-MS 
Control 
Alzheimer’s 
disease 
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available during this study. The investigation was carried out under the assumption that the only 
disease patients had were brain tumours. 
 
4.2 Patients and Methods 
4.2.1 Patients 
Cryopreserved paired tissue and serum samples from 55 brain tumour patients of different 
gender and age were obtained from the Preston Royal Teaching Hospital with full ethical 
consent. The tissue and serum samples were paired from the same patients making up a total 
of 110 samples. These samples were grouped according to their histological type into three main 
groups, glioblastoma multiforme, meningioma I and meningioma II. The fourth group, OTHER 
was made up of various types of brain tumours (meningioma III, Medulloblastoma, glioneuronal 
with PNET component, gliosarcoma, Oligoastro III/GBM, lymphoma, Oligo III, Schwannoma, 
fibromyxoid, normal brain and astrocytoma III) which had less than 5 samples of the same type.   
4.2.2 Instruments 
Elemental analysis was conducted on a Thermo X Series ICP-MS (Thermo Fisher Scientific, 
Bremen, Germany) for all the experiments. Lyophilisation of brain tissue was done at -40°C using 
an E.C Modulyo with a RV12 Vacuum Pump Freeze Drying System (Thermo Electron Corporation, 
USA). Microwave digestion was carried out using a MARSX microwave system (CEM Microwave 
Technology Ltd, Buckingham, UK). 
4.2.3 Reagents 
A multi-element standard solution 10 µg/mL ea: Al, Ca, Cs, Cr3, Co, Cu, Fe, Li, Mg, Mn, Ni, K, Rb, 
Ag, Na, Sr, Zn (Inorganic Ventures, Virginia, USA) was used with the samples. A 2 and 20% nitric 
acid solution was made up from 70% Nitric acid for trace metal analysis (Fisher Scientific, 
Leicestershire, UK). Bismuth 100 µg/mL (Inorganic Ventures, Virginia, USA) was used as internal 
standard. An in-house Ultra-pure grade water was used from a Barnstead NANOPURE machine 
(Thermo Scientific, Triple Red Lab, Buckinghamshire, UK). Multi-element Tune A, 25 mL: Ba, Be, 
Bi, Ce, Co, In, Li, Ni, Pb, U 10 mg/L (each) in 5% HNO3 (Thermo Electron Corporation, USA) was 
used to calibrate the ICP-MS before analysing samples. 
4.2.4 Sample Preparation 
Biopsies of brain tissue in the range 0.1g-1g wet weight were subjected to cryogenic 
preservation and serum samples from 55 brain tumour patients with various types of tumours 
(Table 3) were obtained from the Preston Royal Teaching Hospital, through the Brain Tumour 
North West Biobank with full ethical approval. Samples were stored in closed polyethylene 
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vessels at -80°C until sample digestion. 1g of brain tissue wet weight was rinsed in ultrapure 
water and lyophilised at -40°C in an E.C Modulyo system (Thermos, USA) in 10 mL polyethylene 
tubes sterilised in 20% nitric acid for 24 hrs and rinsed with ultra-pure grade water. Biopsies of 
about 30 mg dry weight were placed in Teflon PFA vials (6 mL capacity) which were previously 
sterilised in 20 % nitric acid for 24 hrs prior and rinsed in ultra-pure grade water were mixed 
with 0.3 mL of concentrated nitric acid.  
Microwave digestion was carried out at 20 cycles 110°C within 10 min, hold at 110°C for 15 min 
and vent for 20 min in a sealed 100 mL digestion bomb previously sterilised in 20% nitric acid for 
24 hrs and rinsed with ultra-pure grade water.  
A blank sample was included corresponding to each set of digest. An internal standard was 
added before digestion instead of during ICP-MS analysis to compensate for possible aerosol 
losses on opening the bomb or for incomplete transfer of the digest. The experiment was 
repeated three times and an average of the results used for the final data analysis. 
Table 6. Paired tissue and serum tumour groups from 55 patients with brain tumours 
Tumour Group Number of Patients 
Glioblastoma Multiforme 21 
Meningioma I 6 
Meningioma II 13 
Meningioma III 1 
PNET with glial differentiation 1 
Medulloblastoma 1 
Glioneuronal with PNET component 1 
Gliosarcoma 2 
Oligoastro III / GBM 1 
Lymphoma 3 
Oligo III 1 
Schwannoma 2 
Fibromyxiod tumour 1 
Normal Brain 1 
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4.2.5 Certified Reference Materials (CRMs) 
The quality of the analysis was ensured by the use of three certified reference materials, BCR-
185R Bovine liver (15g UoM)-Trace Elements (LGC Standards, Middlesex, UK), NRCTORT-2 
Lobster hepatopancrease (35g UoM) - Trace elements and methyl-mercury (LGC Standards, 
Middlesex, UK), NRCDOLT-4 Dogfish liver (25g UoM) -Trace elements (LGC Standards, Middlesex, 
UK).  
4.2.6 ICP-MS Analysis 
Tune A 10 ppb was prepared by taking 10 mg/L to prepare 1L of 10ppb using the formula: 
  C1V1 = C2V2 therefore (10 000ppb)V1 = (1000 mL) (10ppb) 
   V1= 1 mL 
1 mL of the 10 ppb Tune A was added to a 1Litre volumetric flask using an Eppendorf pipette. 
The flask was filled to mark with 2% nitric acid solution. Accuracy with the pipette was taken to 
make sure the Tune A was at 10 ppb to ensure accurate calibration.  
Calibration standards were prepared using a multi-element standard by diluting 100 µL of 10 
µg/µL to 10 mL with 2% nitric acid, giving a final volume of 100 ng/µL. From the 100 ng/µL 9 
different amounts ranging from 10, 30, 50, 70, 100, 300, 500, 700 and 1000 µL were taken and 
added to 9 separate 10 mL polyethylene tubes (previously sterilised in 20 % nitric acid for 24 hrs 
and rinsed in ultra-pure grade water) along with 100 µL of Bi (Internal standard) and made up 
to 10 mL with 2 % nitric acid.  
A 100 µL of serum from each sample was added to 10 mL polyethylene tubes (Sterilised in 20% 
nitric acid for 24 hrs and rinsed in ultra-pure high grade water) and 100 µL of Bi (Internal 
standard) added before ICP-MS analysis. Three biological replicates of tissue and serum were 
analysed in triplicates and run alongside calibration standards, CRMs, reagent and digestion 
blanks for quality control on a Thermo X-Series ICP-MS instrument.  
The machine was run with vacuum pump speed 1000-Hz, Exp. 2.7 x 102 mbar, Ana: 1.5 x10-7, 
Load: 0.92A. Argon pressure was between 90-100 psi. Chiller was set for a water temperature 
of 20°C. Nebuliser pressure was between 1.5-2.0 bar. Sample uptake time 40s, Washout time 
60s, and Acquisition mode: Pulse counting. 
Astro III 1 
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4.2.7 Epidemiological Study 
Epidemiological data from 55 patients with different types of brain tumours shown in Table 6 
was compiled based on tumour histology, sex, and date of birth, date of first diagnosis and date 
of death. This data was used to investigate any correlations and relationships between type of 
tumour and age and type of tumour and gender. Where information relating to whether a 
patient is alive or dead is not given, the date of first diagnosis is used to work out the age. The 
date of first diagnosis is used to calculate the age at first presentation.  
4.2.8 Statistical Analysis 
Data generated was converted to mg/kg from ppb and analysed using R programming statistical 
software (R Development Core Team, Austria). The concentrations of the elements in parts per 
billion were converted to micrograms per millilitre using the following; 1 µg/mL = 1000 ppb; 1 
ppb = 0.001 µg/mL. 
4.3 Results and Discussion  
4.3.1 Brain tissue 
The elemental distribution of the four elements Mg, Fe, Cu, and Zn in the brain tumour tissue 
samples was analysed using R statistical software. The statistical tests used were checked to see 
if the data fit the model using diagnostic tests. The data used for the analysis was an average 
from three biological replicates analysed in triplicates. Three groups of tumours, glioblastoma 
multiforme (GBM, n = 21), meningioma I (men, n = 6) and meningioma II (MEN, n = 13) were 
grouped based on their histological classification, whilst the other group OTHER (OTH, n = 15) 
comprised of different types of tumours because their numbers were too small (Table 6) to make 
up a significant group. The proportions showing the distribution of the five elements in the four 
groups were assessed (Figure 29) with the following average concentrations, meningioma I 
(7.908 µg/mL), meningioma II (4.052 µg/mL), GBM (4.345 µg/mL) and OTHER (4.052 µg/mL). An 
overview picture of the concentrations of the five elements across the four groups is shown in 
the plot below (Figure 28).  
[87] 
 
 
Figure 28. Plot showing the concentrations of the five elements Mg, Fe, Cu, Zn and Rb across the four groups 
in tissue samples. The four groups are colour coded as shown by the key. The elements Cu, Rb and Zn have 
the lowest concentrations across the four brain tumour groups, whilst Fe and Mg have relatively higher 
concentration with outliers represented by the coloured dot and the average by the horizontal line across 
the box. The whiskers represent variability outside the upper and lower quartiles.  
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Figure 29. Plot showing the distribution of elemental concentrations of Mg, Fe, Cu, Zn and Rb in the four 
groups glioblastoma, meningioma I, meningioma II and OTHER (consisting of various types of tumours) in 
tissue samples. 
 
Magnesium (Mg) 
There was a significant difference between the distribution of Magnesium (Mg) in the four 
groups (F3, 51= 8.196, P=0.001), Glioblastoma (GBM) (mean = 4.504 µg/mL), Meningioma I (men, 
(mean = 23.740 µg/mL), Meningioma II (MEN, (mean = 10.107 µg/mL) and OTHER (OTH, (mean 
= 10.209 µg/mL) based on the ANOVA test as shown in (Figure 30). A TukeyHSD test was used 
to explore the differences between the groups which are shown in (Table 7).  
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Table 7. Results from the TukeyHSD test showing the differences between the four brain tissue tumour 
groups based on the differences between their means with the lower and upper values in the group and 
their associated P values. Where P=< 0.05 represents a significant difference. 
GROUP Difference Lower Upper P-Value 
men-GBM 19.236 8.837 29.634 0.001 
MEN-GBM 5.602 -2.295 13.500 0.247 
OTH-GBM 5.705 -2.013 13.423 0.215 
MEN-men -13.633 -24.776 -2.490 0.010 
OTH-men -13.530 -24.547 -2.514 0.010 
OTH-MEN 0.102 -8.593 8.798 0.999 
 
The residuals of the data showed a normal distribution using a QQ-plot whilst heteroscedasticity 
was checked using the Levene’s test (F3, 51 = 2.369, P = 0.081) for homogeneity which showed 
uniform variance.   
 
Figure 30. Plot showing the concentration of Mg in four brain tissue tumour groups glioblastoma (GBM), 
Meningioma I (men), Meningioma II (MEN and OTHER (OTH). 
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Iron (Fe) 
The element concentrations of iron between the four groups did not have a normal distribution. 
The Kruskal-Wallis test which is a nonparametric test was used to evaluate differences in the 
concentrations of the element in the four groups. This test is analogous of a one-way ANOVA. 
There was no Significance difference between the iron concentration in the four groups (X2 = 
3.564, DF = 3, P = 0.312). The median iron concentration across the groups were Glioblastoma 
(GBM) = 8.526 µg/mL, Meningioma I (men) = 16.116 µg/mL, Meningioma II (MEN) = 6.863 µg/mL 
and OTHER (OTH) = 5.364 µg/mL see (Figure 31). 
 
Figure 31. Plot showing the tissue concentration of Fe in four brain tumour groups, GBM (Glioblastoma), 
men (Meningioma I), MEN (Meningioma II) and OTH (OTHER, made up of various types of tumours shown 
in Table 3).         
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Copper (Cu) 
An analysis of variance (ANOVA) showed no Significance difference between the concentrations 
of copper (F3, 51 = 2.771, P = 0.05) between the four groups with mean copper concentrations of 
Glioblastoma (GBM) = 0.018 µg/mL, Meningioma I (men) = 0.044 µg/mL), Meningioma II (MEN) 
= 0.008 µg/mL and OTHER (OTH) = 0.023 µg/mL as shown in (Figure 32).  
 
Figure 32. Plot showing tissue copper concentration between Glioblastoma (GBM), Meningioma I (men), 
Meningioma II (MEN) and OTHER (OTH) made up of different types of brain tumours shown in table 3. 
The data followed a normal distribution with uniform variance and the model was appropriate 
for the data which was checked using a QQ-plot and Levene’s test for homogeneity (F3, 51 =2.072, 
P = 0.115).    
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Zinc (Zn) 
The concentration data of zinc slightly deviated from a normal distribution and was transformed 
by raising it to the power 0.2 based on the BoxCox transformation data. The data was analysed 
using ANOVA and the results back transformed to reflect the true values.  
There was no Significance difference between the concentrations of zinc between the groups 
(F3, 51 = 2.299, P = 0.088). The mean concentration values of the four groups were, Glioblastoma 
(GBM) = 0.018 µg/mL, Meningioma I = 0.036 µg/mL, Meningioma II (MEN) = 0.019 µg/mL, OTHER 
(OTH) = 0.020 µg/mL) see (Figure 33). 
 
Figure 33. Plot showing tissue concentration of Zinc distribution between four brain tumour groups, 
Glioblastoma (GBM), Meningioma I (men), Meningioma II (MEN) and OTHER (OTH) consisting of various 
types of brain tumour shown in table 3. 
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The data showed homoscedasticity and back transformation was performed to provide accurate 
concentration values.  
4.3.2  Serum 
An investigation into the elemental distribution of Mg, Fe, Cu, and Zn between the four brain 
tumour groups, Glioblastoma, Meningioma I and II, and OTHER which consists of various other 
types of brain tumours was carried out in R using appropriate models checked using diagnostic 
tests which looked at normality and variance.  
Magnesium (Mg) 
There is a Significance difference in the concentration distribution of Mg in serum between the 
four brain tumour groups (F3, 51 =5.050, P = 0.003) using ANOVA, see (Figure 34). Meningioma II 
(mean=1.104 µg/mL, SE = 0.277) had on average 0.980 µg/mL less Mg concentration to 
Glioblastoma (mean = 2.084 µg/mL, SE = 0.169). There was no Significance difference between 
the remaining groups as seen in (Table 8).  
Table 8. Mg concentration results from a TukeyHSD multiple comparison test of serum brain tumour group 
means with 95% family wise confidence level. 
GROUP Difference Lower Upper P-Value 
MEN-GBM -0.980 -1.716 -0.243 0.004 
OTH-GBM -0.401 -1.121 0.318 0.455 
MEN-men -0.047 -1.086 0.992 0.999 
OTH-men 0.530 -0.496 1.558 0.522 
OTH-MEN 0.578 -0.232 1.389 0.243 
Men-GBM -0.932 -1.902 0.037 0.063 
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Figure 34. Plot showing Mg concentration in serum across the four brain tumour groups, GBM, men, MEN, 
and OTH. There is a Significance difference between Meningioma II and Glioblastoma. 
 
Iron (Fe) 
There was a Significance difference between the concentrations of Fe in the four groups (F3, 51 
=3.748, P = 0. 016) see Figure 35. The main difference was between Meningioma II (mean = 
0.186 µg/mL, SE = 0.016) and Glioblastoma (mean = 0.239 µg/mL, SE = 0.01). The remaining 
groups showed no Significance difference. (Table 9) shows the results from the TukeyHSD 
multiple comparison test. 
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Table 9. Fe results from a TukeyHSD multiple comparison test of serum brain tumour group means with 95% family 
wise confidence level. 
GROUP Difference Lower Upper P-Value 
men-GBM -0.043 -0.102 0.015 0.211 
MEN-GBM -0.053 -0.097 -0.008 0.013 
OTH-GBM -0.024 -0.067 0.019 0.454 
MEN-men -0.009 -0.072 0.053 0.978 
OTH-men 0.019 -0.042 0.081 0.842 
OTH-MEN 0.028 -0.020 0.077 0.415 
 
 
Figure 35. Plot showing the distribution of Fe concentration in serum between the four brain 
tumour groups. There is a Significance difference between GBM and Meningioma II (MEN). 
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Copper (Cu) 
The copper concentration between the four groups showed no Significance difference 
(F3, 51 =1.336, P = 0.272) based on an analysis of variance ANOVA, see (Figure 36) 
 
Figure 36. Plot showing the distribution of Cu concentration in serum between the four brain tumour 
groups. There is no Significance difference between the groups. 
The mean concentrations between the groups GBM (mean = 0.012 µg/mL, SE= 0.0008), 
Meningioma I (mean = 0.009 µg/mL, SE = 0.001), Meningioma II (mean= 0.011 µg/mL, SE = 0.001) 
and OTHER (mean = 0.012 µg/mL, SE = 0.001).  
Zinc (Zn) 
There is a Significance difference in the concentration of zinc between the groups (F3, 51 = 3.274, 
P = 0.028) based on ANOVA.  A comparison of the different groups using TukeyHSD test Table 
10 shows where the differences lie between the groups. The test shows a Significance difference 
between Meningioma II (mean = 0.001 µg/mL, SE = 0.0001) and Glioblastoma (mean = 0.002 
µg/mL, SE = 0.0001, P = 0.020). There was no difference between the rest of the groups, see 
(Figure 37).  
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Figure 37. Plot showing the distribution of Zn concentration in serum between the four brain tumour 
groups. There is a Significance difference between Meningioma II and GBM groups. 
 
Table 10. Output table showing the results of Zn concentration from a TukeyHSD multiple comparison of 
group means 95% family-wise CI. The result show a Significance difference between meningioma II and 
GBM. 
GROUP DIFF LWR UPR P-VALUE 
 
MEN-GBM -0.00037 -0.00101 0.00026 0.40 
MEN-GBM -0.00054 -0.00103 -0.00006 0.02* 
OTH-GBM -0.00016 -0.00063 0.00031 0.81 
MEN-MEN -0.00017 -0.00085 0.00051 0.91 
OTH-MEN 0.00022 -0.00045 0.00090 0.82 
OTH-MEN 0.00039 -0.00015 0.00092 0.22 
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4.3.3 Brain Tumour Tissue and Serum Comparative study 
A comparison of the results from the analysis of tissue and serum was done based on the four 
groups Glioblastoma, Meningioma I and II, and OTHER (comprising of various types on tumours 
shown in (Table 6). A direct comparison of tissue and serum concentrations was done and 
showed a Significance difference (X2 = 48.246, DF = 1, P = 0.001) using the Kruskal-Wallis test 
(Figure 38). Serum samples had relatively lower concentrations compared to tissue. The starting 
amounts of the two samples, tissue and serum were 30 g and 100 µL respectively. 
A comparison of the results to check if the two groups, tissue and serum had the same elemental 
distribution across the four brain tumour groups was investigated.  
 
 
Figure 38. Comparison of tissue and serum elemental concentrations across the four brain tumour groups. 
Each brain tumour group consists of a total of all the four elements, Mg, Fe, Cu, and Zn combined together. 
There was a Significance difference in the concentration distribution of Mg in both tissue and 
serum, with main differences between meningioma I and all the groups (P = 0.001) in tissue, see 
(Table 7), whilst serum had meningioma II and glioblastoma (P = 0.004) see (Table 8). The rest 
of the elements showed no Significance difference in their distribution in both tissue and serum 
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shown in (Table 7) and (Table 8) with slightly higher concentrations associated with low grade 
tumour and lower concentrations with high grade tumours.  
4.3.4 Epidemiology study 
Meta data from Biobank of 55 brain tumour patients was collated (Table 11).  
Table 11. Meta data comprising of history from 55 brain tumour patients. The data was collated based on 
diagnosis,         gender, date of birth (D.O.B), date of diagnosis (D.O.DI), date of death (D.O.D), age and tumour 
group for statistical analysis. 
Diagnosis Gender D.O.B D.O.DI D.O.D Age Group 
 
GBM F 20/11/1975 17/07/2009 20/03/2010 35 GBM 
Lymphoma M 09/08/1959 21/07/2009 02/10/2009 50 OTH 
GBM F 08/03/1965 22/07/2009 31/07/2010 44 GBM 
GBM M 03/09/1929 02/09/2009 03/12/2009 80 GBM 
Meningioma II F 20/09/1916 03/09/2009 22/07/2011 93 MEN 
Meningioma II F 16/02/1930 10/09/2009 Alive 85 MEN 
GBM M 08/12/1940 10/09/2009 17/09/2010 70 GBM 
GBM M 18/11/1943 01/10/2009 16/05/2010 66 GBM 
Meningioma I F 22/05/1932 02/10/2009 Alive 83 men 
Meningioma I F 11/07/1967 06/10/2009 Alive 48 men 
Meningioma I F 24/11/1940 08/10/2009 Alive 75 men 
GBM M 27/09/1947 15/10/2009 13/03/2010 63 GBM 
GBM M 28/12/1947 16/10/2009 10/03/2010 63 GBM 
Glioneuronal with PNET 
component 
F 18/11/1960 21/10/2009 17/06/2010 50 OTH 
Meningioma I F 28/04/1928 22/10/2009 Alive 87 men 
GBM F 21/12/1972 04/11/2009 16/10/2014 42 GBM 
Fibromyxoid tumour M 09/05/1991 11/11/2009 Alive 24 OTH 
GBM F 08/02/1940 19/11/2009 27/07/2010 70 GBM 
Gliosarcoma F 07/07/1971 01/04/2009 29/03/2010 39 OTH 
GBM M 02/07/1980 26/11/2009 19/01/2010 30 GBM 
GBM with oligo 
component 
M 29/12/1956 14/12/2009 15/03/2011 55 GBM 
Gliosarcoma M 04/06/1957 16/12/2009 19/02/2012 55 OTH 
Meningioma II M 27/05/1934 17/12/2009 Unknown 75 MEN 
Astro III F 31/07/1938 17/12/2009 18/05/2011 73 OTH 
Oligo III M 15/09/1980 18/12/2009 21/10/2011 31 OTH 
GBM with oligo 
component 
M 31/08/1934 13/01/2010 01/04/2010 76 GBM 
GBM M 13/08/1935 19/01/2010 06/03/2010 75 GBM 
Meningioma II F 05/08/1947 22/01/2010 30/08/2011 64 MEN 
Meningioma II F 13/02/1945 22/01/2010 Alive 70 MEN 
Meningioma I F 10/12/1957 04/02/2010 Alive 58 men 
Lymphoma M 16/02/1964 04/02/2010 16/03/2010 46 OTH 
GBM F 01/08/1938 05/02/2010 19/04/2010 72 GBM 
GBM F 17/11/1937 23/03/2010 02/08/2010 73 GBM 
Meningioma I F 28/09/1962 25/03/2010 Alive 53 men 
Meningioma I F 08/04/1948 31/03/2010 Unknown 62 men 
Meningioma I F 28/05/1956 01/04/2010 Alive 59 men 
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GBM M 05/11/1942 08/04/2010 05/10/2010 68 GBM 
Meningioma I F 18/08/1957 14/04/2010 Alive 58 men 
GBM M 22/06/1936 18/03/2010 05/05/2010 74 GBM 
Meningioma I F 08/02/1959 20/04/2010 Unknown 51 men 
Oligoastro III / GBM F 15/06/1950 23/04/2010 11/07/2010 60 GBM 
GBM M 23/01/1943 11/05/2010 05/11/2010 67 GBM 
GBM F 12/01/1948 17/05/2010 17/12/2010 62 GBM 
Medulloblastoma F 25/08/1988 18/05/2010 12/04/2011 22 OTH 
PNET with glial 
differentiation 
F 27/02/1982 19/05/2009 10/05/2011 29 OTH 
GBM M 18/10/1940 21/05/2010 13/04/2011 71 GBM 
GBM M 21/07/1941 25/05/2010 13/08/2011 70 GBM 
Meningioma I M 17/04/1971 26/05/2010 Alive 44 men 
Meningioma I F 20/02/1967 27/05/2010 Alive 48 men 
Meningioma I F 29/11/1958 12/08/2010 Alive 57 men 
Normal brain F 29/11/1958 12/08/2010 Alive 57 OTH 
Meningioma II M 27/06/1964 07/09/2010 Unknown 46 MEN 
Meningioma III F 05/08/1947 22/01/2010 30/08/2011 67 OTH 
Schwannoma F 30/11/1976 13/09/2011 31/01/2014 38 OTH 
Lymphoma M 06/03/1949 24/10/2013 Alive 66 OTH 
Schwannoma F 05/01/1960 12/06/2014 Alive 55 OTH 
           
The data showed a normal distribution with uniform variance. An analysis of variance was 
carried out to investigate the relationship between tumour group and gender based on age. 
There was no Significance difference between the four brain tumour groups based on gender, 
(F3, 1 =0.002, P = 0.960) Figure 39. The interaction between the type of tumour, gender and age 
had no Significance difference (F3, 1 = 1.829, P = 0.154). The relationship between gender, tumour 
group and age was as follows; Female: GBM (mean = 57 years), Male: GBM (mean = 66 years), 
Female: Meningioma I (mean = 62 years), Male: Meningioma I (mean = 44 years), Female: 
Meningioma II (mean = 78 years), Male: Meningioma II (mean = 61 years), Female: OTHER (mean 
= 48 years) and Male: OTHER (mean = 45 years).  
There was a Significance difference between the groups, glioblastoma, meningioma II and 
OTHER based on age (F3, 1 = 5.898, P = 0.001) (Figure 40). The TukeyHSD multiple comparison 
Table 12 shows the differences based on their P-values. The main difference was between 
glioblastoma and the various tumours in the group OTHER, where the mean age of tumour 
development is glioblastoma (mean = 63 years) and OTHER (mean = 47 years) and OTHER with 
meningioma II, OTHER (mean = 47 years) and meningioma II (mean = 72 years).  
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Figure 39. . Plot showing the relationship between gender and age across the four brain tumour groups, 
glioblastoma, meningioma I (men1), meningioma II (MEN2) and OTH (comprising of various types of brain 
tumours). There was no Significance difference. 
  
 
Figure 40. Plot showing the differences between the four tumour groups, glioblastoma, meningioma I, 
meningioma II and OTHER based on age. 
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Table 12. Output results from a TukeyHSD multiple comparison analysis showing significant differences 
between brain tumour groups against different age groups. An asterix signifies a significance difference.  
GROUP DIFF LWR UPR P-VALUE 
 
MEN-GBM -2.769 -16.131 10.592 0.946 
MEN-GBM 9.167 -8.425 26.758 0.514 
OTH-GBM -16.200 -28.990 -3.410 0.007* 
MEN-MEN 11.936 -6.915 30.787 0.343 
OTH-MEN -13.431 -27.904 1.043 0.778 
OTH-MEN -25.367 -43.817 -6.917 0.003* 
 
Table 12 shows the tumour groups that had a significant elemental distribution based on age. 
The actual distribution of brain tumour group against age is given in Figure 40. The role played 
by trace metals has been extensively studied to investigate the pathology of many different 
types of diseases over the years. Empirical data has shown correlations between development 
and progression of disease. A comparison of Mg, Fe, Cu, and Zn was carried out in brain tissue 
and serum from 55 patients with different types of brain tumours. The concentration levels of 
the five elements in brain tissue and serum was assessed separately and compared against the 
four groups. There were significant differences in the distribution of these elements within the 
same sample type (Tissue and/or Serum) and between tissue and serum across the four brain 
tumour groups.  
Magnesium (Mg) 
Magnesium levels have been shown to differ in blood and serum samples of patients with a 
range of diseases. The distribution of magnesium in the blood of patients with active 
schizophrenia was shown to be an important cofactor. The study by Mehmet et al. [130], showed 
that people with active schizophrenia had lower than normal Mg levels compared to a control 
group and that higher levels of Mg was in schizophrenia  patients in remission. In a study to 
evaluate trace elements in patients with liver cirrhosis and to assess their association with 
severity of the disease, deficiency in Mg was found in chronic liver disease and also associated 
with peripheral insulin resistance [131]. The study assessed one hundred and fifty cirrhotic 
patients of either sex ranging in age from 20-70 years and the results compared with fifty age 
and sex matched healthy control subjects. Several early publications suggested that mineral 
deficiencies or excesses influenced cancer. Rodale et al. implicated deficiencies in Mg with 
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cancer [132]. Their study pronounced the beneficial effect of eating dried beef liver on stamina 
and the part played by liver desiccation in cancer. Castiglioni and Maier investigated the 
relationship of magnesium and cancer [133]. The aim of their study was to review current 
knowledge concerning the contribution of magnesium to tumorigenesis, from transformed cells 
to animal models data from human studies. Tumour cells were reported to accumulate 
magnesium and increased intracellular levels of the cation seemed to confer a metabolic 
advantage to the cells. This was also thought to contribute to alterations of the genome, and 
promote the acquisition of an immortal phenotype. In mice models, low magnesium was seen 
to limit and foster tumorigenesis, since inhibition of tumour growth at its primary site is 
observed in the face of increased metastatic colonisation. They also reported epidemiological 
study findings as showing magnesium deficiency as a risk factor from some types of human 
cancers. Impaired magnesium homeostasis was reported in cancer patients who had 
complications in therapy with some anti-cancer drugs.   
The results from the analysis of brain tissue in this study, from patients with glioblastoma, 
meningioma I, meningioma II and various other types in the group OTHER, showed a very low 
concentration of Mg with the most aggressive types of cancer, glioblastoma 4.504 µg/mL and 
meningioma II 10.107 µg/mL. The cancers in the group OTHER were mostly made up of high 
grade tumours which also had a relatively low Mg concentration, 10.209 µg/mL compared to 
the low grade meningioma I, which had very high concentrations of Mg, 23.740 µg/mL. The 
results suggests a negative correlation of Mg concentration with tumour aggressiveness across 
all the brain tumour groups under investigation.  
There was a Significance difference between the Mg concentration in serum between 
meningioma II and glioblastoma. Glioblastoma patients had 0.980 µg/mL more Mg compared to 
meningioma II. The rest of the groups showed no Significance difference in their Mg distribution 
in serum. However the Mg concentration in serum was relatively low for all the groups 
compared to the tissue levels. Magnesium intake may be prophylactic against initiation of 
neoplasms and could be used as a candidate in drug design. Several studies have suggested the 
use of Mg to prevent against the initiation of cancer [130, 134, 135].   
A comparison of the distribution of Mg in tissue groups and serum showed a Significance 
difference. Tissue samples on average had very high levels of Mg compared to serum, Tissue 
(GBM = 4.504 µg/mL, meningioma I = 23.740 µg/mL, meningioma II = 10.107 µg/mL, OTHER = 
10.209 mg/kg) whilst serum had (GBM = 2.084 µg/mL, meningioma I = 1.152 µg/mL, meningioma 
II = 1.104 µg/mL and OTHER = 1.682 µg/mL). 
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Zinc (Zn) 
Zinc is an important essential element that has many functions in mammals, required for the 
activity of over 100 enzymes. Zinc has been associated with tumour development and classified 
as carcinogenic in both humans and experimental animals [136]. There has been some 
controversy over its role as a carcinogenic agent however zinc is known to affect catabolic and 
anabolic enzymes and as such linked to carcinogenesis.  Deficiency in zinc has been well 
correlated with a site-specific cancer of the oesophagus shown by epidemiological studies in 
South Africa, Iran, China and Russia [137]. Some of the links connected to its role in 
carcinogenesis involve its role in RNA and DNA polymerase, inhibitory effects on 
phosphodiesterase and the activation of membrane bound adenyl cyclase [136]. Zinc plays an 
essential role in the growth of normal and malignant tissue, normal immune function and 
superoxide dismutase, an enzyme that clears cells of toxic and mutagenic oxygen radicals [137]. 
Zinc deficiency was observed to play a role in the inactivation of p53, a tumour suppressor gene 
associated with many tumours [138]. Zinc excess in contrast to tumour associated zinc 
deficiency has been linked to tumour incidence in the UK, where zinc content of British soils has 
been directly correlated with the incidence of gastric cancer in several regions [139]. High levels 
of zinc in pooled blood bank specimens from a study of 17 countries showed a relationship 
between high zinc serum levels with mortality from cancers of the breast, lung, prostate, 
leukaemia, skin, ovary, bladder and colon [140]. High levels of zinc, around 300 ppm were 
reported in a study by Mulhern to decrease tumour incidence and increase the latent period of 
PYB6 fibrosacroma cells induced in mice [124].  
The results from the analysis of zinc in tissue showed no Significance difference across the four 
groups. The levels of zinc in the four brain tumour groups were relatively low. Zinc deficiency 
has been associated with tumour development [136, 137] and as such is expected across the 
four brain tumour groups. There was a Significance difference between zinc concentrations in 
serum between glioblastoma and meningioma II with the rest of the groups showing no 
Significance difference. However, all the four brain tumour groups showed very low zinc 
concentration compared to normal levels reported in [49, 57, 129], see (Table 5). 
Iron (Fe) 
Iron is an essential element for maintaining the structure and functioning of the CNS, and the 
relationship of Fe status to brain function, cognition, behaviour and disease has been the subject 
of considerable research [6, 49, 57, 141-144]. Iron catalyses hydrogen peroxide conversion to 
free radical ions which are reactive chemical species that attack cellular membranes leading to 
DNA strand breaks through Fenton-type reaction processes, inhibiting enzymes, depolymerising 
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polysaccharides, and initiating lipid peroxidation [129, 145, 146]. Iron has been linked to the 
promotion of inflammation and increase in cancer cell growth [115].  The deficiency of iron is 
one of the most prevalent nutritional factor in many diseases worldwide [142]. In studies by 
Yokoi [58, 142, 147] numerical method were used for estimating iron requirements using 
population based nutritional indicators. These indicators looked at the prevalence of inadequate 
iron status and distribution of iron intake in a certain population. The 2003-2007 indicators from 
the National Health and Nutrition Surveys held annually by the government of Japan showed, 
less than 30 ng/mL of serum ferritin was considered as indicating inadequate iron status [142]. 
These indicators and levels can be used in other fields such as cancer in monitoring significant 
iron changes in serum which could suggest reoccurrence in remission cases.   
In this study there was no significant difference between the iron concentrations in brain tissue 
across the four brain tumour groups, which all showed very low levels of iron concentration in 
comparison to reported results from studies that looked at normal iron concentrations in a 
population. The median iron concentrations across the four groups were, glioblastoma 8.526 
µg/mL, meningioma I 16.116 µg/mL, meningioma II 6.863 µg/mL and OTHER 5.364 µg/mL. 
Generally the more aggressive high grade tumours had the lowest amount of iron concentration. 
Serum samples showed a significant difference between the iron concentrations in two groups. 
The main difference was between meningioma II (mean = 0.186 µg/mL) and glioblastoma (mean 
= 0.239 µg/mL). However, all samples had relatively low iron concentrations in comparison to 
normal controls reported in the literature [142].   
Copper (Cu) 
Copper is most abundant in serum as part of ceruloplasmin an oxidative enzyme which is a α2-
glicoprotein with molecular weight of about 150 000. The remaining copper found in the body 
is an ionic form found loosely bound to albumin [116]. The normal intake of copper is about 2 
mg/day with the majority of it rapidly converted in the liver to ceruloplasmin. In the cell, copper 
is found in the mitochondria, and the adult body contains about 100 to 150 mg with the highest 
concentration in liver, kidney, heart, brain and pancreas. Excretion through urine accounts for 
about 10 to 60 µg/day.  
Copper has been implicated in a number of diseases that involve both elevated levels and 
deficiency. Copper deficiency have been widely reported in diseases such as kwashiorkor, sprue, 
celiac, marasmic infants, infants with Mentes kinky hair syndrome [116].  Elevated levels of 
copper in serum have been associated with multiple sclerosis, infection, myocardial infarction, 
schizophrenia and chronic liver disease [148]. There was a significant difference in serum copper 
levels reported by Hrgovcic et al. in a study of 236 patients with malignant lymphomas which 
[106] 
 
excluded Hodgkin’s disease. Their study showed elevated copper levels in patients before 
therapy and a significant decrease after therapy, with normal levels during remission [149].  
Changes in the serum levels of copper were used as a premonitor of clinical relapse. The results 
from a study of 28 patients with Hodgkin’s disease showed that values between 71 and 131 
µg/100 mL were observed in 5 patients in complete remission, 172 to 426 µg/100 mL were from 
20 patients with active disease and 2 patients with active disease exhibited normal levels of 69 
to 133 µg/100 mL. The normal levels were taken from 117 persons without the disease [149].  
Elevated serum copper levels have been reported in a number of cancer studies which looked 
at bronchogenic carcinoma, squamous cell carcinoma of the larynx, cervical and other 
gynaecological cancer, bladder and breast, but not in prostate cancer [116].  
There was no significant difference in the copper levels in brain tissue across the groups, which 
were all relatively low. Generally the more aggressive tumour type glioblastoma, meningioma II 
and OTHER (made up of most high grade tumours) had relatively low but not significant levels 
compared to low grade tumour meningioma I. However, serum copper levels showed a different 
trend. Whilst there was no significant difference between the serum copper levels across the 
four groups, the less aggressive tumour, meningioma I had the lowest levels (0.009 µg/mL) 
compared to the more aggressive high grade types which all had similar levels around (0.012 
µg/mL). The observation in serum follows the general trend seen in most studies [116], which 
show high copper concentration in malignant cancers compared to low grade tumours. The 
general observation is that there is copper deficiency in both serum and tissue for most cancers 
compared to controls [116, 130, 149, 150]. In brain, a study of trace elements in 22 malignant 
glioma patients showed significantly low copper levels in serum compared to controls from 22 
healthy patients [130].  
Comparative Study of Serum vs Tissue 
The results from the comparative study shows no significant difference in the distribution of the 
four elements across the brain tumour groups between tissue and serum. Serum samples 
generally showed slightly low concentrations of the elements in comparison to tissue. This 
difference could be attributed to high metabolic activities in tissue samples or to the differences 
in the initial sample volumes (serum = 100 µL and tissue 30 mg) used for the analysis. The overall 
pattern of distribution of all the four elements was similar, where high grade tumour groups 
generally had low concentrations of the elements compared to low grade tumours which had 
slightly higher concentrations. The overall picture is that the four brain tumour groups 
investigated show deficiencies in Mg, Fe, Cu, and Zn compared to normal levels reported in other 
studies [116, 130, 149, 150]. These elements can be used as potential biomarkers in the 
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diagnostic segregation of neoplastic tissue and serum from normal brain tissue and serum. 
Serum has an added advantage of being used as a less invasive monitoring tool for patients in 
remission as their serum levels go back to normal after successful treatment [85].  
Epidemiological study  
A number of studies have shown that cancer is generally more common in old age, with the five 
most common cancers in males and females (breast, lung, prostate, bowel and skin) varying 
considerably by age group [2]. Brain tumours do not follow this pattern, the frequency across all 
age groups is similar including children, teenagers and young adults [24]. However some types 
are more common in certain age groups such as medulloblastoma, this tumour typically affects 
young patients and treatment of the diseases needs to consider implications on the developing 
brain [151]. Tumours such as GBM appear more frequently in patients over 65 years than any 
other age bracket. The reason for this is still unknown, however age remains the most powerful 
prognostic factor among GBM patients [101]. There was no significant difference between the 
distribution of brain tumour type and gender which agrees with other studies as shown in 
(Figure 41). However whilst there was no significant difference, in most cases males seemed to 
be affected by brain tumours much earlier compared to women. Kabat et al. investigated 
whether steroid hormones play a role in the aetiology of gliomas [133]. They suggest based on 
epidemiological data that females enjoy a relative protection from glioma onset during 
premenopausal years. Some gliomas including GBM express oestrogen receptors (ER), such as 
ERβ and aromatase. Aromatase is the enzyme responsible for the conversion of testosterone to 
estradiol. Estradiol and a number of selective oestrogen receptor modulators have been shown 
through experiments to inhibit proliferation of gliomas and induce cell death. Animal models 
have also shown that female mice transplanted with GBM cells grow at a slower rate compared 
to males [133].      
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Figure 41. Results from an epidemiological study of the 20 most common cancer in the UK in 2011.  The plot 
shows no significant difference between males and females affected by brain tumours. This research was 
carried out by the Office of National Statistics and published in Cancer Research UK [24]. 
There was a significant difference between the types of tumour a person would mostly likely get 
with age. The main differences were between glioblastoma and the various tumours in the group 
OTHER, where the mean age of tumour development was glioblastoma (mean = 63 years) and 
OTHER (mean = 47 years), and OTHER with meningioma II, OTHER (mean = 47 years) and 
meningioma II (mean = 72 years). The reasons why certain types of tumours present more in a 
particular age group than the other is still unknown. Tumours such as medulloblastoma seem to 
present more in children whilst GBMs are frequently found in adults. This study shows that it is 
highly likely for people in their late 40s both male and females to be diagnosed with other types 
of brain tumours such as gliosarcoma, Oligo astrocytoma etc. (making up the group OTHER) 
compared to glioblastoma and meningioma II, which are more common at a later stage in life at 
mean age 63 and 72 years respectively. The study shows a significant difference between all the 
brain tumour groups compared to the reported normal levels for the elements under 
investigation. The association of age, gender and brain tumour type can be used in guiding 
people to engage in activities and life styles that are known to reduce the risk of cancer.   
The use of ICP-MS for the analysis of complex matrices from biological materials requires 
following strict methods that have been validated. The digestion of biological materials in 
conventional methods requires a relatively high amount of strong mineral acids. This is 
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particularly problematic when analysing metals in ultra-trace concentrations due to the acids 
producing high blank values [6]. The effects of sample preparation steps on the quality of the 
results are widely known [143]. Sample preparation steps should be coupled with the 
appropriate digestion procedure and its effective combination with the separation and 
detection method to minimize the effects of preparation steps. One of the widely known 
problem is that the amount of total dissolved solids in ICP-MS is limited to about 0.5% to avoid 
blockage of the sampling cone and to reduce signal instabilities [152]. To address this problem 
the sample digest is diluted with acid prior to ICP-MS which introduces analytical uncertainties 
and relatively high detection limits relative to the biological sample [6, 72]. The most common 
problem faced by ICP-MS and similar techniques is contamination. This problem usually dictates 
the choice of method used for the analysis of a particular matrix or sample. Samples with an 
element such as copper can accrue contamination from air, dust, vessels or reagents during 
sampling and preparation. In such instances methods such as colorimetric and gravimetric for 
the measurement of copper are simple and easy to use with very low costs [144]. Their 
usefulness is countered by extreme situations were sensitivity is essential which does not match 
ICP-MS. The use of elemental species as diagnostic tools largely depends on the accuracy of the 
analytical method used to quantify elements with minimal error. Inaccurate measurement may 
have serious consequences to the patient’s treatment regime and care. 
4.4 Conclusion 
The study shows the potential role of trace elements in the body as diagnostic tools to monitor 
changes that could indicate relapse, active disease or remission using serum. The use of tissue 
samples for diagnosis using ICP-MS can potentially provide a quicker method of diagnosis 
between healthy and disease state with the ability of handling more than 150 samples in one 
run. Elemental profiling of disease is finding its place in medical diagnostics with more and more 
correlations being made related to changes in the biological materials such as serum, blood, 
urine etc. These changes with other symptoms can potentially be used to understand the 
mechanics of the disease at the elemental level, which could be helpful in drug design, assay 
development and life style choices with regards to diet and nutrition. The results from this study 
show a potential application of ICP-MS in brain tumour diagnosis, distinguishing between 
normal and cancerous tissue and serum. The advantages of using methods like ICP-MS is that 
they are less subjective and far less invasive when used with samples like serum, blood, urine 
etc., but require a significant level of care during sampling and processing. These two stages 
could be a potential source of error which might significantly affect the results. The biggest 
emphasis has been to ensure that investigations are carried out using procedures for sample 
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collection, preparation and measurement that are adequately validated to allow comparison 
within the same area of study.  
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Chapter 5 
5 Analysis of Brain Tumour Cell Lines using Raman and ATR-FTIR 
5.1 Introduction 
Vibrational spectroscopy is a non-destructive technique which can be used to determine 
important biochemical changes in biological material such as body fluids, tissue and cells. The 
concept of using vibrational spectroscopy as a medical diagnostic tool dates back to the 1950s, 
a time when infrared spectroscopy was in its infancy [151]. The technique took many years of 
intense effort to understand even the basic effects that confound Raman and infrared 
spectroscopy of cells and tissue and develop statistical methods to detect the often minute 
changes in spectra [153]. The increased computational power over the years coupled with 
fundamental theoretical underpinnings propelled spectral cytopathology (SCP, spectral 
diagnosis of cells) and spectral histopathology (SHP, spectral diagnosis of tissue) toward 
industrial applications in medicine [154]. SPH has gained a lot of momentum compared to SCP, 
mostly because standard histopathology is more straightforward, and parallel images from 
histopathology and SHP can be compared [154].  
Raman and Infrared spectroscopy provide a fast, reliable, specific, accurate and low-cost method 
for the analysis of biological material [94]. Insights into human disease are important in the 
development of treatments that are effective in broad patient populations. Models that 
resemble human disease with great accuracy are essential in understanding disease 
pathogenesis. Stem cells possess a capability of self-renewal and differentiation mechanisms 
which are ideal for generating disease models and obtaining the large quantities of cells needed 
for drug development and transplantation therapies [155]. Cell lines have been used as disease 
models, and can be derived from stem cells or isolated from diseased tissue. Cellular 
reprogramming has made it possible for pluripotent stem cells representing a variety of genetic 
diseases to be produced from patient tissue and used in experiments [156]. This is a relatively 
new and fast growing area and shows promise in the study of a wide range of diseases. 
A number of models in cancer studies utilise cell lines derived from the culture of a single cell 
and consist of cells with a uniform genetic makeup. In a study of stomach cancers, Yao et al. 
investigated apoptosis of single human gastric cancer cells using the human gastric carcinoma 
cell line SGC-7901 with Raman spectroscopy. The study induced apoptosis on the cells using a 
drug (5-FU) and acquiring Raman spectra. A comparison of the single gastric carcinoma cells and 
the induced apoptotic cells through scan excitation mode allowed the differentiation of the two 
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cells using principal component analysis (PCA). The major difference between apoptotic cells 
and the cancer cells was the reduction in intensity of vibrational bands generated by cellular 
lipids, proteins and nucleic acids from peaks at 782, 1092, 1320, 1340 and 1578 cm-1 [157]. This 
reduction in intensities correlates to a reduction in the molecules or functional groups 
represented by the vibrational bands. 
A study of biochemical changes in cervix and bladder cancer was investigated with FTIR 
spectroscopy. Two cell lines were used for this study, HeLa human cervix carcinoma and the 
5637 human bladder carcinoma cell line, coupled with multivariate statistics [158]. The 
investigation identified 16 peaks which were specific to the two cell lines, three groups for the 
5637 human bladder carcinoma cell line (5637A, 5637B, 5637C) and another for the HeLa human 
cervix carcinoma cell line. The study suggests vibrational spectroscopy and imaging are tools 
which can have a major impact in quantum molecular biology, biophysical chemistry and 
molecular medicine. Some of the challenges in the use of these techniques relate to the 
complexities that lie in the theoretical treatment and non-transparent interpretation of the 
changes, observed and their use as biomarkers of the diseased states [159].  
There are a number of techniques that can be used to monitor in vitro interactions among cells 
and their environment. The majority of traditional techniques for the analysis of cells require 
fixation or their lysis from substrates where they are fixed. The problem with these methods 
arise where the expanded cell cultures are required to be used for clinical implantation. Studies 
have focused on developing alternative methods for monitoring in vitro interactions among cells 
and their environment. A study by McManus et al. examined the capabilities of Raman 
spectroscopy to provide useful information on key biochemical markers within cells [160]. Their 
study highlights the capabilities of Raman spectroscopy with different laser spot sizes (532 and 
785 nm) for use as a non-invasive, rapid, and specific method to perform in situ analysis of 
primary bovine aortic endothelial cells (BAECs). The study showed notable spectral differences 
in DNA/RNA region from individual live cells placed on fused silica substrates and clusters of live 
cells placed on the same substrate, indicative of the relative cytoplasmic and nuclear 
contributions. The separation of cell clusters was due to spectral peaks that showed slight 
variations in the intensity of the phenylalanine peak (1004 cm-1) indicating variations in protein 
contribution. Other spectral differences seen resulted from other cellular components such as, 
proteins, lipids, nucleic acids and carbohydrates. Spectroscopic studies by Diem et al. showed 
cell-morphology-dependent effects, their study investigated the differences between cultured 
cervical HeLa cells and normal exfoliated cells from the human cervix [153]. The cultured cells 
had large thick nuclei which gave good infrared absorption spectra and exhibited strong protein, 
DNA, and RNA features. Their cytoplasm was thin and spread out with pronounced pseudopod 
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features that are common for cultured cells which give very scant spectra dominated by protein 
features and strong band distortions at the edges of the cells. The cytoplasm of exfoliated cells 
was stronger and exhibited pronounced glycogen features. Their condensed nuclei exhibited no 
DNA/RNA features. In this case a comparison of the two cells does not give you any helpful 
information that has medical value. 
Neurones which are directly involved in electrical transmission and information processing make 
up about 19 % of the nervous system and glial cells which primarily have a supportive role 
outnumber neurones 3 to 1, and in other places 10 to 50 times making up the large part of 
nervous tissue [147]. Glial cells have four subclasses, astrocytes, oligodendrocytes, ependymal 
and microglia [161]. Spectral changes between disease state or cell morphology can be difficult 
to distinguish especially when comparing samples that are heterogeneous, the differences could 
be a result of confounding variations of spectral features based mostly on morphological 
changes within the tissue or cell investigated [162]. A better comparison between normal and 
diseased tissue would be between samples belonging to the same group, such as cell type and 
subclass. Any variations between these groups could be attributed to the cell or tissue biological 
event.  
Astrocytes are both heterogeneous and pleomorphic, since the 19th century two classes of 
astrocytes were described using similar nomenclature used today; fibrous astrocytes of white 
matter, and protoplasmic astrocytes of grey matter [163]. Golgi staining revealed that 
protoplasmic astrocytes are complex cells with numerous fine processes, while fibrous 
astrocytes are less complex with fewer branching processes. Astrocytes are defined by their 
morphological features and relationship to both neurons and capillaries to describe their 
phenotype more so than any single molecular marker.  
This study investigates the potential use of Raman and ATR-FTIR to segregate between two types 
of brain tumours, glioblastoma WHO grade IV and astrocytoma WHO grade II coupled with 
multivariate statistics using U87MG, 1321N1 and a control, SVGP12 cell lines.  
5.2 Materials and Methods 
5.2.1 Raman 
Raman spectral measurements were taken using a Horiba-Yvon LabRam HR800 spectrometer 
(Horiba Scientific, UK) with an air cooled CLDS point mode diode 785 nm laser with a single edge 
filter (cut off to 100 cm-1) and an output power of 300 mW. Spectra were acquired with a grating 
of 300 gr/mm and blazed at 1000 nm. Point spectra were acquired using x50LWD objective with 
a confocal hole set at 100 µM with 2 accumulations at 150 sec acquisition time. Instrument 
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calibration was carried out before spectral acquisition to silicon at spectral line of 520 cm-1. 
Spectra acquisition covered the region 900-1800 cm-1. A camera mounted on the microscope 
allowed the use of dark field images to visualise locations of spectral acquisition. A total of (n = 
90) spectra were collected from the three cell lines, (n = 30) spectra for each cell line making up 
277 data points. Three biological replicates were used for each cell line from which (n = 10) 
spectra were collected from each replicate to make up a total of (n = 30) spectra per cell line. 
Subtraction of background fluorescence was carried out using a 6th order polynomial fit with 
LabSpec 6 software (Horiba Scientific, UK).  
5.2.2 ATR-FTIR 
Infrared spectra was measured using a JASCO FTIR-410 spectrometer (JASCO, USA) equipped 
with a Specac ATR single reflection diamond Golden Gate™ with a spectral range of between 
4000-600 cm-1 at a resolution of 4 cm-1 over 64 co-scans. Three biological replicates for each cell 
line were analysed taking 10 spectra randomly from different locations on each replicate. A total 
of (n = 85) spectra were taken (777 data points) for the three biological replicates of the three 
cell lines. The ATR crystal was cleaned with distilled water and dried with dry tissue before the 
acquisition of a background and spectra for each sample. Raw spectra used for analysis covered 
the region 1800-1000 cm-1, which includes the fingerprint region. 
5.2.3 Cell Lines 
Three cell lines U87MG, 1321N1 and SVGP12 (LONZA, Slough, UK) were grown in culture in 75 
cm-1 flasks following the manufacturer’s instructions using the following medium for each cell 
line; U87MG- 500 mL of EMEM, 50 mL of 10 % FBS, 5 mL L-glut, 5 mL Na Pyruvate and 5 mL NAA 
(1-Napthaleneacetic acid). Split sub-confluent cultures (70-80%) 1:3 to 1:6 i.e. seeding at 2-4x10, 
000 cells/cm2 using 0.25% trypsin or trypsin/EDTA; 5% CO2; 37°C,  1321N1-500 mL of DMEM, 50 
mL of 10 % FBS, 5 mL L-glut.  Split sub-confluent cultures (70-80%) 1:2 to 1:6 i.e. seeding at 2-4 
× 10,000 cells/cm² using 0.25% trypsin or trypsin/EDTA; 5% CO2; 37°C, SVGP12-500 mL of EMEM, 
50 mL of 10 % FBS, 5 mL L-glut, 5 mL Na Pyruvate and 5 mL NAA (1-Napthaleneacetic acid). Split 
sub-confluent cultures (70-80%) 1:3 to 1:6 i.e. seeding at 2- 4 x 10 000 cells/cm2 using 0.25% 
trypsin or trypsin/EDTA; 5% CO2; 37°C. 
Substrates - The cells were reseeded in petri dishes on calcium fluoride (CaF2) slides in fresh 
medium until 80 % confluent.   
5.2.4 Fixation 
Media was removed and cells washed using PBS (Sigma-Aldrich, UK), for 5 min followed by 
double distilled water (ddH2O) and then fixed using 4 % formalin (Sigma-Aldrich) for 20 min. Cells 
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were then air dried at room temperature and placed in a desiccator until analysis by Raman and 
ATR-FTIR.   
5.2.5 Data pre-processing 
Raman spectral data in the region 900-1800 cm-1 was baseline corrected using 6th order 
polynomial fit with LabSpec 6 software (Horiba Scientific, UK). ATR-FTIR spectra in the range 
1800-1000 cm-1 was converted into absorbance by JASCO Spectra Manager software (JASCO, 
USA). Raman and ATR-FTIR data was analysed in MatLab™ (Mathworks®, Natick, USA) and R (R 
Foundation for Statistical Computing, Vienna, Austria). The data was analysed using four 
statistical tests, Principal component analysis (PCA), Discriminant function analysis (DFA), 
Support vector machine (SVM) and Permanova following three models commonly used in 
spectroscopy; 
Model A: Noise reduction (60 PCs), vector normalisation 
Model B: Noise reduction (60 PCs), first derivative (7 pts), vector normalisation (Appendix A) 
Model C: Noise reduction (60 PCs), second derivative (15 pts), vector normalisation (Appendix 
A)  
PCA is a non-supervised technique which is a method of exploring data. PCA summarises data 
into ordered and non-trivial components represented by the axes, with the first components 
describing the non-trivial variation. The components are independent and uncorrelated. The 
assumptions are that the sample size is greater than 5x the number of variables, selected 
variables are meaningfully related, variables are correlated (>30%) and normality is necessary if 
applying a significance test. The eigenvectors or loadings are similar to a regression slope and 
describe the direction of the component relative to the original variable. A scores plot allows 
visualisation of segregation of classes whilst derived loadings determine the wavenumber 
responsible for the segregation. PCA can be applied before DFA to reduce computational 
complexity and increase the recognition accuracy in different classes. DFA also known as linear 
discriminant analysis (LDA) is a supervised technique which forms linear combinations of 
variables dependent on differences between classes. The model is trained on data classes before 
the final classification on the basis of PCs on an unknown data set. Support Vector Machine 
(SVM) is a supervised technique which produces complex curves know as kernel function or 
linear boundaries in many dimensions. The model finds an optimum hyperplane to separate 
between classes. The model carries out a cross validation using complexity boundary, radius of 
Gaussian peak and gives a classification accuracy. The confusion matrix from the model is used 
to calculate sensitivities and specificities. Permanova is a Permutational MANOVA, which uses 
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distance or dissimilarity between pairs of samples or variables (Bray-Curtis). The model uses 
permutation techniques to compute p-value without making any assumptions of the distribution 
of data. The model uses actual Bray-Curtis coefficients which preserves more information and 
allows for partitioning of variability, similar to ANOVA, which in turn allows for more complex 
designs such as multiple factors, nested factors, interactions and covariates. The p-value is 
calculated from a pseudo-F statistic.   
The accuracy of the classification models from DFA and SVM is quantified using sensitivities and 
specificities. These measures are given by the equations 1 and 2;  
 
Sensitivity = 
𝑇𝑟𝑢𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠 
𝑇𝑟𝑢𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠+𝐹𝑎𝑙𝑠𝑒 𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒
     (eq. 11)  
 
Specificity = 
𝑇𝑟𝑢𝑒 𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒
𝑇𝑟𝑢𝑒 𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒𝑠+𝐹𝑎𝑙𝑠𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠
    (eq. 12) 
True Positives refers to the number of spectra where samples were correctly identified as 
U87MG, 1321N1 and SVGP12. True Negatives are the number of spectra where samples have 
been correctly identified as not belonging to the wrong group. False negatives refer to the 
number of spectra where the model has incorrectly identified the samples as U87MG, 1321N1 
or SVGP12. False positives refers to the number of spectra where the model has incorrectly 
identified samples as U87MG, 1321N1 or SVGP12.  
5.3 Results and Discussion 
The data from Raman and ATR-FTIR were analysed in the same way using the three models A, B 
and C in MatLab™ and R. The results from Model B and C were similar to Model A and are found 
in Appendix A. Raman and infrared are complementary spectroscopic techniques with some 
molecular vibrations favoured by one technique rather than the other. Molecular vibrations 
which produce a strong Raman signal usually produce weak IR signals and vice versa. An example 
of such vibrations is polar bonds and asymmetric molecules which tend to absorb strongly for IR 
spectroscopy compared to Raman which produce poor intensities for the same molecules and 
bonds [164].  This study looked at both techniques to investigate how robust Raman and ATR-
FTIR faired on the same samples, glioma cell lines and how well the techniques could segregate 
U87MG, 1321N1 and SVGP12. 
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5.3.1  Raman 
Model A (Vector Normalised) 
Baseline corrected spectral data (6th order polynomial fit),  from LabSpec 6 was plotted in 
MatLab™, seen in (Figure 42) showing the combined spectra of the three cell lines, U87MG, 
1321N1 and SVGP12 before any arithmetical treatments. A total of 90 spectra were taken from 
3 biological replicates (n = 30) for each cell line. The 90 spectra correspond to 277 data points in 
the region 900-1800 cm-1.  
 
Figure 42. Plot showing baseline corrected combined raw spectra of 1321N1, SVGP12 and U87MG cell lines 
from 900 to 1800 cm-1 wavenumbers plotted prior to pre-processing in MatLab.  
The replicate spectra for each cell line were averaged and plotted against each other, (Figure 
43) for better visual view. A number of spectral differences could be seen in the combined plot 
of the three cell lines based on the presence and absence of peaks. Some of the spectral 
differences are shown in the offset spectra of the three cell lines in (Figure 44) circled in red 
found between the wavenumber regions 1150-1000 cm-1 and 1550-1650 cm-1.  
 
Figure 43. Plot showing the baseline corrected averaged combined raw spectra of U87MG (Blue), SVGP12 
(Red) and 1321N1 (Green), no spectral treatment has been carried. 
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Figure 44. Plot showing offset raw spectra of U87MG (Blue), 1321N1 (Red) and SVGP12 (Green) for better 
comparison of noticeable spectral differences which are circled in red. 
Noise Reduction (60 PCs) 
The signal to noise ratio adjustment of the combined spectra was performed using noise 
reduction function with 60 PCs (Figure 45). The first 60 principal components were used and the 
rest binned. 
 
Figure 45. Plot of noise reduced (60 PCs) combined spectra of U87MG, 1321N1 and SVGP12 cell lines. Noise 
reduction is performed to reduce the signal to noise ratio by using the first 60 PCs and binning the rest.  
Vector Normalisation 
The baseline corrected spectra (6th order polynomial fit), noise reduced using 60 PCs was vector 
normalised to correct for baseline shifts (Figure 46). This process concluded data pre-processing 
for Model A.  Spectral differences were analysed using multivariate statistics, PCA, DFA, SVM 
and Permanova using MatLab™ and R. 
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Figure 46. Plot showing the vector normalised, baseline corrected (6th order polynomial fit), noise reduced 
(60 PCs), spectra of U87MG, 1321N1 and SVGP12 cell lines. This concludes the pre-processing steps for 
Model A. The data is analysed using multivariate statistics in both MatLab™ and R.   
Principal Component Analysis (PCA) 
Spectral differences between the three cell lines, U87MG, 1321N1 and SVGP12 were observed 
using PCA, which showed differences between the three groups shown in Figure 47. The test 
summarises the data into ordered and non-trivial components represented by the axes. The first 
component (PC1) describes the non-trivial variation. The second component PC2 describes the 
residuals of the first component or the trivial Variation. All the components are independent 
and uncorrelated. 
 
 
Figure 47. Principal components 1 and 2 from Model A data showing differences between 1321N1 (Blue), 
SVGP12 (Red) and U87MG (Green). The plot shows component 1 with 40 % of the non-trivial variation and 
component 2 with 13.6%. PC1 and 2 shows good separation of the data with no overlap. 
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To investigate where the differences lie based on principal components, PC loadings were used 
(Figure 48) and (Figure 49).  
 
           
Figure 48. Principal component loading 1 (PC1) showing peaks responsible for data separation which are 
associated with known functional groups and molecules shown in Appendix I, Table 29. 
 
Figure 49. Principal component loading 2 (PC2) showing peaks responsible for data separation which are 
associated with known functional groups and molecules shown in Appendix I, Table 29. 
Model A has only been vector normalised to remove baseline shifts and its PC loadings (Figure 
48) and (Figure 49) were used to discern the peaks responsible for discrimination.  Tentative 
assignment were done for the major vibrational modes based on [111] shown in Appendix I, 
Table 29.  
Discriminant Function Analysis (LDA) 
The three cell lines were classified into three groups (Figure 50) based on a training set (Symbol 
= O) and test set (Symbol = +). The model was provided with information about group 
membership using the training set. The model was able to separate the groups based on their 
biochemical composition shown in the PC loadings. Spectra of groups belonging to similar 
[121] 
 
biochemical composition exhibit good clustering. Sensitivity and specificity for the classification 
accuracy are given in Table 13.  Sensitivity in this context refers to the proportion of cells within 
a particular group correctly classified and found within 95% and 90% CI and specificity refers to 
the proportion of cells that do not belong to that group that have been correctly classified as 
not belonging to that group within 95% and 90% CI. The model had an overall classification 
sensitivity of 70 % and 93 % at 95 and 90 % CI and 100 % specificity for both 95 and 90 % CI 
shown in Table 13.   
 
Figure 50. DFA plot of (1321N1 =Blue), (SVGP12 =Red) and (U87MG =Black) based on the training set 
(symbol = O) and test set (symbol = +) with 95 % (Inner ellipse) and 90% (Outer ellipse) confidence intervals. 
Any observed clustering of groups would be suggesting a common underlying biochemical signature.  
The axes in (Figure 50) of the DFA plot have positive and negative directions. The peaks in the 
positive direction of the y axis in the PCA loadings plot correspond to the spectral peaks that the 
model is using to discriminate U87MG (Black) and SVGP12 (Blue) from 1321N1 (Red). Peaks in 
the negative direction of the y axis discriminate SVGP12 (Blue), 1321N1 (Red) from U87MG 
(Black). 
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Table 13. Sensitivity and Specificity of DFA Raman classification of 1321N1, SVGP12 and U87MG at 90 and 
95% Confidence intervals. 
 
 
        1321N1  SVGP12  U87MG Overall 
Model A 
Confidence 
limit 
95% 90% 95% 90% 95% 90% 95% 90% 
Sensitivity 40 100 80 90 90 90 70 93.33 
Specificity 100 100 100 100 100 100 100 100 
 
Model B 
Confidence 
limit 
95% 90% 95% 90% 95% 90% 95% 90% 
Sensitivity 100 100 43.33 100 100 100 81.11 100 
Specificity 100 100 100 100 100 100 100 100 
 
Model C 
Confidence 
limit 
95% 90% 95% 90% 95% 90% 95% 90% 
Sensitivity 60 90 83.33 93.33 86.67 96.67 76.66 93.33 
Specificity 100 100 100 100 100 100 100 100 
     
Averaged cell spectra of the three cell lines (Figure 44) show some of the noticeable differences 
between the three cell lines which lie in the spectral region 1150-1000 cm-1, 1550-1650 cm-1, 
which can be attributed to differences in protein and lipids at 1461, 1155, 1604 cm-1, lipids C-C 
stretch at 1130 cm-1 from trans-segments and C-N stretches at 1130 cm-1 of proteins. The 
majority of the differences were based on protein and lipids CH2 deformations at 1461 cm-1, 
nucleic acids at 1554 cm-1. The PC loadings show positive and negative peaks which correspond 
to increases and decreases of functional groups or molecules found in that spectral region.  
 
[123] 
 
High grade and low grade glioma 
The peaks that separate U87MG (GBM) high grade glioma cells from 1321N1 (astrocytoma WHO 
grade II) low grade glioma cells are in the negative direction which signifies a reduction in lipids 
and proteins in the U87MG cells. These results are consistent with previous studies by Krafft et 
al. looking at differences between similar brain tumour cell lines and normal cells. In their study 
a comparison of the different IR spectra of astrocytoma WHO grade II and grade IV (GBM) in 
cells showed a double increase in intensities in bands that coincided with contributions from 
cholesterol and lipids. The results showed a correlation between a decrease in cholesterol and 
lipids with an increase in malignancy. The study also looked at the distribution of the 
lipid/protein ratio between normal tissue, astrocytoma WHO grade (II, III and IV) tissue. They 
used this parameter to describe IR spectroscopic maps of the samples. Normal samples showed 
high maxima (0.69-0.71), astrocytoma grade (II = 0.27 ± 0.05, III = 0.17 ± 0.05 and IV = 0.11 ± 
0.03). These ratios were consistent with results from cell culture investigations of the same 
tumour types which showed an increase in malignancy correlates with a decrease in lipids 
including cholesterol [85].   
This information alone is not helpful unless we are able to apportion the differences to known 
biological processes that can contribute to these differences. Vibrational spectroscopy is a 
presumptive testing technique and not confirmatory. The inferences that can be made regarding 
the functional groups or molecules are a result of known biological events taking place in that 
cell or tissue. U87MG cells like glioblastoma tumour cells are poorly differentiated and expected 
to release microvesicles (exosomes) containing mRNA, miRNA and angiogenic proteins. These 
microvesicles are taken up by normal host cells, such as brain microvascular endothelial cells 
[165]. These angiogenic proteins are expected to be high in glioblastoma cells compared to 
anaplastic astrocytoma and normal cells, which could explain the protein differences between 
U87MG from 1321N1 and SVGP12 at 1461, 1554 and 1604 cm-1. Tropomyosin is a highly 
conserved actin-binding protein [166]. Tropomyosin is present in both muscle and non-muscle 
cells and its role in non-muscle cells is less well understood. However, it is known that 
tropomyosin together with other actinin binding proteins such as α-actinin are down regulated 
in differentiated astrocytes. Increased levels of high molecular weight tropomyosin are found in 
more anaplastic astrocytomas than in normal differentiated astrocytes [167].  
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Normal Cells vs Gliomas  
 The peaks in PC loadings 2 are negative and separate SVGP12 (representing non-tumorigenic 
brain cells)  from U87MG (Glioma cells) and 1321N1(Glioma cells), due to lipids and proteins in 
the spectral region 1451 and 1515 cm-1, and nucleic acids at 1120 and 1200 cm-1. The 
proliferation of normal cells are expected to follow the normal cell cycle which is expected of 
SVGP12 cells compared to U87MG and 1321N1 which have accumulated mutations and 
proliferate uncontrollably due to changes in their DNA. Studies have shown that the growth of 
tumours is accompanied by significant changes at the expense of the cell surface.  
These changes can be ascribed to differences seen in the PC loadings 2 being used to separate 
the cell lines. Lipids perform a critical role to all biological media by forming the cell wall that 
keeps biological media organised in their compartments. They also help in the flow of biological 
molecules from one side of a lipid barrier to the other a process often assisted by imbedded 
proteins that form the passage for these molecules called channels [64]. Campanella, in a study 
of human astrocytomas of various grades [168] showed that an increase in malignancy 
correlated with; 
a) Reduction of the total lipids which involved all the principal classes of the plasma 
membrane, cholesterol, phospholipids, neutral and acidic glycosphingolipids, and 
sulphatides correlating exponentially with an increase in histological grading. 
b) A gradual accumulation of lattosyceramide and GD3 molecules that are part of 
glycosphingolipids. These molecules are seen as valid markers for malignancy grade. 
Glycolipid composition of high grade and low grade gliomas differ significantly. 
c) A gradual increase in the area of phospholipids, of PC/PE and PC/SM ratios which are 
indices of the microviscocity of the membrane.   
d) In brain tumours this organisation is expected to change as the cell changes form and 
function. This change is expected to increase with degree of malignancy. SVGP12 is 
expected to maintain a normal arrangement compared to U87MG and 1321N1 which 
can explain the differences being used by the model. Table 29 shows the proposed 
biomolecular assignments for discriminant function 1 and 2 which are similar to PC1 and 
PC2 loadings (Figure 48) and (Figure 49).   
Permanova 
There was a significant difference between the three groups, 1321N1, SVGP12 and U87MG using 
Permanova (Manhattan) in R. The test looked at the dissimilarity distance between U87MG, 
1321N1 and SVGP12 using 3 PCs (F2, 6 = 3.89, R2 = 0.34, P = <0.001, Permutations = 10 000).  
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Support Vector Machine (SVM) 
The vector normalised data was classified using SVM, the model carried out a cross validation 
with the following optimal parameters yielding classification accuracy = 100%, cost (C) = 2048, 
gamma (g) = 512. A decision matrix generated in the output table was used to calculate 
sensitivities and specificities shown in (Table 14).  The model was able to classify all the three 
cell lines, U87MG, 1321N1 and SVGP12 to their correct group. 
Table 14. SVM results showing the best parameters, yielding Accuracy = 100%, are: C= 2048, gamma = 512 
 1321N1 SVGP12 U87MG 
Model A 
Sensitivity 100 % 100 % 100 % 
Specificity 100 % 100 % 100 % 
Model B 
Sensitivity 100 % 100 % 100 % 
Specificity 100 % 100 % 100 % 
Model C 
Sensitivity 100 % 100 % 100 % 
Specificity 100 % 100 % 100 % 
 
5.3.2 Attenuated total reflection-fourier transform infrared (ATR-FTIR) 
Model A (Vector Normalised) 
Spectral data from Jasco Spectral Manager software was plotted in MatLab™, seen in (Figure 51) 
showing the combined spectra of the three cell lines, U87MG, 1321N1 and SVGP12 before any 
arithmetical treatments. A total of (n = 85) spectra were taken from 3 biological replicates 
1321N1 (n = 30), SVGP12 (n = 25) and U87MG (n = 30). The (n = 85) spectra correspond to 777 
data points in the region 1800-1000 cm-1.  
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Figure 51. Plot showing combined raw spectra of 1321N1, SVGP12 and U87MG cell lines from 4000-600 cm-
1 before cutting it to 1800-1000 cm–1 wavenumbers and plotted before any pre-processing in MatLab. 
The spectral region 1800-1000 cm-1 was selected for analysis (Figure 52) which included the 
fingerprint region 1800-900 cm-1. This region was used for pre-processing before multivariate 
statistical analysis. The noise reduced spectra of the combined cell lines, 1321N1, U87MG and 
SVGP12 was vector normalised (Figure 53) to standardise the scale of all three cell lines before 
multivariate statistical analysis. This step concludes the pre-processing steps for Model A. The 
data is analysed using PCA, DFA, SVM and Permanova. 
 
Figure 52. Plot showing combined spectra of U87MG, 1321N1 and SVGP12 noise reduced (60 PCs) which is 
cut to the region 1800-1000 cm-1. 
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Figure 53. Plot showing the vector normalised, noise reduced (60 PCs), spectra of U87MG, 1321N1 and 
SVGP12 cell lines. This concludes the pre-processing steps for Model A. The data is analysed using 
multivariate statistics, PCA, DFA, SVM and Permanova. 
Principal Component Analysis (PCA) 
PCA was carried on the vector normalised data and component 1 and 3 showed the best 
grouping of the three cell lines and constituted a combined 87 % of the variation which accounts 
for the separation shown in Figure 54.  
 
              
Figure 54.Plot showing principal component 1 and 3 plot for Model A noise reduced (60 PCs), vector 
normalised spectra of 1321N1 (Red), SVGP12 (Blue) and U87MG (Green). 
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Figure 55. PC loadings 1 showing peaks of functional groups and molecules responsible for grouping and 
separation of the three cell lines. 
 
     
Figure 56. PC loadings 3 showing functional groups and molecules responsible for the separation of data 
with arrows showing the peaks contributing to the separation in the negative direction. 
Tentative assignment of IR spectra 
Separation based on PCA was checked using loadings 1 (Figure 55) and 3 (Figure 56)  which 
showed the peaks responsible for the separation as nucleic acids and polysaccharides (1200-900 
cm-1) with symmetric PO2- vibrations of phosphodiester groups from DNA at ~1080 cm-1 , lipid 
esters (1800-1700 cm-1) and proteins (1700-1500 cm-1) consisting of C=O stretching vibrations 
based on tentative assignments Appendix J, Table 30. These results generally correspond to the 
results by Raman spectroscopy.  
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Discriminant Function Analysis (LDA)  
Spectra (n = 85) were randomly divided into 2/3 training and 1/3 tests making up 777 data 
points. The DFA model (Figure 57) provides good visual representation on how well the model 
classified the three cell lines 1321N1, SVGP12 and U87MG based on Model A pre-processing 
data. The DFA model classified the three cell lines based on their biomolecular differences as 
shown by the loadings. The model classified the test data (+) made up of a blind set of n= 18 to 
the corresponding training data (O) made up of n = 57.  
 
 
Figure 57. Discriminant function analysis plot of Model A, Red= (1321N1), Blue= (SVGP12) and Black= 
(U87MG), (Train data = O) and (Test data = +). 
 
Table 15 shows the individual and overall sensitivity and specificity of Model A classifications at 
95% and 90% confidence interval (CI). Sensitivity in this context refers to the proportion of cells 
within a particular group correctly classified and found within 95% and 90% CI and specificity 
refers to the proportion of cells that do not belong to that group that have been correctly 
classified as not belonging to that group within 95% and 90% CI. The highest sensitivity is 
achieved at 90% CI for Model A and since all the groups were clearly separated with no overlap 
the model achieved a 100% specificity at both 95% and 90% CI. Appendix J, Table 30 shows major 
peaks tentatively assigned which were used to discriminate the three cell lines. 
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Table 15. Sensitivity and Specificity of DFA ATR-FTIR classification of 1321N1, SVGP12 and U87MG at 95 and 90% 
Confidence intervals.  
Cell Line 1321N1 SVGP12 U87MG Overall 
Model A 
Confidence 
limit 
95% 90% 95% 90% 95% 90% 95% 90% 
Sensitivity 96.67 100 10 100 0 93.33 35 97.77 
Specificity 100 100 100 100 0 100 66.66 100 
Model B 
Confidence 
limit 
95% 90% 95% 90% 95% 90% 95% 90% 
Sensitivity 90 93.33 66.67 83.33 13.33 90 56.66 88.88 
Specificity 100 100 100 100 100 100 100 100 
Model C 
Confidence 
limit 
95% 90% 95% 90% 95% 90% 95% 90% 
Sensitivity 83.33 93.33 80 93.33 46.67 93.33 70 93.33 
Specificity 100 100 100 100 100 100 100 100 
 
Permanova 
There is a significant difference between the groups based on 3 PCs of model A (Vector 
Normalisation) using Permanova, (F2, 6 =92.711, R2= 0.925, P = <0.001, Permutation =10 000, 
Method = Manhattan). 
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Support Vector Machine (SVM) 
The noise reduced (60 PCs), vector normalised data was classified using SVM, the model carried 
out a cross validation with the following optimal parameters yielding classification accuracy = 
100% where, cost (C) = 2048, gamma (g) = 512. A decision matrix generated in the output table 
was used to calculate sensitivities and specificities shown in Table 16.   
Table 16. SVM results showing the best parameters, yielding Accuracy = 100%, are: C= 2048, gamma = 512 
Model 1321N1 SVGP12 U87MG 
Model A 
Sensitivity 100 % 100 % 100 % 
Specificity 100 % 100 % 100 % 
Model B 
Sensitivity 100 % 100 % 100 % 
Specificity 100 % 100 % 100 % 
Model C 
Sensitivity/ 100 % 100 % 100 % 
Specificity 100 % 100 % 100 % 
 
The results from ATR-FTIR show similar information to Raman spectroscopy which shows the 
separation of the cell lines being based broadly on differences in lipids, proteins and nucleic 
acids. Raman and IR spectral changes in normal and tumour cells are reproducible and the 
differences can be attributed to differences in the proliferative status of the cells. Similar 
experiments [169] have shown that these changes are reproducible as shown by these two 
studies. 
There has been significant advances in the past four decades in molecular biology and 
fundamental genetic discoveries that have improved our understanding of neoplastic cellular 
transformations and their full blown development into advanced neoplastic progression [168, 
170]. A significant amount of work has been carried to improve histopathology which has seen 
morphological research of tissue and cells being revitalised and revolutionised by 
immunohistochemistry and immunocytochemistry. Today histological investigation of 
neoplastic tissue and cells coupled with immunohistochemistry have become the gold standard 
in the diagnosis of tumours in that functional aspects can now be easily associated with 
morphological descriptions. These tests can be time consuming and at times require 
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hospitalisation, and have been reported to be subjective during histological grading [11, 171, 
172]. There have been also a number of other tests developed for the screening and diagnosis 
of some types of cancer such as the prostate specific antigen (PSA) test in prostate cancer and 
Papanicolaou test (Pap) in cervical cell screening for cancer. These tests whilst being successful 
have been shown to produce a number of false positives and false negatives [89].  The ability to 
diagnose brain tumour cells and tissue rapidly whilst providing accurate grading, corresponds to 
lower costs, decreases in mortality, morbidity, and the potential for more effective therapy and 
care. A number of studies carried out on cultured cells demonstrated that vibrational 
spectroscopy can detect the stages of cell division cycle [151], effects of drug treatment on cells 
[173-175], degree of aggressiveness [85, 154, 169, 176], microRNA expression [55] and a few 
others. The use of multivariate statistics is particularly important in spectroscopic studies 
because it allows the visualisation of spectral variations which cannot be picked up easily. 
Studies have shown that spectra may appear identical to the naked eye, but statistical analysis 
of these data sets reveal changes that can be interpreted biochemically [14]. The use of 
vibrational spectroscopy on tissue would require a robust method of sampling during spectra 
acquisition because of the expected heterogeneity of the tissue samples.    
Whilst this study provides a good proof of principle to use Raman and Infrared techniques for 
the diagnosis of brain tumour tissue and cells a number of issues need to be taken into 
consideration. Cell line models do not quite represent the behaviour of the tumours they are 
derived from and would have lost a significant number of characteristics over the years through 
different passages. However, they provide good models to test techniques such as vibrational 
spectroscopy because of their homogeneity. Sampling is much easier compared to actual 
tumour samples which may have different histological grades on a single biopsy. The SVGP12 
cell line, whilst often used as a control for normal cells it does not reflect the behaviour of normal 
glial cells because of changes due to passages numbers, culture conditions and immortalisation. 
Henriksen et al. reported that the SVGP12 cell line contained infectious BK polyomavirus [177]. 
This discovery is a cause for concern to studies working on drug targets as well as pathology. In 
the case of this study this was not a major problem because the primary focus of the study was 
to investigate whether vibrational spectroscopy can separate the three cell lines based on 
biochemical information. The inferences made based on these separations whilst in line with 
other studies should also take into account potential factors that might bring bias to the results, 
such as contamination of the cell lines with viruses, changes in the genetic makeup of the 
tumours due to passages and culture conditions over the years. Wenger et al. compared two 
established cancer cell lines, MCF-7 and Ishikawa using comparative genomic hybridisation 
(CGH) which showed changes due to passage number and culture conditions [178].   
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5.4 Conclusion 
This study looked at three different cell lines, U87MG, 1321N1 and SVGP12 commonly used for 
the study of brain tumours. The spectral data was treated using three commonly used pre-
processing techniques and produced identical results. The three models successfully segregated 
the three cell lines based on their biochemical profiles. Raman and ATR-FTIR provide structural 
information as well as relative quantification of biological constituents such as lipids, 
phosphorylated biomolecules, proteins, carbohydrates and other molecules found within cells 
and tissue [177, 179]. The differences in the distribution of these molecules and functional 
groups in cells has been used in this study as biological markers to distinguish between high 
grade and low grade gliomas, and normal cells versus tumour cells. The use of multivariate 
statistics identifies very small changes that are significant enough to detect degree of 
malignancy as well as normal versus tumour. This technique has the potential for developing 
specific spectral biomarkers in the form of wavenumber panels that show a significant difference 
between different types of brain tumours against normal tissue and cells from brain tumour 
patients.  
This study has established that vibrational spectroscopy, Raman and ATR-FTIR are sensitive tools 
for analysing biological materials. The techniques successfully differentiated between three 
different cell lines and tentatively assigned spectra based on known functional groups and 
molecules in the literature. Histopathology has been primarily used as the gold standard in 
medical diagnostics for many years in nearly all types of cancer. Although the technique has high 
sensitivity and specificity in detecting cancers it is somewhat subjective and ambiguous when it 
comes to grading the disease in terms of degrees of malignancy.  
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Chapter 6 
6 Analysis of Brain Tumour Tissue using Raman Spectroscopy 
6.1 Introduction 
Brain and spinal cord tumours are collectively known as central nervous system (CNS) tumours.  
Brain tumours are difficult to treat, and survival time for patients with high grade tumours is 
short. The need to accurately grade the tumour is of paramount importance for both treatment 
and patient care. A lot of research has been performed to understand the molecular 
mechanisms behind CNS tumours but several questions remain unanswered with a lot of 
difficulty to predict useful treatment using current information. Data from the National Cancer 
Institute, Surveillance, Epidemiology, and End Results Program (SEER), Figure 58 shows United 
States estimated new cases and deaths in 2015 based on data from 1992-2012. The data shows 
an increase in the number of new cases and relatively lower number of deaths per 100 000 men 
and women.   
 
 
Figure 58. United States statistical data of brain and other nervous system cancers at a glance showing 
number of new cases and deaths per 100 000 people. The number of new cases of brain and nervous system 
tumours was 6.4 per 100 000 men and women per year. The number of deaths was 4.3 per 100 000 men 
and women per year. The rates are age adjusted based on 2008-2012 cases and deaths. Data reproduced 
from [111].   
The brain is made up of different cell types which serve different purposes in the brain. These 
cells can be classified into two major groups, neurons and glia cells [25]. The glial cells constitute 
the majority of the cells in the brain which occupy about half the volume of the brain. They carry 
out a lot of important functions both in development and during normal brain function of the 
mature system [8]. These cells have also been shown to play a major role in the reaction of 
nervous system disease and trauma. Glial cells have four subclasses, astrocytes, 
oligodendrocytes, ependymal and microglia [16]. In the CNS, the major glial types are astrocytes 
and oligodendrocytes. In the peripheral nervous system (PNS), the major glial cells are Schwann 
cells.  The development of glial cells and neurones of the CNS stem from neural precursor cells 
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of a germinal layer called the ventricular zone, which lines the lumen of the developing spinal 
cord and the ventricles of the brain [9]. 
6.1.1 Astrocytes and Astrocytomas 
Astrocytes form the majority of the cells and have many radiating processes which interweave 
in complex and intimate ways between neuronal cell bodies and fibres, (Figure 59). Neurons are 
directly involved in electrical transmission and information processing [16].  
 
Figure 59. The arrangement between astrocytes, capillaries and neurons. Astrocytes (white), typically carry 
numerous processes many of which spread along capillaries (brown) and connected to the neurons (green) 
or associate intimately with axon terminals at synaptic junctions (blue). Image taken from [101].  
Astrocytes continuously cover the entire CNS and contribute to the many essential complex 
functions in a healthy CNS. They are involved in synaptic transmission and information 
processing by neural circuit functions [31]. Astrocytes are involved in the response to CNS insults 
through a process known as reactive astrogliosis, which serves as a pathological hallmark of CNS 
structural lesions [163]. There are two main subtypes of astrocytes, protoplasmic and fibrous. 
These have been divided on the basis of differences in their cellular morphologies and 
anatomical locations [31]. Protoplasmic astrocytes (Figure 60) are found throughout the grey 
matter of the brain, which exhibit a morphology of several stem branches that give rise to many 
finely branching processes in a uniform globoid distribution, as shown using classical silver 
impregnation techniques. Fibrous astrocytes (Figure 60) are found throughout white matter and 
show a morphology of many long fibre like processes.  
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Figure 60. Image shows three types of CNS glial cells drawn as they would appear with a Golgi stain. Astrocytes are 
relatively large. Two types of astrocytes are described, fibrous astrocytes, located in white matter, have long sparsely 
branched processes. Protoplasmic astrocytes, located in grey matter, have numerous short highly branched 
processes. Oligodendrocytes are relatively small and form myelin sheaths in the CNS, in addition to having a 
metabolic role. Microglia are small and tend to have elongate cell bodies, resident phagocytes, and relatively rare in 
normal CNS tissue. Image taken from [180] 
Both subtypes of astrocytes have been shown through empirical studies to have extensive 
contact with blood vessels. Electron microscopic analyses shows that protoplasmic astrocytes 
processes envelop synapses whilst fibrous astrocyte processes contact nodes of Ranvier. Both 
types of astrocytes have been shown to form gap junctions between distal processes of 
neighbouring astrocytes [25]. The vast number of brain tumours are derived from glial cells or 
their progenitors, and most of them have an astrocytic component [9]. This high degree of 
heterogeneity makes it very difficult to determine the cell of origin. Specific markers at the single 
cell level to identify and characterise healthy and pathological tissue are essential.  
Astrocytic tumours display a variety of morphological features and differ in their biological 
behaviour [163]. The current grading system is based on the assessment of tumour cellularity, 
nuclear pleomorphism, mitotic activity, endothelial hyperplasia/vascular proliferation and 
necrosis. The low grade WHO grade II, diffuse astrocytoma have a slow growth rate and diffusely 
infiltrate the surrounding brain parenchyma. They have a tendency to progress to high grade 
tumours, from anaplastic astrocytoma WHO grade III to glioblastoma WHO grade IV  [15].  
Diffuse astrocytomas constitute 10-15 % of all astrocytic brain tumours an estimated 1.4 new 
cases per million population per year [9]. The peak incidence is between 30-40 years in 25 % of 
the cases with a spread of 10 % below the age of 20, 60 % between 20-45 years and 30 % over 
45 years and a predominance for males with a male to female ration of (M:F 1.18:1). Diffuse 
astrocytomas develop supratentorial in cerebrum (frontal and temporal most common) but may 
[137] 
 
appear anywhere. Histologically they are composed of well differentiated fibrillary or 
germistocytic neoplastic astrocytes on a background of loosely structured microcystic tumour 
matrix. There is nuclear atypia but mitotic activity is usually absent. Anaplastic astrocytomas 
WHO grade III, differ from diffuse astrocytomas in grade and spread. Anaplastic astrocytomas 
have a focal or dispersed area of anaplasia [181]. Histopathologically they have similar features 
as diffuse astrocytomas but with increased cellularity, nuclear atypia and mitotic activity. There 
is no endothelial hyperplasia or necrosis. The Ki67 proliferation index is higher during staining. 
The tumours tend to progress to GBM with a mean survival time of 2 years. Glioblastoma (GBM) 
is a malignant astrocytic tumour which can be both primary and secondary. Primary GBMs make 
up 90 % of cases and have a very short clinical history with no evidence of a pre-existing lesion. 
Secondary GBMs are a result of progression of a diffuse astrocytoma or anaplastic astrocytomas. 
These make up 10 % of GBMs and are usually found in younger patients [31, 182]. The peak 
incidence is between 45-75 years with an average age of 61 years. The tumour usually appears 
in the subcortical area of white matter in the cerebral hemispheres. Tumour infiltration extends 
to the adjacent cortex and through corpus callosum into the contralateral hemisphere. They are 
anaplastic histopathologically with cellular glioma composed of poorly differentiated, often 
pleomorphic astrocytic tumour cells, which include multinucleated giant cells with brisk mitotic 
activity. Necrosis and microvascular proliferation are essential diagnostic features. Variants of 
GBM include, small cell and giant cell GBMs, gliosarcoma and glioblastoma with oligodendroglial 
component. Staining for GFAP is positive but has been shown to be variable intensity in tumour 
cells. The Ki67 proliferative index is high. Prognosis is usually less than 12 months [16, 31].      
6.1.2 Oligodendrocytes and Oligodendrogliomas 
Oligodendrocytes are the myelinating cells of the CNS which are an end product of a cell lineage 
that has to undergo complex and precise timed program of proliferation, migration, 
differentiation, and myelination to finally produce the insulating sheath of axons [31, 183]. The 
vast majority of our knowledge on oligodendrocytes comes from studies in rodents which led to 
the understanding of important principles of oligodendrocyte development and myelin 
formation. In rodents, studies show that the spinal cord and brain contain different subclasses 
of oligodendrocytes which derive from multiple sources [16]. Oligodendrocytes in the spinal 
cord are derived from a specialised domain of the ventral ventricular zone, that initially gives 
rise to motor neuron precursors, and then switch to oligodendrocyte precursor cells/progenitors 
(OPCs) [183].  
The OPCs migrate all through the spinal cord and differentiate into myelin-forming 
oligodendrocytes. An additional source of OPCs arise in the dorsal spinal cord, contributing to 
10-15 % of the final oligodendrocyte population in the spinal cord [184]. OPCs in the forebrain 
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originate in the medial ganglionic eminence and anterior entopeduncular area of the ventral 
forebrain. These cells populate the entire embryonic telencephalon including the cerebral 
cortex, and then by another batch of OPCs derived from the lateral and/or caudal ganglionic 
eminences [183]. The third wave of OPCs arise within the postnatal cortex [183], and these 
different populations of OPCs are functionally redundant. In the mice model studies showed 
that when any one of these are destroyed by the expression of a toxin gene, the remaining cells 
spread into the vacant area and restore the normal distribution of OPCs. The functional 
redundancy of the different populations of OPCs is thought to be responsible for their fierce 
competition during development [184]. The mechanisms involved during development that 
gives rise to the final population of oligodendrocytes found in the organ differ between the 
forebrain and spinal cord [184].  
Oligodendrogliomas are classified as WHO grade II, and the majority of them appear in adults 
between the age of 40 and 45 years. Most tumours of this type are found in the cortex and white 
matter of cerebral hemispheres with the frontal lobe being the most common [185].  
6.1.3 Meninges and Meningeal tumours 
Meningiomas arise from the meningothelial cells and generally grow very slow and benign [16]. 
These tumours have been classified under three distinct groups under the WHO system, grade 
I, II and III. Meningioma Grade I, tumours mostly appear in middle aged and elderly with a peak 
incidence between 60-70 years. They usually appear intracranial, intraspinal and orbital. 
Histopathologically they have a wide range of appearances but generally they are medium-sized, 
oval/spindle cells with nuclear pseudo-inclusions, arranged in lobules and in whorls. Most 
common variants are Meningothelial, fibrous, transitional and psammomatous. Staining for 
EMA and CD99 produces a positive result with a low Ki67 proliferation index [9]. They have good 
prognosis associated with long survival but recurrence may occur within 20 years. Atypical 
meningioma WHO grade II show increased cellularity, small cell change, sheeting, prominent 
nucleoli and necrosis. They are two histological subtypes, clear cell and choroid meningiomas. 
Anaplastic meningioma WHO grade III has histological features of frank malignancy, often with 
sarcoma like appearance. Histological subtypes include papillary and rhabdoid meningiomas. 
This type of tumour is usually fatal with a median survival rate of less than 2 years [20, 186] 
6.1.4 Medulloblastomas 
Medulloblastomas (MBs) are a cerebellar primitive neuroectodermal tumour which appears 
more frequently in children, making them the most common type of solid malignant childhood 
brain tumour [187]. These tumours have been recently classified into four distinct molecular 
subgroups, SHH, WNT, group 3 and 4 which display different demographics and clinical 
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outcomes [188]. Group 3 are considered the most metastatic which carry the worst prognosis 
and characteristically overexpress c-Myc. Medulloblastoma is designated WHO grade IV with a 
peak incidence of 7 years with approximately 65 % of cases being male. Approximately 75 % of 
the tumours arise in the cerebellar vermis and project into the 4th ventricle. The tumour is 
composed of densely packed cells with round to oval hyperchromatic nuclei surrounded by 
scanty cytoplasm which is occasionally arranged in rosettes. The tumour cells show nuclear 
pleomorphism and high mitotic activity. Histological variants include, desmoplastic/nodular, 
medulloblastoma with extensive nodularity, anaplastic medulloblastoma and large cell 
medulloblastoma. Staining shows positive with antibodies to synaptophysin, antibodies to GFAP 
and neurofilament protein also label occasional cells. The Ki67 proliferative index is high and the 
prognosis is a 60-70 % 5 year survival [188].  
6.1.5 Challenges in brain tumour diagnosis 
Diagnosis of a brain tumour is not always a straightforward process as the signs and symptoms 
can overlap with other neurological diseases which can mimic brain neoplasms on neuroimaging 
and histological examination. Diseases such as multiple sclerosis, stroke, pyogenic abscess, 
toxoplasmosis, tuberculosis, cysticerosis, fungal infection, syphilis, sarcoidosis, radiation 
necrosis, venous thrombosis and others have been shown to mimic brain tumours [189, 190]. 
Tumours such as GBMs, low grade gliomas, CNS lymphomas and brain metastasis can present in 
the absence of typical tumefactive lesions, making diagnosis challenging. Timely and accurate 
diagnosis is a key component in neuro-oncology [191, 192]. The treatment of cancer is toxic, but 
the risk of the toxic effects are justified by the subsequent gains in survival seen in patients given 
the right treatment. Therefore the need for timeous and accurate diagnosis is of paramount 
importance as it can have very dire consequences if the wrong treatment is assigned to a patient. 
To this end the diagnosis of a brain tumour requires a systematic approach within a 
multidisciplinary team to minimise mistakes. A number of institutions have developed protocols 
that ensure everyone involved in the diagnosis of a brain tumour follows. These protocols 
include thorough assessment of history, physical examination, and a minimal workup which can 
provide important clues on the nature of the lesion such as neoplastic versus vascular, 
inflammatory or infectious lesions [192].  
The actual histological assessment of biopsies presents some challenges. Classification of 
tumours such as gliomas which are on a continuous spectrum of histology and malignancy into 
distinct categories is a challenge. To compound this challenge some tumour subtypes such as 
glioblastoma with oligodendroglial components, oligoastrocytoma and oligodendroglioma have 
characteristics of two or more histologies making them particularly problematic to replicate. 
There are other tumours which have ambiguous morphological appearance for which no clear 
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consensus exists [190]. Pathological discrepancies have been reported to occur in up to 43 % of 
specimens’ assessed using histopathology and in another study in Rhone-Alpes, France, primary 
diagnoses were systematically compared with second opinion from regional and national 
experts which showed major discrepancies related to histological grade 19 %, type 11 %, subtype 
5 %, grade plus subtype or grade plus histological type 12%. Over 45 % of first histological 
diagnoses were modified at second reading resulting in different treatment decisions [193].     
These challenges have necessitated changes in histopathology and have led to consideration of 
new techniques to compliment current methods. The development of techniques that allow the 
surveying of the entire mutations tumour cells harbour provides an opportunity to ascertain 
which alterations drive the growth and ability of tumours to progress. Molecular pathology is 
becoming an important technique used to aid diagnosis of brain tumours in most centres around 
the world. Currently the technique faces challenges shown by meta-analysis studies in which no 
final decision on specific biomarkers has been taken. This is mostly related to inappropriate 
study design, low level of standardisation of methods and microdissection of tissue and variable 
pre-analytical conditions. They also lack defined verification and validation of processes of new 
prognostic and predictive biomarkers [190, 194]. However this is a new and exciting area which 
has changed targeted molecular therapies for patients with cancer. DNA methylation 
fingerprinting is another area that is gaining ground in the area of cancer diagnosis. Recent 
developments in genomics technology have brought about a huge varieties of new discoveries 
in the field of neuro-oncology. Stefan et al. in Germany have created a national program known 
as Molecular Neuropathology 2.0 aimed at the molecular classification of CNS tumours which 
uses DNA methylation fingerprints and gene panel sequencing. The method uses DNA 
methylation fingerprints which are thought to closely reflect the cell of origin to accurately 
classify brain tumours into biologically and clinically meaningful subgroups. To date the group 
has created a reference sample of 2200 tumours with good histopathological and clinical 
annotation covering 80 different entities and subgroups from 10 000 analysed CNS specimens 
[195, 196].   
6.1.6 Vibrational Spectroscopy 
Raman and Infrared spectroscopy are powerful tools for detecting changes in human tissues and 
cells. These techniques are non-destructive, quick to perform, cost effective and easy to operate. 
The Raman spectra is complimentary to IR and carry the same information about the sample. 
Over the years a number of optical technologies such as fluorescence spectroscopy [197], 
polarised light scattering [198] and others emerged as promising tools for the diagnosis of 
different types of diseases including cancer. The potential of Raman and IR as a diagnostic tool 
in cancer has also been recognised. A number of studies established that FTIR [158, 199, 200], 
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Raman spectroscopy [13, 89, 133, 144, 201] can be used for detecting spectral changes in 
malignant and pre-malignant cells. Raman spectroscopy is more suitable for biological studies 
because of minimal interference from water which is almost present in most specimens studied. 
Raman spectroscopy is based on inelastic light scattering. The biological specimen is illuminated 
by monochromatic light from a laser source and interactions between the incident photons and 
molecules in the specimen result in the scattering of light. The exact energy required to excite 
the vibrations of bonds in the molecule depend on the masses of the atoms involved in the 
vibration and the type of chemical bonds between the atoms and may be influenced by 
molecular structure, molecular interactions and chemical microenvironment of the molecule. 
The positions of the bands and their intensity and shape carry detailed information about the 
molecular composition of the specimen [202]. Previous studies have demonstrated the versatile 
use of vibrational spectroscopy to analyse lung [151], cervix [203], brain [11, 64, 204], breast 
[150], prostate [200] and separate diseased specimens from normal, identification of tumour 
margins and correlation of spectra to tumour grade. Brain tumour studies have been carried out 
in a number of areas which include spectro-imaging of collagen scaffolds during glioma tumour 
development [199], separation of normal and neoplastic tissue using both Raman and IR [11] 
amongst others.  
This study focuses on the potential use of Raman spectroscopy as a diagnostic tool for the rapid 
assessment of diseased tissue from normal tissue, intraoperative tool during tumour resection 
to guide the surgeon by distinguishing between diseased and normal tissue. Spectral data will 
be analysed using multivariate statistics PCA and SVMs to classify the specimens into their 
distinct groups based on the biochemical information obtained from the spectral data. The study 
will compare three brain tumour groups, gliomas, medulloblastomas and meningiomas as well 
as a fourth group formed from different tumours from other CNS groups to a group of normal 
brain tissue and their subgroups. 
6.2 Patients and Methods 
The study was carried out with full ethical approval from both the University of Central 
Lancashire and the Royal Preston Teaching Hospital under STEM 120/BTNW 1409 respectively. 
A total of 358 tissue blocks were obtained from the Brain Tumour North West (BTNW) and after 
processing and quality sorting a total of 263 samples were assigned into four major tumour 
groups, gliomas (n= 128), medulloblastoma (n= 26), meningioma (n= 83) and a group OTHER 
made up different CNS tumours that did not have enough numbers to make up individual groups 
(n= 26) and a fifth group Normal (n= 15) consisting of normal brain tissue. Three more groups 
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were created from the glioma group, GBM (n = 105) and two other groups were formed from a 
subset of the glioma group, high grade gliomas (n= 29) and low grade gliomas (n= 12).    
6.2.1 Sample Preparation 
Thin tissue sections 10 µm in thickness were cut using a microtome (Leica RM2235) and placed 
on Low-E slides (Kevley Technologies, Chesterland, OH, 44026, USA) for Raman spectroscopy. 
The tissue sections were dewaxed by immersion in two sequential baths of xylene for 10 min, 
then washed and cleared in two sequential baths of ethanol for 10 min each and left to air dry. 
The sections were stored in a desiccator until analysis. The sections used in this study were 
previously analysed and graded by a neuropathologist through histopathology at the Royal 
Preston teaching hospital. The sections for biospectroscopy were picked randomly in no 
particular order based on tumour group and then analysed using Raman spectroscopy.   
6.2.2 Raman Acquisition Parameters 
Raman spectra were acquired from each sample using the Horiba Jobin-Yvon LabRam HR800 
spectrometer with an air cooled CLDS point mode diode 532 nm laser with a single edge filter 
(cut off to 100 cm-1) and an output power of 300 mW. Spectra were acquired with a grating of 
300 gr/mm and blazed at 1000 nm. Multiple point map spectra were acquired using Leica 
x50LWD objective with 100 % laser power exposure. The filter was adjusted accordingly based 
on the intensity of the spectral peaks (high intensity required lowering the filter, whilst low 
intensity resulted in increasing the filter). The confocal hole was set at 100 μm for 532 nm 
spectral collections with two accumulations at 15 sec acquisition time. Instrument calibration 
was carried out before spectral acquisition to silicon at spectral line of 520 cm-1. A total of 7890 
spectra from randomly chosen locations were obtained with 30 spectra acquired for each 
sample. Spectra were taken in the range 3200-400 cm-1 and then cut to 1800-800 cm-1 using 
LabSpec 6 (Horiba Scientific, France) for analysis. LabSpec 6 software was used to pre-process 
the spectra by averaging each sample, baseline correction and normalisation. Background 
subtraction was done using a 6th order polynomial fit and de-noised in MATLAB using 60 PCs 
before multivariate analysis.   
6.2.3 Histopathology 
One biological replicate for each brain tumour tissue was histologically assessed by a qualified 
neuropathologist and graded using histopathology as shown in Appendix B. The histological 
groups and grades were subsequently used to group the specimens used for biospectroscopy.    
6.2.4 Raman Data Processing 
A total of 307 data points were produced from the spectral range 1800-800 cm-1.  7890 spectra 
were taken from 263 patients, with 30 spectra for each patient on randomly chosen locations 
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on the tissue. LabSpec 6 (Horiba Scientific, France) software was used to pre-process the spectra 
by averaging each sample, baseline correction using a 6th order polynomial fit using a maximum 
of 107 points and 10 noise points. Normalisation was by area for all the samples de-noised in 
MATLAB (The MathWorks, Inc, USA) using 60 PCs before multivariate analysis. The sample size, 
number of spectra (n = 7890) was greater than 5x the number of variables (n = 307), PCA was 
performed on all the spectra to reduce data dimensionality by summarising data into ordered 
and non-trivial components that can capture more than 95 % of the variance present in the 
original dataset. The selected variables were meaningfully related and correlated. The 
Eigenvectors, also known as the loadings, are similar to a regression slope. They represent 
weights for each component which were used to inform the variance the model used for 
diagnostic segregation of the spectral data. PCA was applied before SVM and its components 
used to reduce computational complexity and increase the recognition accuracy in different 
classes of the SVM. Support Vector Machines (SVMs) (LibSVM 3.12 package), were trained in 
MATLAB with a subset of the sample using two thirds and then tested with a blind set (one third) 
from the remaining sample. Statistical significance for each tumour group compared was carried 
out using Permanova in R Studio (R Foundation for Statistical Computing, Austria).  Permanova 
is a permutational multivariate analysis method in the context of more sampling structures and 
models by adopting a more parametric approach which allows, measuring or testing interactions 
among factors or treatments which can be defined by reference to modelled main effects. The 
model does not assume distributions but works with any distance measure that is appropriate 
to the data by using permutations to make it distribution free.       
6.3 Results and Discussion 
6.3.1 Gliomas vs Normal brain tissue 
A total of 3840 spectra gliomas from 128 glioma patients were combined (Figure 61) and 
compared against normal brain spectra (n = 450) from 15 individuals (Figure 62). The two groups, 
normal and gliomas were combined together, vector normalised using area in LabSpec 6 and 
noise reduced in MATLAB using 60 PCs Figure 63 before PCA.  
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Figure 61. Plot of (n = 128) glioma spectra from all subgroups with both high and low grades combined 
together. 
 
Figure 62. Plot of the spectral range 1800-800 cm-1 of normal human brain tissue spectra (n = 15) taken 
using Raman spectroscopy. These spectra were used to compare normal and diseased tissue from glioma 
patients. 
 
Figure 63. Plot of averaged normal brain tissue (n = 15) and gliomas (n = 128) from various subgroups vector 
normalised in LabSpec 6 using area. Spectra offset for better visualisation. 
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Principal component analysis was carried out in MATLAB (Figure 64) which showed good 
clustering within the two groups’ normal tissue and gliomas. The plot also shows further 
clustering within the glioma groups which reflects the various subgroups, GBMs, astrocytomas, 
gliosarcomas, oligoastrocytomas etc. within the glioma group. Gliomas arise from glia cells 
which are further divided into four groups, astrocytes, oligodendrocytes, microglia and 
ependymal. The actual histological assessment of biopsies presents some challenges as shown 
in a number of studies. The PCA plot highlights some of the challenges faced in histopathology 
when classifying tumours such as gliomas which are on a continuous spectrum of histology and 
malignancy into distinct categories especially tumours such as GBMs which may have two or 
more histologies, glioblastoma with oligodendroglial components, Oligoastrocytoma and 
oligodendroglioma. However, the use of spectral histopathology makes the distinctions 
apparent and easy to replicate as seen in the PCA plot (Figure 64). Classification of tumours such 
as gliomas which are on a continuous spectrum of histology and malignancy into distinct 
categories is a challenge.  
PC1 Loadings 
The PCA plot shows principal component 1 with 37.1 % of the non-trivial variation responsible 
for the separation of normal bran tissue and gliomas. Component 2 with 24.6 % of the variation 
further separates normal brain and other glioma subgroups. Tentative spectral assignments of 
the principal component loadings were based on [11, 57]. Principal component 1 (PC1) loadings 
(Figure 65) shows the major peaks in the positive direction of the Y-axis, corresponding to 
increases in the spectral region 998.9 cm-1 (Glucose-1-phosphate and symmetric ring breathing 
mode of phenylalanine). G1P has been implicated in cancer metabolism in the pentose 
phosphate pathway [205]. The pentose phosphate pathway is one of the main metabolic 
pathway that contributes to the production of macromolecules in mammalian cells. Signalling 
by oncogenes has been shown to drive many of the pathways that are responsible for the 
metabolic response of normal cells to growth-promoting signals. High grade tumours show a 
very high proliferative index (Ki-67) which suggests very high metabolic activity compared to low 
grade tumours [206, 207]. Expression of Ki-67 was shown to correlate with histopathological 
grade and proliferative status in a study to discriminate astrocytomas. The study showed a 
gradual increase in Ki-67 antigen expression with mitotic index and histopathological 
classification of low grade gliomas to high grade gliomas [208].    
An increase at 1046 cm-1 (C-H bending mode in Phenylalanine, C-N stretching in proteins), 1100 
cm-1 (>PO2- symmetrical stretching), and 1449 cm-1 (CH (CH2) bending mode in proteins and 
carbohydrates. High grade gliomas have shown changes in protein and phosphoprotein levels 
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from serum starvation in cell lines [209]. Researchers have theorised about what defines cancer 
and features that signal the metastatic phenotype. Some of the features suggested are the 
ability to grow in medium, as a three dimensional mass, ability to withstand various forms of 
physical stress. Cancer cells have been shown to adapt better to a changing environment than 
normal cells and produce cytokines to create new blood vessels, alter their metabolism to 
become more efficient through anaerobic glycolysis [209]. These observed cell behaviours could 
be attributed to the increases in proteins, carbohydrates observed between high grade and low 
grade gliomas. Peaks in the negative direction, which correspond to decrease in the spectral 
range 1589 cm-1 (Adenine, Guanine (DNA/RNA); C=C bending mode of Phenylalanine and 1639 
cm-1 (Amide I (C=O stretching, C-N stretching and N-H bending, Proteins).   
 
Figure 64. Principal Component Analysis (PCA) plot of normal brain tissue (green) and gliomas 
from various tumour groups (red). The plot shows good separation between normal tissue and 
diseased tissue from gliomas of various subgroups. The plot also shows subgroup clustering within 
gliomas. 
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Figure 65. Plot of principal component 1 loadings showing the specific spectral region accounting 
for 40.1 % of the non-trivial variation used by the model to separate normal brain tissue from 
diseased (gliomas). 
 
 
 
Figure 66. Plot of principal component 2 loadings showing the specific spectral region accounting for 24.6 
% of the variation used by the model to separate normal brain tissue from diseased (gliomas). 
PC2 Loadings 
Principal component 2 (PC2) loadings (Figure 66), accounting for 24.6 % variations separates 
normal and diseased (glioma) brain tissue as follows; in the positive Y-axis direction increase in 
the spectral range 900 cm-1 (C-C stretching mode of Proline and Valine), 1002 cm-1 (C-C aromatic 
ring stretching in Phenylalanine), 1130 cm-1 (C-N stretching in proteins; C-O stretching in 
carbohydrates), 1170 cm-1 (C-H in plane bending mode of Tyrosine and Phenylalanine; Cytosine, 
Guanine), 1236 cm-1 (Amide III), 1311 cm-1 (CH3/CH2) twisting mode of collagen and lipid, 1341 
cm-1 (Guanine (DNA/RNA), CH deformation in proteins and carbohydrates), 1451 cm-1 (CH (CH2) 
bending mode in proteins and lipids), 1585 cm-1 (Adenine, Guanine (DNA/RNA); C=C bending 
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mode of Phenylalanine), 1670 cm-1 (Amide I (C=O stretching, C-N stretching and N-H bending), 
proteins). The negative direction in the Y-axis shows a decrease in the spectral region 1087 cm-
1 (C-O stretching).   
 
 
Figure 67. Plot of offset normal brain tissue spectra (green) and glioma tissue spectra (blue) showing the spectral 
peaks used by PCA to segregate the two groups based only on principal component 1 loadings which carried 37.1 % 
of the variation. The peaks as seen in the loadings are in the positive direction which corresponds to an increase in 
the spectral intensity of the corresponding bands.  
The Raman spectra of normal and glioma tissue does show a number of similarities in 
appearance but noticeable differences can be seen as shown by the offset spectra of the two 
groups (Figure 67). The offset spectra is an average of all the normal brain tissue spectra and 
glioma spectra made into two spectra. The plot highlights the major wavenumber differences in 
the region 1100 cm-1 to 998 cm-1 which correspond to carbohydrate moieties which have been 
previously suggested to indicate variations in the ganglioside profile of human gliomas with 
increasing degree of malignancy [11, 129]. 
Support vector machines 
Spectra were organised into sets, a training set (two thirds), n = 85, from both normal and glioma 
groups and a blind set (one third), n = 43, from normal and glioma groups. A radial basis function 
kernel linear support vector machine (RBF-SVM) which used principal component 1 and 2 data 
was used to classify the groups using the LibSVM 3.12 package in MATLAB. The optimal Cost and 
Gamma parameter values used were obtained by a grid search combined with a one versus rest 
(OVR) mode. An initial wide grid search was performed and the best parameters yielding; 
Accuracy = 100 % were; cost = 11.3137, gamma = 1.1892. Figure 68 shows a pictorial 
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representation of how well the model performed by comparing decision values and predicted 
labels, true labels with output labels. The closer the resemblance the better the classification.   
 
Figure 68. Plot showing the decision values and predicted labels, true labels and the output labels after machine 
training. The decision values are identical to the predicted labels which resulted in the machine output labels being 
similar to the true labels based on cost = 11.3137 and gamma = 1.1892 parameters.   
In order to assess the quality of the discrimination measures of sensitivity and specificity were 
used based on the confusion matrix. Sensitivity measures the ability of the machine to correctly 
classify (Eq. 1) and specificity measures the ability of the machine not to misdiagnose (Eq. 2) 
[58]. The model was able to classify the test data 38 gliomas and 5 normal brain tissue into the 
correct groups yielding a sensitivity and specificity of 100 %. Sensitivity and specificity was 
calculated as; 
𝑆𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 =  
𝑇𝑟𝑢𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒
𝑇𝑟𝑢𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒+𝐹𝑎𝑙𝑠𝑒 𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒
 (13) 
𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦 =  
𝑇𝑟𝑢𝑒 𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒
𝑇𝑟𝑢𝑒 𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒+𝐹𝑎𝑙𝑠𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒
 (14) 
True positives: Number of spectra where samples were correctly identified as cancerous 
(gliomas) 
True negatives: Number of spectra identified as non-cancerous (normal) 
False positives: Number of spectra where the model incorrectly identifies samples as non-
cancerous (normal) when they are cancerous (gliomas). 
False Negatives: Number of spectra where the model has incorrectly identified samples as non-
cancerous when it is cancerous. Table 17 shows the conditions used to identify the correct 
disease or non-disease entities used in the sensitivity and specificity equation.  
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Table 17.  Sensitivity and Specificity table giving the conditions for true positive, false positive, false negative 
and true negative. 
 Disease Non-Disease 
Disease True Positive False Positive 
Non-Disease False Negative True Negative 
 
Significance Testing 
The statistical significance of the difference between normal brain tissues versus gliomas was 
carried out based on principal component 1 which carried 37.1 % of the non-trivial variation, 
using data from the weighted loadings which the model used to separate the two groups. The 
Mann-Whitney U-test was carried out to determine if the median of functional groups or 
molecules at the wavenumber used by the model to classify was significantly different. Although 
the data were normally distributed a two sample T-test was not used because the data showed 
heteroscedasticity and as such a non-parametric test was appropriate. A summary of the results 
of the test and their associated averages are shown in (Table 18). The individual plots of the 
wavenumber regions which had a significant differences are shown in, Figure 69, Figure 70, 
Figure 71, Figure 72, Figure 73.  
The differences in the amount of protein between normal brain tissue and gliomas could be 
attributed to a number of known biological events. HSP90α protein has been shown through 
experiments to be expressed only in glioma tissue and cells and not normal brain tissue and 
cells. Shervington el al. showed that HSP90α protein was expressed in gliomas and not normal 
brain tissue and cells. Their study looked at 3 glioma cell lines and 2 controls and brain tissue 
specimens from 10 patients, 8 gliomas and 2 normal brain tissue. They reported no HSP90α 
protein expression in the normal brain tissue and cells. All the glioma samples both tissue and 
cells expressed HSP90α [210]. Other studies highlighted increases in the expression of 
housekeeping gene human MutS homologue (hMSH2) in gliomas compared to normal brain 
tissue [211], overexpression of B-Cell lymphoma 2 (bcl-2) which plays an important role in 
inhibiting apoptosis in gliomas [49]. Alderson et al. reported a correlation between 
overexpression of blc-2 in gliomas and wild-type p53 [57], Poly (ADP-ribose) polymerase 1 
(PARP-1) gene plays an important role in maintaining genome integrity. PARP-1 protein is 
involved in the apoptosis inducing factor (AIF) translocation from mitochondria to the nucleus. 
Galia et al. reported the overexpression of PARP-1 in GBMs and not in normal brain tissue [6].   
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Table 18. Shows differences between gliomas and normal brain tissue based on the wavenumber areas used 
by the PCA model to classify the two groups using weighted loadings. These figures were based on PC1 
loadings. Where P-values were very low 0.001 was used to avoid the use of very huge small numbers with 
plenty of zeros.  
WAVENUMBER P-VALUE W-
STATISTIC 
MEDIAN PLOT 
Glioma Normal 
PC1 LOADINGS 
998 CM-1 0.001* 1534 0.295 0.169 Fig. 69 
1046 CM-1 0.001* 1432 0.338 0.178 Fig. 70 
1100 CM-1 0.001* 1625 0.460 0.127 Fig. 71 
1449 CM-1 0.001* 1550 0.464 0.283 Fig. 72 
1589 CM-1 0.001* 1407 0.189 0.106 Fig. 73 
 * Significant threshold ≤0.05 
 
 
Figure 69. Boxplot showing the differences between the intensities at 998 cm-1 between gliomas (G=red) 
and normal (N=Green) brain tissue. There is a significant difference between the two groups with P=<0.001. 
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Figure 70. Boxplot showing the differences between the intensities at 1046 cm-1 between gliomas (G=red) 
and normal (N=Green) brain tissue. There is a significant difference between the two groups with P=<0.001. 
 
 
Figure 71. Boxplot showing the differences between the intensities at 1100 cm-1 between gliomas (G=red) 
and normal (N=Green) brain tissue. There is a significant difference between the two groups with P=<0.001. 
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Figure 72. Boxplot showing the differences between the intensities at 1449 cm-1 between gliomas (G=red) 
and normal (N=Green) brain tissue. There is a significant difference between the two groups with P=<0.001. 
 
 
Figure 73. Boxplot showing the differences between the intensities at 1449 cm-1 between gliomas (G=red) 
and normal (N=Green) brain tissue. There is a significant difference between the two groups with P=<0.001. 
 
6.3.2 High grade gliomas vs Low grade gliomas 
A subset of the glioma group (n = 1230 spectra) from 41 patients was divided into high (n = 870 
spectra) and low (n =360 spectra) grade groups. The two groups were combined together, vector 
normalised using area in LabSpec 6 and noise reduced in MATLAB using 60 PCs, (Figure 74).   
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Figure 74. Plot of averaged high grade gliomas from (n = 29 patients) and low grade gliomas (n = 12) in the 
spectral range 1800-800 cm-1 was vector normalised in LabSpec 6 using area and noise reduced using 60 
PCs in MATLAB. 
 
The spectral data was then classified using PCA to reduce dimensionality as well as extract the 
best components for SVM and significant testing. PC1 and 2 produced relatively good clustering 
with some overlap as seen in (Figure 75)    
 
Figure 75. Principal Component Analysis (PCA) plot of high grade gliomas (red) and low grade gliomas (blue). 
The plot shows relatively good separation with overlap of the high grade gliomas clustering with low grade 
gliomas. 
The PCA plot shows an overlap of samples with high grade gliomas being grouped with low grade 
gliomas. In the high grade glioma group a few sub-clusters can be seen with at least one low 
grade glioma being grouped with the high grade glioma group. Gliomas arise from glial cells and 
the two main types in CNS are astrocytes and oligodendrocytes. High grade gliomas used in the 
model consisted of GBMs, astrocytomas grade III, gliosarcoma IV, and GBMs with focal oligo 
features IV. The low grade group consisted of ependymoma grade II, astrocytoma grade I and II, 
and oligodendroglioma grade II. The model shows two major clusters separating some but not 
all high grade and low grade gliomas using PC 1 which has 45.4 % of the non-trivial variation. 
Sub-clusters within both the high grade and low grade glioma groups are seen Figure 75 which 
are consistent with histological type represented in the groups. The plot illustrates the 
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challenges faced in histopathology when trying to classify tumours such as gliomas which are on 
a continuous spectrum of histology and malignancy into distinct categories. To compound this 
challenge some tumour subtypes such as glioblastoma with oligodendroglial components, 
oligoastrocytoma and oligodendroglioma have characteristics of two or more histologies making 
them particularly problematic to replicate. However the PCA model appears to form clusters 
which groups them very well together making it easier to identify them. There are other tumours 
which have ambiguous morphological appearance for which no clear consensus exists [6], which 
makes such types of specimens very difficult to classify.  
A number of high grade tumours GBMs have been classified as low grade mostly with other low 
grade astrocytomas grade II. These samples would require further analysis with the view of 
changing the classification as this would greatly affect therapeutic management and prognosis. 
As previously shown discrepancies related to histological grade 19 %, type 11 %, subtype 5 %, 
grade plus subtype or grade plus histological type 12% are currently a challenge in 
histopathology. In centres were reviews are carried out over 45 % of first histological diagnoses 
were modified at second reading resulting in different treatment decisions [57, 143, 212]. 
Spectral histopathology can prove to be a good tool to identify specimens which pose such a 
challenge as shown in Figure 75.  PC1 and 2 loadings (Figure 76, Figure 77) show the spectral 
peaks the PCA model used to separate the two groups based on a 65.9 % variation.  
 
Figure 76. Plot of PC 1 loadings with 45.4 % non-trivial variation separating the two groups high and low 
grade glioma. 
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Figure 77.  Plot of PC 2 loadings with 20.5 % variation separating the two groups high and low grade glioma. 
PC1 Loadings 
The major peaks from PC1 positive direction loadings separating high and low grade gliomas 
show an increase in band intensities at 998.9 cm-1 (Glucose-1-phosphate and symmetric ring 
bending mode of phenylalanine), 1042 cm-1 ( C-H bending mode in Phenylalanine, C-N stretching 
in proteins), 1242-1266 cm-1 (Amide III(C-N stretching, N-H bending, proteins), PO2 asymmetric 
stretching (DNA/RNA), 1308 cm-1 (Lipid, collagen, protein Amide III, DNA purine bases, 
phenylalanine), 1340 cm-1 (Guanine (DNA/RNA), CH deformation in proteins and carbohydrates), 
1447 cm-1 (CH(CH2) bending mode in proteins and lipids, 1584-1657 cm-1 (Adenine, Guanine 
(DNA/RNA); C=C bending mode of Phenylalanine, C=C Phenylalanine, Tyrosine and Tryptophan, 
Amide I (C=O stretching, C-N stretching and N-H bending, proteins). The negative direction of 
PC1 loadings shows a decrease in intensities at 1089-1170 cm-1 (C-H bending mode in 
Phenylalanine, C-N stretching in proteins, PO2 symmetric stretching (DNA/RNA), C-O stretching, 
C-N stretching in proteins; C-O stretching in carbohydrates, C-C and C-N stretching of 
proteins/lipids, C-H in plane bending mode of Tyrosine and Phenylalanine; Cytosine, Guanine).    
PC2 Loadings 
PC2 loadings (Figure 77) accounted for 20.5 % of variation used by the model to separate high 
and low grade gliomas. Loadings in the positive direction represented an increase in the intensity 
of bands at, 1002 cm-1 (C-C aromatic ring stretching in Phenylalanine), 1039 cm-1 (C-H bending 
mode in Phenylalanine, C-N stretching in proteins), 1457 cm-1 (Protein δ(Ch2/CH3), 1657-1710 
cm-1 (Amide I(C=O stretching, C-N stretching and N-H bending, proteins). The negative direction 
peaks representing a decrease in intensities for spectral bands at; 995.6 cm-1 (Glucose-1-
phosphate and symmetric ring breathing mode of Phenylalanine), 1308 cm-1 (Lipids, collagen, 
protein Amide III, DNA purine bases, Phenylalanine), 1370 cm-1 (Guanine (DNA/RNA), CH 
deformation in proteins and carbohydrates), 1428 cm-1 (CH(CH2) bending mode in proteins and 
lipids), 1585 cm-1 (Adenine, Guanine(DNA/RNA); C=C bending mode of Phenylalanine), 1632 cm-
1 (Amide I (C=O stretching, C-N stretching and N-H bending, Proteins).    
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Support vector machines 
The training set was made up of spectra (n = 450) from 15 patients with high grade gliomas and 
spectra (n = 180) from 6 patients with low grade gliomas. The blind set consisted of spectra from 
14 high grade glioma patients (n = 420) and 6 low grade glioma patients (n = 180). Machine 
training was carried out using the first two principal components from the PCA model on an SVM 
using the LibSVM 3.12 package in MATLAB. The optimal Cost and Gamma parameter values used 
were obtained by a grid search combined with a one versus rest (OVR) mode. The best 
parameters yielding; Accuracy = 80.9 % were; cost = 4.7568, gamma = 0.37163. Figure 78 shows 
the decision values, true labels predicted labels and the output labels the machine used based 
on the cost and gamma parameters.  
The machine was able to correctly classify 12 high grade glioma patients as having high grade 
gliomas, 4 patients with low grade gliomas incorrectly as having high grade gliomas, 2 low grade 
glioma patients correctly as having low grade gliomas and incorrectly classifying 2 high grade 
glioma patients as having low grade gliomas. Classification accuracy of the machine was 
calculated based on sensitivity and specificity; Sensitivity = 75 % and Specificity = 50 %.    
 
Figure 78. Plot showing the decision values and predicted labels, true labels and the output labels after 
machine training. Differences can be seen with the decision values and the predicted labels which resulted 
in the machine output labels being different to the true labels based on cost = 4.7568 and gamma = 0.37163 
parameters.  
Significance Testing 
A significant test was carried out on the major spectral peaks identified by principal component 
loadings as providing the greatest non-trivial variation responsible for the separation of the two 
groups. Wavenumbers corresponding to the peak areas were selected and their intensities 
tested to investigate statistical significance between the two groups. A Two Sample T-Test was 
used to determine if the mean of the two groups at the chosen wavenumbers was significantly 
different. The model assumptions were checked using diagnostic checks in R Studio and the 
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model was appropriate for the data. Differences between the two groups at specific 
wavenumbers are shown in Figure 79, Figure 80, and Figure 81.  
Table 19. Shows differences between high grade gliomas and low grade gliomas based on the wavenumber 
areas used by the PCA model to classify the two groups using weighted loadings. These figures were based 
on PC1 loadings.  
WAVENUMBER P-VALUE T-STATISTIC MEAN PLOT 
High grade 
Glioma 
Low grade 
Glioma 
PC1 LOADINGS 
998 CM-1 0.523 0.647 2.083 2.212 N/A 
1042 CM-1 0.180 1.404 3.062 4.040 N/A 
1242 CM-1 0.053* 1.998 0.944 1.168 Fig. 81 
1308 CM-1 0.146 1.484 1.259 1.483 N/A 
1340 CM-1 0.324 1.656 1.553 1.704 N/A 
1447 CM-1 0.118 1.656 3.203 3.796 N/A 
1584 CM-1 0.178 1.411 1.350 1.936 N/A 
1656 CM-1 0.008* 2.865 2.160 3.098 Fig. 86 
1090 CM-1 0.001* 3.860 3.654 2.425 Fig. 87 
* Significant threshold ≤0.05 
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Figure 79. Boxplot showing the differences between the intensities at 1242 cm-1 between high grade 
gliomas (H=red) and low grade gliomas (L=Green) tumours. There is a significant difference between the 
two groups (P=<0.05). 
 
 
 
Figure 80. Boxplot showing the differences between the intensities at 1656 cm-1 between high grade 
gliomas (H=red) and low grade gliomas (L=Green) tumours. There is a significant difference between the 
two groups (P=<0.008). 
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Figure 81. Boxplot showing the differences between the intensities at 1090 cm-1 between high grade 
gliomas (H=red) and low grade gliomas (L=Green) tumours. There is a significant difference between the 
two groups (P=<0.001). 
PC 1 loadings carried 45.4 % of the non-trivial variation used by the model to separate high and 
low grade gliomas, most of the major peaks showed no significant difference between the two 
groups has shown in Table 19. This could explain why specificity from the support vector 
machines is 50 %. Three regions at wavenumbers, 1090, 1242 and 1656 cm-1, had spectral peaks 
that showed a significant difference, with two of the regions, 1242 and 1656 cm-1 showing 
significantly high intensities with low grade gliomas and 1090 cm-1 showing high intensities with 
high grade gliomas. These spectral areas have the potential of becoming good diagnostic tools 
for differential diagnostics of high and low grade gliomas in spectral histopathology. The 
diagnostic importance of the lipid to protein ratio was demonstrated by Campanella, in a study 
of human astrocytomas of various grades [168] which showed that an increase in malignancy 
correlated with; 
1. Reduction of the total lipids which involved all the principal classes of the plasma 
membrane, cholesterol, phospholipids, neutral and acidic glycosphingolipids, and 
sulphatides correlating exponentially with an increase in histological grading. 
2. A gradual accumulation of lattosyceramide and GD3 molecules that are part of 
glycosphingolipids. These molecules are seen as valid markers for malignancy 
grade. Glycolipid composition of high grade and low grade gliomas differ 
significantly. 
3. A gradual increase in the area of phospholipids, of PC/PE and PC/SM ratios which 
are indices of the microviscocity of the membrane.   
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In brain tumours this organisation is expected to change as the cell changes form and function. 
This change is expected to increase with degree of malignancy as shown by the results of this 
study.  
Tree Analysis 
Running the model again using tree analysis, based on the spectral region which had shown 
statistically significant differences between the two groups improved the classification accuracy 
from 50 % to 93 %. The model output, (Table 20) is another way of presenting information shown 
by the plot with some additional information. Line 1 labelled “Root” relates to the starting group 
comprising all individuals, the size of which (41) is the first number given. The second value is 
the amount of deviance which is 49.570 which is the same as the sum of squares. As we go down 
the tree the value of deviance reduces. The next on line 1 is the word High. This tells us which 
of the groups (species) is more numerous in the group. If there is the same number e.g. High 
and Low the first group alphabetically or numerically will be given. In our data at node 2, there 
are 25 brain tumour samples all of which are less than 3.840 in intensity at wavenumber 1090 
cm-1 made up of 13 (25 x 0.5200) high grade gliomas and 12 low grade gliomas and a deviance 
of 34.620.     
 
Figure 82. Plot showing part of a tree model used to classify high grade and low grade gliomas based on 
three spectral regions, 1090, 1242 and 1656 cm-1. These regions showed statistical significance between 
the two groups. The tree model had 41 nodes with a classification accuracy of 93 %.  
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Table 20. Shows another version of the tree analysis plot with some additional information relating to 
how the model classified the data. 
1) Root 41  49.570  high  (0.7073  0.2927) 
2) 1090 cm-1 < 3.84053         25         34.620  high  (0.5200  0.4800) 
4) 1090 cm-1 < 2.46009         9           9.535  Low    (0.2222  0.7778) 
8) 1242 cm-1 < 1.30106         4           0.000  Low    (0.000   1.0000)* 
9) 1242 cm-1 > 1.30106         5           6.730   Low    (0.4000  0.6000)        
      18) 1656 cm-1 < 3.59365           3          3.819   High   (0.06667  0.3333)* 
      19) 1656 cm-1 > 3.59365           2          0.000  Low    (0.0000   1.0000)* 
       5)   1090 cm-1 > 2.46009          16       19.870  High  (0.6875  0.3125)   
10) 1090 cm-1 < 3.37763         12       10.810  High  (0.8333  0.1667) 
       20)  1242 cm-1 < 0.999958       5         6.730  High   (0.6000  0.4000) 
       40)  1656 cm-1 < 3.08814         3         3.819  Low    (0.3333   0.6667)* 
       41)  1656 cm-1 > 3.08814         2         0.000  High   (1.0000   0.0000)* 
       21)   1242 cm-1 > 0.999958      7        0.000   High   (1.0000   0.0000)* 
11)  1090 cm-1 > 3.37763         4        4.499  Low    (0.2500   0.7500) * 
3)  1090 cm-1 > 3.84053        16       0.000  High   (1.000    0.0000)* 
 
The model had 41 nodes, and misclassified 3 samples from a total of 41 resulting in a 
classification accuracy of 93 % which is up 43 % compared to SVM previous classification based 
on major peaks of PC1 loadings. Targeting specific spectral regions where intensities show a 
statistical significance improves classification accuracy which can provide better diagnostic 
outcomes when dealing with challenging specimens such as glioma subgroups.  
A study by Gajjar et al. used a similar approach to distinguish differences between and with brain 
tumour subtypes by using multivariate statistical models to evaluate spectral data [11]. In their 
Raman study they used a two-category discriminant analysis using PCA-LDA following Raman 
spectroscopy. Their approach compared normal brain tissue with each tumour subtype and 
using the loading plots to identify the wavenumber region responsible for the separation. The 
study reported similar wavenumber regions used by this study to separate the different groups 
and their subtypes. This provides strong evidence that Raman spectroscopic diagnosis is 
reproducible. The difference in the Gajjar study to this study is that they used the ratio of 
phospholipids-to-nucleic acids/proteins which was obtained by calculating the Raman peak 
intensities for phospholipids and nucleic acids in their spectral data to determine histological 
grade. The lipid to nucleic acid ratio has been previously reported to correlate with 
histopathological studies grading malignancy by nucleic acid-to- cytoplasmic ratio [133]. This 
study instead looked at spectral regions which had a significant difference in separating the two 
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groups’ high grade and low grade gliomas used by the multivariate statistical model and 
identified by the PCA loadings.    
6.3.3 Glioblastoma vs Normal  
A total of 3150 raw spectra from GBM (n = 89) and normal (n = 16) brain tissue from 105 
individuals, were combined (Figure 83), vector normalised using area in LabSpec 6 and noise 
reduced with 60 PCs in MATLAB before PCA.  
 
Figure 83. Plot of averaged GBM from (n = 89 patients) and normal (n = 16) in the spectral range 1800-800 
cm-1, vector normalised in LabSpec 6 using area and noise reduced using 60 PCs in MATLAB. 
 
The spectral data was then classified using PCA to reduce dimensionality as well as extract the 
best components for SVM and significant testing. PC1 and 2 (Figure 84, Figure 85) produced 
good clustering with evidence of subgrouping of GBM samples.   
 
Figure 84. Principal Component Analysis (PCA) plot of GBM (red) and normal brain (green). The plot shows 
good separation with evidence of further subgrouping of GBM samples. 
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Figure 85. Plot of PC 1 loadings with 40.1 % non-trivial variation separating the two groups GBM and Normal. 
 
 
 
Figure 86. Plot of PC 2 loadings with 24.8 % variation separating the two groups GBM and Normal. 
PC1 Loadings 
PC1 loadings (Figure 85) had 40.1 % of the non-trivial variation spread over the entire spectral 
region. However major bands were used to evaluate the weight of the loadings and their 
contribution to the separation of the two groups. The positive bands represented an increase in 
spectral intensity at, 998 cm-1 (Glucose-1-phosphate and symmetric ring breathing mode of 
Phenylalanine), 1046 cm-1 (C-H bending mode in Phenylalanine, C-N stretching in proteins), 1079 
cm-1 (PO2 symmetric stretching (DNA/RNA), 1453 cm-1 (CH(CH2) bending mode in proteins and 
lipids, 1638-1675 cm-1 (Amide I(C=O stretching, C-N stretching and N-H bending, proteins). In 
the negative direction a decrease at 1584 cm-1 (Adenine, Guanine (DNA/RNA); C=C bending 
mode of Phenylalanine).  
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PC2 Loadings 
PC2 components (Figure 86) contributed 24.8 % of the variation used by the model to separate 
the two groups. Spectral bands in the positive direction represented an increase at, 1002 cm-1 
(Lipids and proteins, Phenylalanine), 1079 cm-1 (PO2 symmetric stretching (DNA/RNA), 1242 cm-
1 (Amide III), and 1581 cm-1 (Adenine, Guanine (DNA/RNA); C=O bending mode of Phenylalanine) 
and at 1311, 1451, 1635 and 1666 cm-1.  
Support Vector Machines 
The training set was made up of two thirds (n = 1770 spectra) from 59 patients with GBMs and 
one third (n = 300 spectra) from 10 normal brain tissue. The blind set consisted of spectra (n = 
900) from 30 GBM patients and spectra (n = 180) from 6 normal brain tissue. Machine training 
was carried out using the first two principal components from the PCA model on an SVM using 
the LibSVM 3.12 package in MATLAB. The optimal Cost and Gamma parameter values used were 
obtained by a grid search combined with a one versus rest (OVR) mode. The best parameters 
yielding; Accuracy = 100 % were; cost = 4.7568, gamma = 0.77111. Figure 87 shows the decision 
values, true labels predicted labels and the output labels the machine used based on the cost 
and gamma parameters.  
The machine was able to correctly classify 30 GBM patients as having GBM, 5 normal brain tissue 
as normal brain tissue, and 1 normal brain tissue incorrectly as a GBM. Classification accuracy of 
the machine was calculated based on sensitivity and specificity; Sensitivity = 97 % and Specificity 
= 100 %.    
 
Figure 87. Plot showing the decision values and predicted labels, true labels and the output labels after 
machine training. Differences can be seen with the decision values and the predicted labels which resulted 
in the machine output labels being different to the true labels based on cost = 4.7568 and gamma = 0.37163 
parameters. 
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Significance Testing 
A significance test was carried out on the major spectral peaks identified by principal component 
loadings as providing the greatest non-trivial variation responsible for the separation of the two 
groups. Wavenumbers corresponding to the peak areas were selected and their intensities 
tested to investigate statistical significance between the two groups. The Mann-Whitney U-test 
was carried out to determine if the median of functional groups or molecules at the 
wavenumber used by the model to classify was significantly different. Table 21 shows the results 
from the test and (Figure 88, Figure 89, Figure 90, Figure 91, Figure 92, Figure 93) shows the 
differences. Although the data was normally distributed a two sample T-test was not used 
because the data showed heteroscedasticity and as such a non-parametric test was appropriate; 
Table 21. Shows Significance differences between GBM and normal brain tissue based on the wavenumber 
areas used by the PCA model to classify the two groups using weighted loadings. The spectral areas were 
based on PC1 loadings. 
WAVENUMBER P-VALUE W-
STATISTIC 
MEDIAN PLOT 
GBM Normal 
PC1 LOADINGS 
998 CM-1 0.001* 1302 0.303 0.173 Fig. 88 
1046 CM-1 0.003* 1042 0.352 0.254 Fig. 89 
1079 CM-1 0.001* 1345 0.386 0.127 Fig. 90 
1454 CM-1 0.001* 1297 0.440 0.279 Fig. 91 
1638 CM-1 0.001* 1175 0.230 0.147 Fig. 92 
1584 CM-1 0.001* 1194 0.181 0.107 Fig. 93 
* Significance threshold ≤0.05 
These panels represented by the 6 wavenumber regions can be selected and used in new 
classification models to achieve even higher sensitivities as previously shown with Tree Analysis 
Model.    
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Figure 88. Boxplot showing the differences between the intensities at 998 cm-1 between GBM (G=red) and 
normal brain tissue (N=Green). There is a significant difference between the two groups (P=<0.001). 
 
 
Figure 89. Boxplot showing the differences between the intensities at 1046 cm-1 between GBM (G=red) 
and normal brain tissue (N=Green). There is a significant difference between the two groups (P=<0.003). 
 
Figure 90. Boxplot showing the differences between the intensities at 1079 cm-1 between GBM (G=red) 
and normal brain tissue (N=Green). There is a significant difference between the two groups (P=<0.001). 
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Figure 91. Boxplot showing the differences between the intensities at 1454 cm-1 between GBM (G=red) 
and normal brain tissue (N=Green). There is a significant difference between the two groups (P=<0.001). 
 
 
Figure 92. Boxplot showing the differences between the intensities at 1638 cm-1 between GBM (G=red) 
and normal brain tissue (N=Green). There is a significant difference between the two groups (P=<0.001). 
 
 
Figure 93. Boxplot showing the differences between the intensities at 1584 cm-1 between GBM (G=red) 
and normal brain tissue (N=Green). There is a Significance difference between the two groups (P=<0.001). 
PCA of normal brain compared to GBM tissue showed good separation of tissue classes with a 
subclasses of GBM tissue. The within class differences could be attributed to the inherent 
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heterogeneity of the tumour tissue as well as possible misclassification of histological grading 
by histopathology. There is a need to review the individual specimens found in the clusters 
outside the main group using other techniques such as molecular pathology. 
6.3.4 Meningioma vs Normal 
A total of 2490 spectra from meningioma and normal brain was taken from 83 individuals, 
meningioma (n =66) and normal brain tissue (n = 17) were combined, vector normalised using 
area in LabSpec 6 and noise reduced with 60 PCs in MATLAB before PCA (Figure 94).  
 
Figure 94. Plot of averaged meningioma spectra from (n = 66 patients) and normal brain tissue (n = 17) in 
the spectral range 1800-800 cm-1, vector normalised in LabSpec 6 using area and noise reduced using 60 
PCs in MATLAB. 
 
The spectral data was then classified using PCA to reduce dimensionality as well as extract the 
best components for SVM and Significance testing. PC1 and 2 (Figure 95) produced good 
clustering of member from the same group with slight overlap. 
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Figure 95. Principal Component Analysis (PCA) plot of meningioma (red) and normal brain (green). The plot 
shows good separation with slight overlap between the groups.  
PC1 Loadings 
PC1 loadings had 39.1 %, (Figure 96) of the non-trivial variation spread over the entire spectral 
region. Only major bands were used to evaluate the weight of the loadings and their 
contribution to the separation of the two groups. The positive bands represented an increase in 
spectral intensity at, 998 cm-1 (Glucose-1-phosphate and symmetric ring breathing mode of 
Phenylalanine), 1046 cm-1 (C-H bending mode in Phenylalanine, C-N stretching in proteins), 1079 
cm-1 (PO2 symmetric stretching (DNA/RNA), 1453 cm-1 (CH(CH2) bending mode in proteins and 
lipids, 1675 cm-1 (Amide I(C=O stretching, C-N stretching and N-H bending, proteins). In the 
negative direction a decrease at 1584 cm-1 (Adenine, Guanine (DNA/RNA); C=C bending mode 
of Phenylalanine).  
PC2 Loadings 
PC2 loadings Figure 97 accounted for 30.1 % of variation used by the model to separate high and 
low grade gliomas. Loadings in the positive direction represented an increase in the intensity of 
bands at, 1002 cm-1 (C-C aromatic ring stretching in Phenylalanine), 1039 cm-1 (C-H bending 
mode in Phenylalanine, C-N stretching in proteins), 1457 cm-1 (Protein δ(Ch2/CH3), 1657-1710 
cm-1 (Amide I (C=O stretching, C-N stretching and N-H bending, proteins). The negative direction 
peaks representing a decrease in intensities for spectral bands at; 998 cm-1 (Glucose-1-
phosphate and symmetric ring breathing mode of Phenylalanine), 1447 cm-1 (CH(CH2) bending 
mode in proteins and lipids), 1585 cm-1 (Adenine, Guanine (DNA/RNA); C=C bending mode of 
Phenylalanine), 1670 cm-1 (Amide I (C=O stretching, C-N stretching and N-H bending, Proteins).    
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Figure 96. Plot of PC 1 loadings with 39.1 % non-trivial variation separating the two groups’ meningioma 
and Normal. Most of the major peaks are broad peaks covering a wide area.  
 
Figure 97.  Plot of PC 2 loadings with 30.1 % variation separating the two groups’ meningioma and Normal. 
Support vector machines 
The training set was made up of two thirds (n = 1320 spectra) from 44 patients with meningioma 
and 11 normal brain tissue (n = 330 spectra). The blind set consisted of spectra (n = 660) from 
22 meningioma patients and spectra (n = 180) from 6 normal brain tissue. Machine training was 
carried out using the first two principal components from the PCA model on an SVM using the 
LibSVM 3.12 package in MATLAB. The optimal Cost and Gamma parameter values used were 
obtained by a grid search combined with a one versus rest (OVR) mode. The best parameters 
yielding; Accuracy = 96.3 % were; cost = 2048, gamma = 0.015625. (Figure 98) shows the decision 
values, true labels predicted labels and the output labels the machine used based on the cost 
and gamma parameters.  
The machine was able to correctly classify 22 high meningioma patients as having meningioma, 
5 normal brain tissue correctly as normal brain, and incorrectly classifying 1 normal brain tissue 
as meningioma. Classification accuracy of the machine was calculated based on sensitivity and 
specificity; Sensitivity = 100 % and Specificity = 83 %.    
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Figure 98. Plot showing the decision values and predicted labels, true labels and the output labels after 
machine training. Differences can be seen with the decision values and the predicted labels which resulted 
in the machine output labels being different to the true labels based on cost = 2048 and gamma = 0.015625 
parameters. 
Significance Testing 
A significance test was carried out on the major spectral peaks identified by principal component 
loadings as providing the greatest non-trivial variation responsible for the separation of the two 
groups. Wavenumbers corresponding to the peak areas were selected and their intensities 
tested to investigate statistical significance between the two groups. A Two Sample T-Test was 
used to determine if the mean of the two groups at the chosen wavenumbers was significantly 
different. The model assumptions were checked using diagnostic checks in R Studio and the 
model was appropriate for the data. A panel of 6 spectral regions showed significant differences 
between the two groups as shown in The differences between the groups are shown in Figure 
99, Figure 100, Figure 101, Figure 102, Figure 103, Figure 104.  
Table 22. The differences between the groups are shown in Figure 99, Figure 100, Figure 101, 
Figure 102, Figure 103, Figure 104.  
Table 22. Shows Significance differences between meningiomas and normal brain tissue based on the wavenumber 
areas used by the PCA model to classify the two groups using weighted loadings. The spectral areas were based on 
PC1 loadings. 
WAVENUMBER P-VALUE T-
STATISTIC 
MEAN PLOT 
Meningioma Normal 
PC1 LOADINGS 
998 CM-1 0.001* 4.889 0.295 0.196 Fig. 99 
1046 CM-1 0.002* 3.267 0.398 0.261 Fig. 100 
1079 CM-1 0.001* 12.234 0.404 0.145 Fig. 101 
[173] 
 
1454 CM-1 0.001* 3.85 0.453 0.319 Fig. 102 
1675 CM-1 0.001* 5.368 0.341 0.212 Fig. 103 
1584 CM-1 0.001* 3.286 0.191 0.130 Fig. 104 
* Significance threshold ≤0.05 
 
 
Figure 99. Boxplot showing the differences between the intensities at 998 cm-1 between Meningioma 
(M=red) and normal brain tissue (N=Green). There is a significant difference between the two groups 
(P=<0.001). 
 
 
Figure 100. Boxplot showing the differences between the intensities at 1046 cm-1 between Meningioma 
(M=red) and normal brain tissue (N=Green). There is a significant difference between the two groups 
(P=<0.002). 
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Figure 101. Boxplot showing the differences between the intensities at 1079 cm-1 between Meningioma 
(M=red) and normal brain tissue (N=Green). There is a significant difference between the two groups 
(P=<0.001). 
 
 
 
Figure 102. Boxplot showing the differences between the intensities at 1454 cm-1 between Meningioma 
(M=red) and normal brain tissue (N=Green). There is a significant difference between the two groups 
(P=<0.001). 
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Figure 103. Boxplot showing the differences between the intensities at 1657 cm-1 between Meningioma 
(M=red) and normal brain tissue (N=Green). There is a significant difference between the two groups 
(P=<0.001). 
 
 
Figure 104. Boxplot showing the differences between the intensities at 1657 cm-1 between Meningioma 
(M=red) and normal brain tissue (N=Green). There is a significant difference between the two groups 
(P=<0.001 
There is a considerable difference between the protein levels of meningiomas and normal tissue 
identified in this study evidenced by the wavenumber regions used to separate the two groups. 
Das et al. investigated the overexpression of mdm2 and p53 and their association with 
progesterone receptor in benign meningiomas [101]. In their study progesterone was frequently 
found expressed in meningiomas at high levels. The study identified a correlation between 
overexpression of progesterone with overexpression of nuclear mdm2. Nuclear mdm2 
overexpression was confined to progesterone receptor positive tumours, while p53 
overexpression was not confined to progesterone receptor expression. The relationship 
between p53 and the presence of progesterone receptor may have important applications in 
the development of progesterone receptor targeted therapies for meningioma and could 
explain the significant presence of protein in meningiomas compared to normal brain tissue. 
This could also explain why meningiomas incidence appears double in women compared to men. 
Wang et al. investigated gene expression in meningiomas and brain arachnoid tissue [151]. Their 
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study showed that the EGFL6 a protein coding gene which encodes a member of the epidermal 
growth factor (EGF) repeat superfamily, was overexpressed in benign meningioma. The gene 
product contains a signal peptide, an EGF repeat region consisting of 4 complete EGF-like 
repeats and 1 partial EGF-like repeat, 3 of which have a calcium binding consensus, an arg-gly-
asp integrin association motif, and a MAM domain which has adhesive function [151].  
6.3.5 Medulloblastoma vs Normal 
A total of 780 spectra, Figure 105 from medulloblastoma and normal brain was taken from 26 
individuals, medulloblastoma (n =12) and normal brain tissue (n = 14) were combined, vector 
normalised using area in LabSpec 6 and noise reduced with 60 PCs in MATLAB before PCA (Figure 
106).  
 
Figure 105. Plot of averaged medulloblastoma from (n = 12 patients) and normal (n = 14) in the spectral 
range 1800-800 cm-1, vector normalised in LabSpec 6 using area and noise reduced using 60 PCs in MATLAB. 
 
The spectral data was then classified using PCA to reduce dimensionality as well as extract the 
best components for SVM and Significance testing. PC1 and 2 produced clustering of member 
from the same group with some overlap (Figure 106). 
 
Figure 106. Principal Component Analysis (PCA) plot of medulloblastoma (red) and normal brain (green). 
The plot shows separation with some overlap between the groups. 
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PC1 Loadings 
PC1 loadings had 38.4 %, (Figure 107) of the non-trivial variation spread over the entire spectral 
region. Only major bands were used to evaluate the weight of the loadings and their 
contribution to the separation of the two groups. The positive bands represented an increase in 
spectral intensity at, 998 cm-1 (Glucose-1-phosphate and symmetric ring breathing mode of 
Phenylalanine), 1046 cm-1 (C-H bending mode in Phenylalanine, C-N stretching in proteins), 1129 
cm-1 (C-N stretching in proteins; C-O stretching carbohydrates),1454 cm-1 (Protein δ (CH2/CH3), 
1675 cm-1 (Amide I(C=O stretching, C-N stretching and N-H bending, proteins). In the negative 
direction a decrease at 1584 cm-1 (Adenine, Guanine (DNA/RNA); C=C bending mode of 
Phenylalanine).  
PC2 Loadings 
PC2 loadings (Figure 108) accounted for 27.6 % of variation used by the model to separate 
medulloblastoma and normal brain tissue. Loadings in the positive direction represented an 
increase in the intensity of bands at, 1002 cm-1 (C-C aromatic ring stretching in Phenylalanine), 
1039 cm-1 (C-H bending mode in Phenylalanine, C-N stretching in proteins), 1457 cm-1 (Protein 
δ(Ch2/CH3), 1657-1710 cm-1 (Amide I (C=O stretching, C-N stretching and N-H bending, proteins). 
The negative direction peaks representing a decrease in intensities for spectral bands at; 998 
cm-1 (Glucose-1-phosphate and symmetric ring breathing mode of Phenylalanine), 1447 cm-1 
(CH(CH2) bending mode in proteins and lipids), 1585 cm-1 (Adenine, Guanine (DNA/RNA); C=C 
bending mode of Phenylalanine), 1670 cm-1 (Amide I (C=O stretching, C-N stretching and N-H 
bending, Proteins).    
 
Figure 107.  Plot of PC 1 loadings with 34.4 % non-trivial variation separating the two groups’ 
medulloblastoma and Normal. Most of the major peaks are broad peaks covering a wide spectral 
wavenumber area. 
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Figure 108.  Plot of PC 2 loadings with 27.6 % variation separating the two groups’ medulloblastoma and 
Normal. Most of the major peaks are broad peaks covering a wide wavenumber area. 
Support vector machines 
The training set was made up of two thirds (n = 240 spectra) from 8 patients with 
medulloblastoma and 150 spectra from 5 normal brain tissue. The blind set consisted of 120 
spectra from 4 medulloblastoma patients and 150 spectra from 5 normal brain tissue. Machine 
training was carried out using the first two principal components from the PCA model on an SVM 
using the LibSVM 3.12 package in MATLAB. The optimal Cost and Gamma parameter values used 
were obtained by a grid search combined with a one versus rest (OVR) mode. The best 
parameters yielding; Accuracy = 88 % were; cost = 64, gamma = 1.1892. Figure 109 shows the 
decision values, true labels predicted labels and the output labels the machine used based on 
the cost and gamma parameters.  
The machine was able to correctly classify 4 medulloblastoma patients as having 
medulloblastoma, 5 normal brain tissue correctly as normal brain. Classification accuracy of the 
machine was calculated based on sensitivity and specificity; Sensitivity = 100 % and Specificity = 
100 %.    
 
Figure 109. Plot showing the decision values and predicted labels, true labels and the output labels after 
machine training. Similar pattern shades can be seen with the decision values and the predicted labels which 
resulted in the machine output labels being similar to the output labels based on cost = 64 and gamma = 
1.1892 
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Significance Testing 
A significance test was carried out on the major spectral peaks identified by principal component 
loadings as providing the greatest non-trivial variation responsible for the separation of the two 
groups. Wavenumbers corresponding to the peak areas were selected and their intensities 
tested to investigate statistical significance between the two groups. A Two Sample T-Test was 
used to determine if the mean of the two groups at the chosen wavenumbers was significantly 
different. The model assumptions were checked using diagnostic checks in R Studio and the 
model was appropriate for the data. Only 1 region from a panel of 6 spectral regions showed 
significant differences between the two groups as shown in Table 23. Figure 110 shows the 
difference between the groups. 
 
 
 
Table 23. Shows Significance differences between medulloblastoma and normal brain tissue based on the 
wavenumber areas used by the PCA model to classify the two groups using weighted loadings. The 
wavenumbers were based on PC1 loadings. 
Wavenumber P-Value T-
Statistic 
Mean Plot 
Medulloblastoma Normal 
PC1 Loadings 
998 cm-1 0.002* 3.452 0.154 0.211 Fig. 
135 
1046 cm-1 0.404 0.845 0.467 0.535 N/A 
1129 cm-1 0.512 0.666 0.257 0.279 N/A 
1453 cm-1 0.122 1.616 0.504 0.575 N/A 
1675 cm-1 0.386 0.888 0.347 0.378 N/A 
1584 cm-1 0.906 0.119 0.264 0.257 N/A 
* Significance threshold ≤0.05 
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Figure 110. Boxplot showing the differences between the intensities at 998 cm-1 between Medulloblastoma 
(M=red) and normal brain tissue (N=Green). There is a significant difference between the two groups 
(P=<0.002). 
There was only 1 panel out of 6 chosen that showed a significant difference between the two 
groups. An exploratory exercise of looking for other areas within the spectral region used by PC1 
loadings would greatly improve the number of panels that could be used as specific targets for 
differential diagnostics. Most of the major peaks shown in PC1 are broad peaks which cover a 
wider spectral area encompassing proteins which contributed significantly in separating 
medulloblastoma and normal tissue. The protein differences between medulloblastoma and 
normal tissue can be explained, but are not limited to, a number of known biological conditions. 
Studies [22, 213] have shown that medulloblastomas overexpress repressor element-1 silencing 
transcription (REST)/neuron-restrictive silencer factor (NRSF). REST/NRSF plays an oncogenic 
role in the development of brain tumours and has been linked to other cancers. Normal brain 
tissue does not express REST/NRSF which could account for the huge protein difference between 
medulloblastoma and normal tissue being used by the model to separate the two groups. Gene 
expression analysis of medulloblastoma show gene expression patterns associated with 
overexpression of the platelet-derived growth factor receptor alpha (PDGFRA) and members of 
the RAS/MAPK pathways which have been associated with medulloblastoma metastasis [111, 
177].    
6.3.6 Other Types of Brain Tumours vs Normal 
A total of 780 spectra Figure 111 from a group OTHER made up of various types of brain tumours 
(Table 24) and normal brain tissue. The group OTHER had 330 spectra from 11 patients and the 
group normal had 450 spectra from 15 normal brain tissue which were combined, vector 
normalised using area in LabSpec 6 and noise reduced with 60 PCs in MATLAB before PCA.  
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Table 24. Tumour groups and diagnosis making up the group OTHER for the segregation of diseased and 
non-diseased brain tissue. 
Tumour Group Diagnosis 
OTHER Fibromyxoid Tumour 
OTHER Lymphoma 
OTHER Germinoma High Grade 
OTHER Schwannoma 
OTHER Neurilemmoma 
 
 
Figure 111. Plot of averaged group OTHER from (n = 11 patients) and normal tissue (n = 15) in the spectral 
range 1800-800 cm-1, vector normalised in LabSpec 6 using area and noise reduced using 60 PCs in MATLAB. 
The spectral data was then classified using PCA to reduce dimensionality as well as extract the 
best components for SVM and significance testing. PC1 and 2 produced good clustering of 
member from the same group with slight overlap (Figure 112). 
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Figure 112. Principal Component Analysis (PCA) plot of group OTHER (red) and normal brain (green). The 
plot shows good separation with only one overlap. 
PC1 Loadings 
PC1 loadings had 45 % (Figure 113) of the non-trivial variation spread over the entire spectral 
region. Only major bands were used to evaluate the weight of the loadings and their 
contribution to the separation of the two groups. The positive bands represented an increase in 
spectral intensity at, 998 cm-1 (Glucose-1-phosphate and symmetric ring breathing mode of 
Phenylalanine), 1086 cm-1 (C-O stretching), 1245 cm-1 Amide III(C-N stretching, N-H bending, 
proteins) PO2 asymmetric stretching (DNA/RNA)), 1334 cm-1 (Guanine (DNA/RNA), CH 
deformation in proteins and carbohydrates), 1453 cm-1 (Protein δ (CH2/CH3), 1581 cm-1 
(Adenine, Guanine (DNA/RNA); C=C bending mode of Phenylalanine), 1669 cm-1 (Amide I(C=O 
stretching, C-N stretching and N-H bending, proteins).  
PC2 Loadings 
PC2 loadings (Figure 114), accounted for 22.3 % variation spread over the entire spectral region. 
Only major bands were used to evaluate the weight of the loadings and their contribution to the 
separation of the two groups. The positive bands represented an increase in spectral intensity 
at, 855 cm-1 (Ring breathing in Tyrosine and Proline (proteins)), 1087 cm-1 (C-O stretching), 1239 
cm-1 Amide III(C-N stretching, N-H bending, proteins) PO2 asymmetric stretching (DNA/RNA)), 
1454 cm-1 (Protein δ (CH2/CH3), 1613 cm-1 (C=C Phenylalanine, Tyrosine and Tryptophan), 1670 
cm-1 Amide I (C=O stretching, C-N stretching and N-H bending, proteins). 
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Figure 113. Plot of PC 1 loadings with 45 % non-trivial variation separating the two groups’ OTHER and 
Normal. Most of the major peaks are broad peaks covering a wide area. 
 
Figure 114. Plot of PC 2 loadings with 22.3 % variation separating the two groups’ OTHER and Normal. Most 
of the major peaks are broad peaks covering a wide area. 
Support vector machines 
The training set was made up of two thirds spectra (n = 210) from 7 patients with various types 
of brain tumours shown in Table 24 and 300 spectra from 10 normal brain tissue. The blind set 
consisted of 120 spectra from 4 patients with various types of brain tumours, (Table 24) and 150 
spectra from 5 normal brain tissue. Machine training was carried out using the first two principal 
components from the PCA model on an SVM using the LibSVM 3.12 package in MATLAB. The 
optimal Cost and Gamma parameter values used were obtained by a grid search combined with 
a one versus rest (OVR) mode. The best parameters yielding; Accuracy = 94 % were; cost = 64, 
gamma = 1.1892.   (Figure 115) shows the decision values, true labels predicted labels and the 
output labels the machine used based on the cost and gamma parameters.  
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The machine was able to correctly classify 4 patients as having various types of brain tumours, 
5 normal brain tissue correctly as normal brain. Classification accuracy of the machine was 
calculated based on sensitivity and specificity; Sensitivity = 100 % and Specificity = 100 %.    
 
Figure 115. Plot showing the decision values and predicted labels, true labels and the output labels after 
machine training. Similar pattern shades can be seen with the decision values and the predicted labels which 
resulted in the machine output labels being similar to the true labels.  
Significance Testing 
A significance test was carried out on the major spectral peaks identified by principal component 
loadings as providing the greatest non-trivial variation responsible for the separation of the two 
groups. Wavenumbers corresponding to the peak areas were selected and their intensities 
tested to investigate statistical significance between the two groups. A Two Sample T-Test was 
used to determine if the mean of the two groups at the chosen wavenumbers was significantly 
different. The model assumptions were checked using diagnostic checks in R Studio and the 
model was appropriate for the data. A total of 6 out of 7 spectral regions showed significant 
differences between the two groups as shown in Table 25. Differences between the two groups 
are presented in Figure 117, Figure 118, Figure 119, Figure 120, and Figure 121. 
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Table 25. Shows significant differences between other brain tumours and normal brain tissue based on the 
wavenumber areas used by the PCA model to classify the two groups using weighted loadings. The 
wavenumber areas were based on PC1 loadings. 
WAVENUMBER P-VALUE T-
STATISTIC 
MEAN PLOT 
OTHER 
BRAIN 
TUMOURS 
Normal 
PC1 LOADINGS 
992 CM-1 0.109 1.7542 0.206 0.097 N/A 
1086 CM-1 0.001* 4.182 0.353 0.132 Fig. 141 
1245 CM-1 0.006* 3.967 0.167 0.107 Fig. 142 
1334 CM-1 0.007* 3.297 0.201 0.121 Fig. 143 
1453 CM-1 0.004* 3.511 0.456 0.274 Fig. 144 
1581 CM-1 0.046* 2.252 0.211 0.110 Fig. 145 
1670 CM-1 0.012* 2.931 0.321 0.206 Fig. 146 
* Significance threshold ≤0.05 
 
 
Figure 116. Boxplot showing the differences between the intensities at 1086 cm-1 between OTHER 
(O=green) and normal brain tissue (N=red). There is a Significance difference between the two groups 
(P=<0.001). 
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Figure 117. Boxplot showing the differences between the intensities at 1245 cm-1 between OTHER 
(O=green) and normal brain tissue (N=red). There is a Significance difference between the two groups 
(P=<0.006). 
 
 
Figure 118. Boxplot showing the differences between the intensities at 1334 cm-1 between OTHER 
(O=green) and normal brain tissue (N=red). There is a Significance difference between the two groups 
(P=<0.007). 
 
 
Figure 119. Boxplot showing the differences between the intensities at 1453 cm-1 between OTHER 
(O=green) and normal brain tissue (N=red). There is a Significance difference between the two groups 
(P=<0.004). 
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Figure 120. Boxplot showing the differences between the intensities at 1581 cm-1 between OTHER 
(O=green) and normal brain tissue (N=red). There is a Significance difference between the two groups 
(P=<0.04). 
 
 
Figure 121. Boxplot showing the differences between the intensities at 1670 cm-1 between OTHER 
(O=green) and normal brain tissue (N=red). There is a Significance difference between the two groups 
(P=<0.012). 
 
This exploratory study has shown that Raman spectroscopy has the potential to distinguish 
between normal brain and tumour tissue which has been previously shown in a number of 
studies in cancer [11, 64, 199, 214]. The development of a spectral library based on 
wavenumbers that show Significance differences between groups takes the study a step closer 
to implementing the technique in clinical settings. Wavenumber assignment allows the 
identification of molecular markers that can be utilised to separate normal brain tissue from 
cancerous tissue through the employment of multivariate statistics. Targeting specific 
wavenumber regions improves the accuracy of the classification used by the multivariate 
statistical models with a high degree of sensitivity and specificity. The biomarker panels Table 
26 developed in this study allow sensitivities and specificities above 90 % across all the tumour 
groups investigated. The markers can be used with any statistical model and still produce very 
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high sensitivities and specificities as shown with PCA, SVM, and Tree Analysis. These models 
employ both supervised and unsupervised techniques of data analysis. The data used for 
classification can be used as standards in the classification of blind specimens under similar 
conditions. The construction of a spectral library depends on a number of important factors such 
as correct histological assignment of biopsies before spectral classification, standardised pre-
processing of spectral data and the treatment of blind spectral data under similar conditions as 
the standards. These parameters are followed under the backdrop of specific spectroscopic 
sample preparation methods which mainly involve five steps:  
 Fixation 
 Paraffin embedding 
 Sectioning 
 Mounting on glass 
 Dewaxing 
Potential problems that can affect the spectral library can result from inconsistences from any 
one of these steps. The histological assessment of tissue using histopathology presents another 
area of concern. There is need to ensure that samples used in the spectral library have been 
histologically assessed using a number of robust techniques which include histopathology, 
molecular pathology, imaging and DNA methylation profiling. This allows the assignment of 
tumour groups and grades that are consistent within centres.   
This study has established a panel of spectral markers (Table 26) that can be used to distinguish 
between groups and within groups’ diagnostics. These markers have been selected through use 
of powerful statistical algorithms using both supervised and unsupervised multivariate 
techniques and significance testing of individual markers to establish their robustness.  
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Table 26. Spectral library of biomarkers for the diagnosis of CNS tumours developed using Raman spectroscopy in 
the wavenumber region 1800-800 with a 532 nm laser and human brain tissue. The intensities are dependent on 
normalisation and could defer based on type of scale used.  
 
Tumour Type 
Panel (1800-800) 
wavenumbers / cm-1 
Threshold (AVERAGE)  
Intensity  
 
 
Gliomas vs Normal 
~998 
~1046 
~1100 
~1449 
~1589 
≥ 0.295 
≥ 0.338 
≥ 0.460 
≥ 0.464 
≥ 0.189 
 
High grade gliomas (H) vs Low grade gliomas 
(L) 
~1242 
~1656 
~1090 
≤ 0.944(𝐻), ≥ 1.168(𝐿) 
≤ 2.160(𝐻), ≥ 3.098 (𝐿) 
≥ 3.654(𝐻), ≤ 2.425 (𝐿) 
 
 
GBM vs Normal 
 
 
~998 
~1046 
~1079 
~1454 
~1638 
~1584 
≥ 0.303 
≥ 0.352 
≥ 0.386 
≥ 0.440 
≥ 0.230 
≥ 0.181 
 
 
Meningioma vs Normal 
~998 
~1046 
~1079 
~1454 
~1675 
~1584 
≥ 0.295 
≥ 0.398 
≥ 0.404 
≥ 0.453 
≥ 0.341 
≥ 0.191 
Medulloblastoma vs Normal ~998 ≤ 0.154 
Other types of CNS tumours vs Normal 
Lymphoma 
~992 
~1086 
≥ 0.206 
≥ 0.353 
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Fibromyxoid tumour 
Schwannoma I 
Xanthrocytoma III 
Neurilemmoma 
Germinoma high grade 
Malignant glio-neuronal tumour 
~1245 
~1334 
~1453 
~1581 
~1670 
 
≥ 0.167 
≥ 0.201 
≥ 0.456 
≥ 0.211 
≥ 0.321 
 
 
The thresholds shown in the panel are based on the statistical tests for significance and will 
largely depend on the type of data processing techniques employed and may vary, however the 
proportion between the groups should stay the same. These proportions may also vary when it 
comes to in vivo diagnostics. Raman spectroscopy has an intrinsic advantage over IR for 
biological samples due to the weak scattering of water. Excitation of light in Raman spectroscopy 
can be ultraviolet (UV) (𝜆 < 400 nm), visible (400 ≤  𝜆 ≤ 700 𝑛𝑚) or near-infrared (𝜆 >
700 𝑛𝑚). Studies have shown that different tissue types require optimisation of excitation 
wavelengths [147]. Breast cells are about 10 µm in diameter, with a nucleus of about 5 µm, 
whilst cervical cells range from 10 to 50 µm in diameter with a nucleus of 10-15 µm. The 
measurement of breast tissue with a beam size of 30 µm would result in scattering at each 
wavenumber which will be a weighted average of the scattering resulting from the cell itself, 
including the nucleus and cytoplasm, basement membrane plus some other components 
surrounding the cell, such as connective tissue or fat. However, if the sample was cervical tissue 
or cervical smear composed mostly of superficial layer of cells, and an individual cell was centred 
under the beam, the resulting spectrum would be only of the nucleus plus some cytoplasm of a 
cervical cell. This shows that one design of an experiment does not satisfy investigations of 
tissues and cells from other organs [147]. Therefore it follows that type of laser used should be 
appropriate for the sample under investigation.  
Over the last 23 years studies using vibrational spectroscopy have been conducted on a variety 
of organs with results in distinguishing normal and malignant tissue in the order of 80-100 % 
accuracy coupled with multivariate statistics [25]. This study has produced accuracy above 90 % 
for different types of brain tumours and their subgroups. Given this success with vibrational 
spectroscopy, the questions still remain, why has it not become a routine tool in the clinical 
setting? Is it sufficient to confirm malignancy on a biopsy with accuracy close to 100 %? Will 
spectral libraries replace histopathology? In order to answer some of these questions, it is 
important for us to go through the processes involved in vibrational spectroscopy. Most of the 
[191] 
 
problems relating to reproducibility have been addressed by following specific protocols on 
fixation, paraffin embedding, sectioning, dewaxing and spectroscopic analysis. The major 
challenges arise on data treatment methods to address contributions from fluorescence 
background, Gaussian noise, cosmic spike, and other artefacts based on the experimental effects 
[215]. Some data treatment methods have a profound effect on the downstream processes 
which affect classification and accuracy. Whilst these techniques employed to correct the 
presence of artefacts within the data set are sound, they however affect the reproducibility of 
the experiment. In a study by Bocklitz et al. on how to pre-process Raman spectra for reliable 
and stable models, they reported the influence of spectral pre-processing on the outcome of 
statistical methods. Their study showed that it was possible to enhance the statistical model by 
using “appropriate” combinations to increase the accuracy.  They also showed that techniques 
which employed minimum or no pre-processing yielded better results. An optimised pre-
processing technique should be developed and used as standard across institutions if spectral 
libraries are to become a reality. This allows uniformity and reproducibility of results.   
 The practical usefulness of spectral libraries can be seen in a number of scenarios. Diffuse low-
grade gliomas (LGGs) are infiltrative in nature with low proliferative activity. The discovery of 
molecular markers that have prognostic importance for survival and treatment responsiveness 
[133] can be incorporated with Raman spectroscopic analysis to further classify these tumours. 
The ability to distinguish where the tumour ends and normal tissue begins either by imaging, 
direct observation during surgery or gross pathological examination is still a challenge in the 
clinical setting [133]. Raman spectroscopy and the panel developed in this study have the 
potential to improve the distinction between normal tissue and tumour using the threshold 
established in the spectral library to demarcate boundaries during surgery. Furthermore the 
employment of developments shown in recent studies in molecular techniques presents an 
opportunity on further studies within vibrational spectroscopy to classify subgroups which can 
improve therapies and early intervention of appropriate care.      
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6.4 Conclusion 
Raman spectroscopy in the detection of cancer has not yet been accepted by the medical 
community as a routine tool. However, there has been a lot of progress in the field which has 
yielded good results across the broad spectrum of diseases. There has been good collaborations 
with clinicians evidenced by the number of studies and clinical trials in field. This study was a 
result of such a collaboration with the Royal Preston Teaching Hospital and the Brain Tumour 
North West (BTNW) biobank made up of a group of hospital trusts across the North West of 
England. Raman spectroscopy is a non-destructive technique which has a short turnaround 
diagnostic window with no need for reagents except substrates used to mount the tissue. The 
whole diagnostic process effectively takes place in a matter of minutes making it an ideal tool to 
confirm disease or normal biopsies during surgery. In the surgical theatre the technique can aid 
surgeons with the demarcation of tumour borders which can be a challenge as shown by a 
number of studies. Subgrouping of tumours is a possibility using Raman spectroscopy as 
evidenced in this study and reported in other studies and could effectively go a long way towards 
patient care and management of therapies.  Spectral libraries have the potential to allow sharing 
of useful data amongst institutions as well as making it possible to make a quick diagnosis based 
on standards in the library. There is still need to further characterise different tumour groups 
based on other tools such as molecular pathology to ensure the creation of accurate spectral 
libraries. Currently libraries can only be created based on histological assessment which has 
been shown to be subjective. Future work in this area should focus on characterising tumours 
based on their histology and genetic profiles coupled with further characterisation of functional 
groups.  
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Chapter 7 
7 Overall Discussion, Conclusion and Future Work 
7.1 Discussion and Conclusion 
The diagnosis of brain tumours still remains a challenge despite the strides taken over the years 
evidenced by the amount of research published. Although a good body of work has been carried 
out, most of these new developments have not made their way into the clinical setting mostly 
due to the lack of reproducibility. The improvements in technology and analytical skills has had 
a huge positive impact in the fight against cancer. Research from the past 20 years has shown 
remarkable results in drug design, drug delivery, identification of therapeutic targets, and 
diagnosis. The employment of powerful statistical models has made it possible to detect very 
small changes in data that correspond to subtle changes in the material that can be used to 
classify and segregate materials such as tissue or serum of tumour subtypes. The aims of this 
study were to explore alternative methods to histopathology for the diagnosis of primary brain 
tumours. The objectives were met by; 
1. The use of ICP-MS on fresh human brain tumour tissue and serum to identify elemental 
thresholds, gender and age differences that can be used as diagnostic tools aided by 
multivariate statistics. 
2. Separation of brain tumour cell lines, U87MG and 1321N1 with a control SVGP12 using 
Raman and IR spectroscopy coupled with multivariate statistics. 
3. Segregation of paraffin embedded human brain tumour tissue from brain tumour 
patients and normal brain tissue into subgroups using Raman spectroscopy coupled 
with multivariate statistics. 
4. Development of spectral panels to be used as diagnostic tools for the separation of 
brain tumours and their subtypes from normal brain tissue using multivariate statistics.  
7.1.1 Elemental analysis using ICP-MS 
Instruments such as ICP-MS and their various modalities have revolutionised the analysis of 
trace metals. Trace elements constitute less than 0.01 % by body weight of total body 
composition. The improvements in instrument precision has allowed sensitive analyses of trace 
metals potentially providing insights into the role they play in the formation and progression of 
cancer. However, trace element analysis of biological materials has been a subject of conjecture 
with many conflicting reports from different authors due to the complexities of the sample 
matrix and potential contamination issues connected to sampling techniques.  
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Investigations into the concentration differences of trace elements in brain tumour tissue and 
serum were carried out to enhance our understanding of the differences between different 
tumour groups, subtypes, gender and age with the view of identifying potential diagnostic 
applications. Differences in the starting amounts of brain tissue and serum made it difficult to 
make a direct comparison between the two groups for diagnostic applications. A general 
comparison was done based on the four groups’ glioblastoma, meningioma I and II and OTHER. 
The Kruskal-Wallis test showed a significant difference (X2 = 48.246, DF = 1, P = 0.001), between 
serum samples, which had relatively lower concentrations compared to tissue in all the four 
groups.  
Elemental distribution in tissue and serum 
Magnesium 
The distribution of Mg in meningioma I was significantly different to the rest of the groups in 
tissue (P=0.001), whilst in serum meningioma II and glioblastoma (P=0.004) were significantly 
different. The results from the analysis of brain tissue showed a very low concentration of Mg 
with the most aggressive types of cancer, glioblastoma (mean, 4.504 µg/mL) and meningioma II 
(mean, 10.107 µg/mL) showing a significant difference between the two groups. The cancers in 
the group OTHER were mostly made up of high grade tumours which also had a relatively low 
Mg concentration, (mean, 10.209 µg/mL) compared to low grade meningioma I, which had very 
high concentrations of Mg, (mean, 23.740 µg/mL). The results suggests a negative correlation of 
Mg concentration with tumour aggressiveness across all the brain tumour groups under 
investigation. Magnesium intake may be prophylactic against initiation of neoplasms and could 
be used as a candidate in drug design. Several studies have suggested the use of Mg to prevent 
against the initiation of cancer [130]. An understanding of the distribution of Mg can be useful 
as a preventative measure since deficiencies in magnesium were reported as a risk factor to 
cancer [130, 216].  
Zinc 
The results from the analysis of zinc in tissue showed no significant difference across the four 
groups. The levels of zinc in the four brain tumour groups were relatively low. Zinc deficiency 
has been associated with tumour development [130, 131] and is expected to be low across the 
four tumour groups. Serum samples showed a significant difference in the distribution of Zn 
between glioblastoma and meningioma II with no difference in the rest of the groups. However, 
all the four brain tumour groups showed very low zinc concentration compared to normal levels 
reported in previous studies.  
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Iron (Fe) 
In this study there was no significant difference between the iron concentrations in brain tissue 
across the four brain tumour groups, which all showed very low levels of iron concentration in 
comparison to reported results from population studies that looked at normal iron 
concentration levels. Generally the more aggressive high grade tumours had the lowest iron 
concentrations. Serum samples showed a significant difference between the iron concentrations 
in two groups. The main difference was between meningioma II (mean = 0.186 µg/mL) and 
glioblastoma (mean = 0.239 µg/mL). However, all samples had relatively low iron concentrations 
in comparison to normal controls reported in the literature [138].  
Copper (Cu) 
There was no significant difference in the copper levels in brain tissue across the groups, which 
were all relatively low compared to reported levels. Generally the more aggressive tumour type, 
glioblastoma, meningioma II and OTHER (made up of most high grade tumours) had relatively 
low but not significantly different levels compared to low grade tumour meningioma I. However, 
serum copper levels showed a different trend. Whilst there was no significant difference 
between the serum copper levels across the four groups, the less aggressive tumour, 
meningioma I had the lowest levels (0.009 µg/mL) compared to the more aggressive high grade 
types which all had similar levels around (0.012 µg/mL). The observation in serum follows the 
general trend reported in [112] which show high copper concentration in malignant cancers 
compared to low grade tumours. The general observation is that there is copper deficiency in 
both serum and tissue for most cancers compared to controls [112, 125, 130, 144, 145]. In a 
brain study of trace elements in 22 malignant glioma patients, significantly low copper levels in 
serum compared to controls from 22 healthy patients [125]. 
Comparative Study of Serum vs Tissue 
The results from the comparative study showed no significant difference in the distribution of 
the four elements across the brain tumour groups between tissue and serum. Serum samples 
generally showed slightly low concentrations of the elements in comparison to tissue. This 
difference could be attributed to high metabolic activities in tissue samples or to the differences 
in the initial sample volumes (serum = 100 µL and tissue 30 mg) used for the analysis. The overall 
pattern of distribution of all the four elements was similar, where high grade tumour groups 
generally had low concentrations of the elements compared to low grade tumours which had 
slightly higher concentrations. The overall picture is that the four brain tumour groups 
investigated show deficiencies in Mg, Fe, Cu, and Zn compared to normal levels reported in other 
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studies [125, 144, 145]. Serum has an added advantage of being used as a less invasive 
monitoring tool for patients in remission as their serum levels go back to normal after successful 
treatment [217]. 
Epidemiological study  
The distribution of trace elements based on gender showed no significant difference which is 
consistent with previous epidemiological studies [24]. There was a significant difference 
between elemental distribution and age (F3, 1 = 5.898, P = 0.001) consistent with evidence from 
histological assessments of biopsies by histopathology where tumours such as medulloblastoma 
showed high incidence in children and high grade gliomas in the elderly population [152, 218].   
The use of elemental species as diagnostic tools largely depends on the accuracy of the analytical 
method used to quantify elements with minimal error. Inaccurate measurement may have 
serious consequences to the patient’s treatment regime and care. The successful 
implementation of this technique as a routine clinical tool requires the establishment of a 
dedicated lab used only for elemental profiling to minimise contamination. The use of reported 
elemental levels in normal brain samples weakened the results of this study given the problems 
associated with variability of results reported by other investigators. There is a need to carry out 
a comprehensive study which would include tissue and serum from healthy individuals.  The 
results from this study show a potential application of ICP-MS in brain tumour diagnosis, 
distinguishing between normal and cancerous tissue and serum. The advantages of using 
methods like ICP-MS is that they are less subjective and far less invasive when used with samples 
like serum, blood, or urine but require a significant level of care during sampling and processing. 
These two stages could be a potential source of error which might significantly affect the results. 
7.1.2 Cellular Analysis using Vibrational Spectroscopy 
Vibrational spectroscopy has shown great potential as a diagnostic tool but there still remains a 
number of areas which need to be addressed before its implementation in the clinical setting. 
There are number of factors that have been shown to affect results from vibrational 
spectroscopic analyses. Substrates (CaF2), chemicals used during histological processing 
(HistoClear) or sample preparation methods for spectral analysis can affect the biochemical 
composition of the sample. The use of live cells and fresh tissue for spectroscopic analyses can 
potentially reduce these problems. However, tissue has been historically preserved in hospitals 
using formalin fixed paraffin preserved (FFPP) blocks which are subsequently cut into sections 
for histological processing. It is to this end many studies have been conducted to investigate the 
optimal methods for spectroscopic analysis, which are reproducible and accurate.  
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Substrate effects 
A comparison of background spectra between CaF2, MirrIR and normal glass showed that normal 
glass had the highest intensity baseline with a number of broad peaks spanning the entire 
spectral region (400-1900 cm-1) under investigation. CaF2 had the lowest intensity baseline but 
the highest background noise. Most biological samples are relatively thin and allow incident light 
to pass through the sample and interact with the substrate. A major concern regarding the use 
of normal glass for analysis would be if the constituents of the sample under investigation have 
peaks that are of low intensities falling under the spectral region were the substrate has major 
broad peaks. The right choice of substrate for spectroscopic analysis is important for reducing 
background noise, spectral artefacts and optimising the quality of the spectral data [100]. This 
study showed how easily spectral artefacts can be introduced in the data. The three substrates 
investigated were dewaxed after being embedded with paraffin wax using the same conditions 
used in histology. The procedure is supposed to remove paraffin wax leaving only the sample 
under investigation, however CaF2 substrates showed residual paraffin peaks using HistoClear 
under the 5 min bath regime whilst the rest of the substrates were clear.  
Investigation into paraffin affinity of high grade tumours 
A study by Fullwood et al. [100] suggested a disparity between the degree of malignancy and 
paraffin retention, where high grade tumour retained more paraffin compared to low grade 
tumours during dewaxing of tissue on CaF2 substrates. In order to investigate this claim, this 
study used nitrocellulose membranes which are normally used as tissue models. This study 
showed no correlation between paraffin retention and membrane density and therefore 
suggests that the variation of paraffin peak intensity between normal brain and cancerous tissue 
observed in the study by Fullwood et al. could be due to the dewaxing process and choice of 
clearing agent. CaF2 substrates consistently produced incomplete dewaxing and retention of 
paraffin with HistoClear at 5 min bath intervals as well as on the nitrocellulose membrane filters 
dewaxed using the same protocol across all pore sizes. There was no paraffin residue on CaF2 
with HistoClear using 10 and 15 min bath times. Samples cleared with xylene on all the three 
substrates and bath regimes did not show any paraffin residues. 
Whilst CaF2 substrates are ideal, with a very low baseline intensity care must be taken when 
dewaxing tissue using 5 min bath intervals. Normal glass is not ideal for spectroscopic analysis 
due to its high fluorescence with broad peaks covering the entire spectral region of 400-1900 
cm-1. MirrIR has a number of advantages, although its spectral background is higher compared 
to CaF2, spectral peaks that are detected using CaF2 are also observed using MirrIR. The results 
indicate that tissue processing still remains a challenge in spectral histopathology, using both 
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Raman and IR. Whilst techniques to analyse samples without adding any preservatives have 
been developed and look promising [219-222], issues still remain with traditional samples that 
have been preserved in biobanks using different preservative methods. Current methods used 
in histology to preserve tissue and cells do not significantly change the morphology of these 
samples but when dealing with disease such as cancer, structural integrity of the sample is of 
paramount importance especially for spectral histopathology which tries to discriminate 
samples based on their structure and constituents. Xylene is a better clearing agent, which did 
not leave any paraffin residue across all three substrates, but has be reported to be highly 
carcinogenic. Proper care needs to be taken when handling xylene including the right class of 
fume hoods, face masks and protective wear. 
Analysis of Brain Tumour Cell Lines Using Raman and ATR-FTIR 
To establish a proof of principle for the use of vibrational spectroscopy to study brain tumours, 
two brain tumour cell lines, U87MG and 1321N1 were investigated using Raman and ATR-FTIR 
alongside a control cell line SVGP12. Three pre-processing models, Model A (noise reduction and 
vector normalisation), Model B (noise reduction, first derivative, and vector normalisation), and 
Model C (noise reduction, second derivative, and vector normalisation) commonly used in 
spectroscopy were also assessed. The data from Raman and ATR-FTIR were analysed in the same 
way using the three models A, B and C in MatLab™ and R.  Model B and C despite using different 
spectral data pre-treatment algorithms presented similar results to Model A.   
Three multivariate statistical models, PCA, DFA and SVM were used to evaluate and classify the 
spectral data. All statistical models were able to provide good separation of the groups with very 
high classification accuracy using all three pre-processing models. Permanova was used to 
provide statistical significance. There were statistically significant differences between the three 
groups, U87MG, 1321N1 and SVGP12. This study established that vibrational spectroscopy, 
Raman and ATR-FTIR are sensitive tools for analysing biological materials. The techniques 
successfully differentiated between three different cell lines and tentatively assigned spectra 
based on known functional groups and molecules in the literature. Histopathology has been 
primarily used as the gold standard in medical diagnostics for many years in nearly all types of 
cancer. Although the technique has high sensitivity and specificity in detecting cancers it is 
somewhat subjective and ambiguous when it comes to grading the disease in terms of degrees 
of malignancy. The results of the cell line analysis illustrate a proof of concept in the ability of 
vibrational spectroscopy to differentiate different cell types as well as subtypes. Here we were 
able to show the distinction between U87MG and 1321N1 which are both astrocytomas with a 
different degree of malignancy.  
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7.1.3 Analysis of Brain Tumour Tissue using Raman Spectroscopy 
Raman spectroscopy in the detection of cancer has not yet been accepted by the medical 
community as a routine tool. However, there has been a lot of progress in the field which has 
yielded good results across a broad spectrum of diseases. The whole diagnostic process 
effectively takes place in a matter of minutes making it an ideal tool to confirm normal or disease 
state of biopsies during surgery. This study was able to classify different groups of tissue based 
on their disease state with very high accuracy.  
Gliomas vs Normal Brain Tissue 
PCA and SVM were able to show good clustering of normal tissue and gliomas. The PCA plot 
showed further clustering within the glioma groups which reflects the various subgroups, GBMs, 
astrocytomas, gliosarcomas, and oligoastrocytomas within the glioma group. Since gliomas arise 
from glial cells which are further divided into four groups, astrocytes, oligodendrocytes, 
microglia and ependymal this further clustering is expected. The PCA plot highlights some of the 
challenges faced in histopathology when classifying tumours such as gliomas which are on a 
continuous spectrum of histology and malignancy into distinct categories especially tumours 
such as GBMs which may have two or more histologies present, such as glioblastoma with 
oligodendroglial components, Oligoastrocytoma and oligodendroglioma. However, the use of 
spectral histopathology makes the distinctions apparent and easy to replicate as seen in the PCA 
plots. Significance testing allowed the development of specific spectral panels that can be used 
as spectral biomarkers for the diagnostic segregation of gliomas and normal brain tissue.  
High grade gliomas vs low grade gliomas 
A subset of the glioma group was divided into high and low grade groups. The spectral data was 
then classified using PCA to reduce dimensionality as well as extract the best components for 
SVM and significance testing. The PCA plot showed an overlap of samples with high grade 
gliomas being grouped with low grade gliomas. In the high grade glioma group a few sub-clusters 
could be seen with at least one low grade glioma being assigned to the high grade glioma group. 
Gliomas arise from glial cells and the two main types in CNS are astrocytes and oligodendrocytes. 
High grade gliomas used in the model consisted of GBMs, astrocytomas grade III, gliosarcoma 
IV, and GBMs with focal oligo features IV. The low grade group consisted of ependymoma grade 
II, astrocytoma grade I and II, and oligodendroglioma grade II. The model showed two major 
clusters separating some, but not all, high grade and low grade gliomas. Sub-clusters within both 
the high grade and low grade glioma groups were seen which is consistent with histological type 
represented in the groups. The spectral data shows the challenges faced in histopathology of 
trying to classify tumours such as gliomas which are on a continuous spectrum of histology and 
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malignancy into distinct categories. To compound this challenge some tumour subtypes such as 
glioblastoma with oligodendroglial components, oligoastrocytoma and oligodendroglioma have 
characteristics of two or more histologies making them particularly problematic to replicate. 
However the PCA model appears to form clusters which groups them very well together making 
it easier to identify them. There are other tumours which have ambiguous morphological 
appearance for which no clear diagnosis exists which makes such types of specimens very 
difficult to classify. A number of high grade tumours GBMs have been classified as low grade 
mostly with other low grade astrocytomas grade II. These samples would require further analysis 
with the view of changing the classification as this would greatly affect therapeutic management 
and prognosis. Discrepancies related to histological analysis in grade, tumour type, and subtype 
have been recorded as; grade 19 %, type 11 %, subtype 5 %, grade plus subtype or grade plus 
histological type 12%, currently present a challenge in histopathology. In centres where reviews 
are carried out, over 45 % of first histological diagnoses were modified at a second reading 
resulting in different treatment decisions. The lipid to nucleic acid relationship has been 
previously reported to correlate with histopathological studies grading malignancy by nucleic 
acid-to-cytoplasmic ratio [133]. This study looked at spectral regions which had a significant 
difference in separating the two groups’ high grade and low grade gliomas used by the 
multivariate statistical model and identified by the PCA loadings to differentiate high grade 
gliomas and low grade gliomas instead of the lipid to nucleic acid ratio. Some studies have 
reported a correlation between the protein to lipid ratio with histological grade [223].  
Glioblastoma vs Normal 
Normal brain compared to GBM tissue showed good separation of tissue classes with further 
clustering of GBM samples which seemed to suggest subclasses of GBM tissue. The within class 
differences could be attributed to the inherent heterogeneity of the tumour tissue as well as 
possible misclassification of histological grading by histopathology. There is a need to review the 
individual specimens found in the clusters outside the main group using other techniques such 
as molecular pathology. The differences in the amount of protein between normal brain tissue 
and gliomas used by the model for classification could be attributed to a number of known 
biological events. Several proteins such as HSP90α, MutS, blc-2, PARP-1 have been shown to be 
overexpressed in gliomas compared to normal brain tissue [210, 211], [49],  [57], [6].   
Meningioma vs Normal 
There was a considerable difference between the protein levels of meningiomas and normal 
tissue identified in this study evidenced by the wavenumber regions used to separate the two 
groups. The protein concentration in meningiomas was significantly higher than normal brain 
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tissue. A number of studies have shown an increase in the protein content of meningioma tissue 
compared to normal brain tissue. Das et al. investigated the overexpression of mdm2 and p53 
and their association with progesterone receptor in benign meningiomas [101]. In their study 
progesterone was frequently found expressed in meningiomas at high levels. The study 
identified a correlation between overexpression of progesterone with overexpression of nuclear 
mdm2. Nuclear mdm2 overexpression was confined to progesterone receptor positive tumours, 
while p53 overexpression was not confined to progesterone receptor expression. The 
relationship between p53 and the presence of progesterone receptor may have important 
applications in the development of progesterone receptor targeted therapies for meningioma 
and could explain the significant presence of protein in meningiomas compared to normal brain 
tissue. This could also explain why meningiomas incidence is twice as common in women 
compared to men. Wang et al. investigated gene expression in meningiomas and brain 
arachnoid tissue [151]. Their study showed that the EGFL6 a protein coding gene which encodes 
a member of the epidermal growth factor (EGF) repeat superfamily, was overexpressed in 
benign meningioma. The gene product contains a signal peptide, an EGF repeat region consisting 
of 4 complete EGF-like repeats and 1 partial EGF-like repeat, 3 of which have a calcium binding 
consensus, an arg-gly-asp integrin association motif, and a MAM domain which has adhesive 
function [151].  
Medulloblastoma vs Normal 
Despite using only major bands to evaluate the weight of the loadings and their contribution to 
the separation of the two groups, some of the spectral bands within the broad peaks made no 
significant difference between the two groups. The positive bands represented an increase in 
spectral intensity at, 998 cm-1 (Glucose-1-phosphate and symmetric ring breathing mode of 
Phenylalanine), 1046 cm-1 (C-H bending mode in Phenylalanine, C-N stretching in proteins), 1129 
cm-1 (C-N stretching in proteins; C-O stretching carbohydrates),1454 cm-1 (Protein δ (CH2/CH3), 
1675 cm-1 (Amide I(C=O stretching, C-N stretching and N-H bending, proteins). In the negative 
direction a decrease at 1584 cm-1 (Adenine, Guanine (DNA/RNA); C=C bending mode of 
Phenylalanine). There was only 1 panel out of 6 chosen that showed a significant difference 
between the two groups. An exploratory exercise of looking for other areas within the spectral 
region used by PC1 loadings would greatly improve the number of panels that could be used as 
specific targets for differential diagnostics. Most of the major peaks shown in PC1 are broad 
peaks which cover a broader spectral area encompassing proteins which contributed 
significantly in separating medulloblastoma and normal tissue. The protein differences between 
medulloblastoma and normal tissue can be explained but not limited to a number of known 
biological conditions. Studies [22, 213] have shown that medulloblastomas overexpress 
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repressor element-1 silencing transcription (REST)/neuron-restrictive silencer factor (NRSF). 
REST/NRSF plays an oncogenic role in the development of brain tumours and has been linked to 
other cancers. Normal brain tissue do not express REST/NRSF which could account for the huge 
protein difference between medulloblastoma and normal tissue being used by the model to 
separate the two groups. Gene expression analysis of medulloblastoma show gene expression 
patterns associated with overexpression of the platelet-derived growth factor receptor alpha 
(PDGFRA) and members of the RAS/MAPK pathways which have been associated with 
medulloblastoma metastasis [111, 177].    
Other Types of Brain Tumours vs Normal 
 The group OTHER consisted of fibromyxoid tumours, lymphomas, and germinoma high grade, 
schwannoma, and neurilemmoma tumours. The study despite the limited number of samples to 
form big groups, was able to identify 6 specific panels that can be used to target these tumours 
for diagnostic pathology. The separation was based on the positive bands from the PCA loadings 
which represented an increase in spectral intensity at, 855 cm-1 (Ring breathing in Tyrosine and 
Proline (proteins)), 1087 cm-1 (C-O stretching), 1239 cm-1 Amide III (C-N stretching, N-H bending, 
proteins) PO2 asymmetric stretching (DNA/RNA)), 1454 cm-1 (Protein δ (CH2/CH3), 1613 cm-1 (C=C 
Phenylalanine, Tyrosine and Tryptophan), 1670 cm-1 Amide I(C=O stretching, C-N stretching and 
N-H bending, proteins). 
This exploratory study has shown that Raman spectroscopy has the potential to distinguish 
between normal brain and tumour tissue which has been previously shown in a number of 
studies in cancer [11, 64, 199, 214]. The development of a spectral library based on 
wavenumbers that show significant differences between groups takes the study a step closer to 
implementing the technique in clinical settings. Wavenumber assignment allows the 
identification of molecular markers that can be utilised to separate normal brain tissue from 
cancerous tissue through the employment of multivariate statistics. Targeting specific 
wavenumber regions improves the accuracy of the classification used by the multivariate 
statistical models with a high degree of sensitivity and specificity. This study has established a 
panel of spectral markers that can be used to distinguish between groups and within groups’ 
diagnostics. These markers have been selected through use of powerful statistical algorithms 
using both supervised and unsupervised multivariate techniques and significance testing of 
individual markers to establish their robustness.  
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7.2 Future Work 
This study has shown the potential of both ICP-MS and vibrational spectroscopy for use as 
routine tools in the diagnosis of cancer. ICP-MS was able to produce results that were consistent 
with epidemiological studies and histopathology. Raman and Infrared were able to separate 
tumours and normal tissue with very high classification accuracy.  
ICP-MS 
There is need to carry out a much bigger study in a very sterile environment with different brain 
tumour groups to establish specific trace element levels for each group. There is also a need to 
establish normal elemental levels for each group instead of relying on reported figures in the 
literature. More focus should be towards the use of serum samples instead of tissue. Serum 
samples offer several advantages over tissue, because they are less invasive and provide a 
unique opportunity to monitor patients in remission after successful treatment.    
Raman and IR 
There is need to create spectral libraries of all the tumour groups based only on spectral 
histopathology to minimise potential diagnostic errors highlighted in this study. A more 
robust spectral characterisation of functional groups and molecules would go a long way 
towards identifying protein groups, lipids, nucleic acids and other such functional groups 
that have subgroups. A comparison between results from the same samples analysed 
by two or more different machine platforms would be ideal to show reproducibility and 
efficacy of vibrational spectroscopy in a clinical setting. In order to carry this technique 
into clinical practice there is a need to harmonise protocols used for sample preparation, 
data collection and analysis. There is also a need to carryout out big multicentre studies 
to ensure reproducibility and standardisation. As previously discussed and shown in this 
study, sample preparation can greatly influence results. The biopsy specimens need to 
be treated under optimal conditions using the right clearing agents and substrates in 
order to minimise artefacts. Data needs to be treated and analysed using standard 
techniques. The employment of a number of mathematical algorithms to correct for 
noise and other non-biochemical entities has a tendency to produce results that can be 
difficult to produce with other samples under similar conditions.  
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APPENDIX A (Primary Brain Tumours)         
                                   
Primary brain tumours divided into major groups, neuroepithelial and non- neuroepithelial tumours [28]  
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APPENDIX B (Pre-Processing) 
 
Raman 
Model B (First Derivative) 
Model B consisted of spectra that was noise reduced (60 PCs) spectra which was 
converted into first derivative (Savitzky-Golay algorithm) using 7 smoothing points in 
MatLab™, Figure 122. The first derivative data was vector normalised and analysed using 
PCA, DFA, SVM and Permanova. The use of the first derivative in pre-processing spectra 
removes the additive baseline shift and enhances the biochemical information available 
for discrimination. Factor loadings are not used with first derivative spectral models 
because of the shift of peaks in the raw spectra which become points on the baseline. 
Principal Component Analysis (PCA) 
First derivative spectral data was analysed using PCA as shown in Figure 123  to classify 
the three groups and reduce the dimensionality of the data. Components 1 and 2 
provided the best separation with a combined 36% of the variation between groups.  
 
 
Figure 122. Plot of first derivative (7pts) of noise reduced (60 PCs) and vector normalised spectra of 1321N1, 
SVGP12 and U87MG whole cells. 
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Figure 123. 3D PCA plot of Model B (First derivative) showing good clustering of the groups, 1321N1 (Blue), 
SVGP12 (Red) and U87MG (Green).  
Discriminant Function Analysis (LDA) 
DFA was carried out in MatLab™ to classify the three cell lines based on Model B, Figure 
124. The axes in Figure 124 of the discriminant function plot have positive and negative 
directions. Generally the direction can be used to identify the peaks in a loadings plot 
which are responsible for the separation. However peak information from loadings of 
Model A does not give information that can be trusted since that data is transformed 
during a first derivative. The accuracy of the classification is given in terms of sensitivities 
and specificities shown in  Peaks in the negative direction of the y axis discriminate 
SVGP12 (Blue), 1321N1 (Red) from U87MG (Black)..  
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Figure 124. DFA plot (Model B) first derivative of 1321N1 (Blue), SVGP12 (Red) and U87MG (Black) based 
on the training set (symbol = O) and test set (symbol = +) with 95 % (Inner ellipse) and 90% (Outer ellipse) 
confidence intervals. Any observed clustering of groups suggests a common underlying biochemical profile. 
Permanova 
There was a Significance difference between the three groups based on Permanova 
(Manhattan) using 3 PCs (F2, 6=2.501, R2 = 0.250, P=<0.001, Permutations = 10 000).  
Support Vector Machine (SVM) 
The noise reduced (60 PCs), vector normalised data was classified using SVM, the model 
carried out a cross validation with the following optimal parameters yielding 
classification accuracy = 100% where, cost (C) = 2048, gamma (g) = 512. A decision matrix 
generated in the output table was used to calculate sensitivities and specificities shown 
in Table 14.   
Model C (Second Derivative) 
Model C was made up of noise reduced (60 PCs), second derivative (15 pts) and vector 
normalised spectra shown in Figure 125.  
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Figure 125. Plot of model C second derivative (15pts) of noise reduced (60 PCs) and vector normalised 
spectra of 1321N1, SVGP12 and U87MG cell lines. 
Principal Component Analysis (PCA) 
The transformed second derivative spectral data was analysed using PCA as shown in 
Figure 126  to classify the three groups and reduce the dimensionality of the data. 
Components 1 and 2 provided the best separation with a combined 51.8 % of the 
variation between groups.  
 
Figure 126. 3D PCA plot of model C second derivative (15pts) showing good clustering of the groups, 
1321N1 (Blue), SVGP12 (Red) and U87MG (Green).  
PCA loadings were used to investigate the functional groups responsible for group 
separation shown in Figure 127 and Figure 128.   
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Figure 127. Model C loadings of PC1 showing peaks responsible for data separation marked with a black 
dot, associated with known functional groups and molecules. 
 
 
Figure 128. Model C loadings of PC2 showing peaks responsible for data separation marked with a black 
dot, associated with known functional groups and molecules. 
The axes in Figure 129 of the discriminant function plot have positive and negative 
directions. The peaks in the positive direction of the y axis in the PCA loading plots 
correspond to the spectral peaks that the model is using to discriminate (U87MG = 
Black) from (1321N1 = Red) and (SVGP12 = Blue). The peaks in the negative direction 
discriminate SVGP12 from 1321N1 and U87MG. The separation can be assigned to 
differences in the protein and lipid changes within the three groups of cell lines, where 
U87MG and 1321N1 are expected to have a higher lipid content compared to SVGP12 
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which represents normal cells. Appendix I, Table 29Error! Reference source not found. 
shows tentative peak assignments for model c.  
 
 
Figure 129. Model C DFA plot of 1321N1 (Blue), SVGP12 (Red) and U87MG (Black) based on the training set 
(symbol = O) and test set (symbol = +) with 95 % (Inner ellipse) and 90% (Outer ellipse) confidence intervals. 
Any observed clustering of groups suggests a common underlying biochemical profile of the cells.   
Table 13 shows the individual and overall sensitivity and specificity of Models C DFA 
classifications at 95% and 90% confidence interval (CI). The highest sensitivity is 
achieved at 90% CI for all models and since all the groups were clearly separated with 
no overlap the model achieved a 100% specificity at both 95% and 90% CI. 
Permanova 
There was a Significance difference between the three groups based on Permanova 
(Manhattan) using 3 PCs (F2, 6 =2.989, R2= 0.284, P=<0.001, Permutations= 10 000). 
Support Vector Machine (SVM) 
The second derivative, vector normalised and noise reduced data was classified using 
SVM, the model carried out a cross validation with the following optimal parameters 
yielding classification accuracy = 100% where, cost (C) = 2048, gamma (g) = 512. A 
decision matrix generated in the output table was used to calculate sensitivities and 
specificities shown in Table 14.   
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Attenuated Total Reflection-Fourier Transform Infrared 
Model B (First Derivative) 
Model B consisted of spectra that was noise reduced (60 PCs) which was converted into 
first derivative (Savitzky-Golay algorithm) using 7 smoothing points in MatLab™ Figure 
130. The first derivative data was vector normalised and analysed using PCA, DFA, SVM 
and Permanova. Factor loadings are not used with first derivative spectral models 
because of the shift of peaks in the raw spectra which become points on the baseline. 
 
Figure 130. Plot of first derivative (7pts), noise reduced (60 PCs) and vector normalised spectra of 1321N1, 
SVGP12 and U87MG whole cells. 
Principal Component Analysis (PCA) 
Model B was made up of noise reduced (60 PCs), first derivative (7 pts) data which was 
vector normalised. PCA was carried out on the spectral data Figure 131 and components 
1 and 2 showed the best separation parameters. Component 1 made up 53.5 % of the 
variation and separated U87MG (Green) from 1321N1 (Blue) and SVGP12 (Red). 
Component 2 made up 7.2 % of the variation and separated SVGP12 (Red) from 1321N1 
(Blues) and U87MG (Green).  
Discriminant Function Analysis (LDA)  
Spectral data from Model B was randomly divided into 2/3 training and 1/3 test from 85 
spectra making up 777 data points. The DFA model Figure 132 provides good visual 
representation on how well the model classified the three cell lines. The DFA model 
classified the three cell lines based on the test data (+) made up of a blind set of n= 18 
to the corresponding training data (O) n = 57. Model classification accuracy is given in 
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Table 15. Sensitivity and Specificity of DFA ATR-FTIR classification of 1321N1, SVGP12 
and U87MG at 95 and 90% Confidence intervals. 
 
 
Figure 131. Principal components 1 and 3 from Model B data showing differences between 1321N1 (Blue), 
SVGP12 (Red) and U87MG (Green). The plot shows component 1 with 53.5 % of the non-trivial variation and 
component 3 with 7.2%. PC1 and 3 shows good separation and grouping with a combined 60.7 % of the 
variation.  
 
 
 
Figure 132. Discriminant function analysis plot of Model B, Red= (1321N1), Blue= (SVGP12) and Black = 
(U87MG), Train data= O and Test data = +. 
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Permanova 
There was Significance difference between the three 1321N1, SVGP12 and U87MG 
groups based on Model B with 3 PCs using Permanova (Manhattan), (F2, 6, = 10.489, R2 = 
0.583, P=<0.001, Permutation = 10 000).  
Support Vector Machine (SVM) 
The noise reduced (60 PCs), vector normalised data was classified using SVM, the model 
carried out a cross validation with the following optimal parameters yielding 
classification accuracy = 100% where, cost (C) = 2048, gamma (g) = 512. A decision matrix 
generated in the output table was used to calculate sensitivities and specificities shown 
in Table 16.   
Model C (Second Derivative) 
Principal Component Analysis (PCA) 
Model C was made up of second derivative (15 pts) and vector normalised data (Figure 
133). The data was analysed using PCA (Figure 134). Components 1 and 3 showed the 
best separation, with component 1 making up 52.5 % of the variation and component 3 
making up 5.9 %. Component 1 separated U87MG (Green) from 1321N1 (Blue) and 
SVGP12 (Red). Component 3 separated SVGP12 (Red) from 1321N1 (Blue) and U87MG 
(Green). 
 
Figure 133. Plot of model C second derivative (15pts) of noise reduced (60 PCs) and vector normalised 
spectra of 1321N1, SVGP12 and U87MG cell lines. 
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Figure 134. Principal components 1 and 3 from Model C data showing differences between 1321N1 (Blue), 
SVGP12 (Red) and U87MG (Green). The plot shows component 1 with 52.5 % of the non-trivial variation 
and component 3 with 5.9%. PC1 and 3 shows good separation and grouping with a combined 58.4 % of the 
variation. 
 
  
 
Figure 135. Loadings of PC 1 showing functional groups and molecules responsible for the separation of 
Model C data 
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Figure 136. Loadings of PC 3 showing functional groups responsible for the separation of Model C data. 
 
 Discriminant Function Analysis (LDA) 
Spectra was randomly divided into 2/3 training and 1/3 test from 85 spectra making up 
777 data points for the supervised DFA model, Figure 137 which provides good visual 
representation on how well the statistical model classified the three cell lines 1321N1, 
SVGP12 and U87MG based on Models C. The DFA model classified the three cell lines 
based on their biomolecular differences as shown by the loadings Figure 135 and Figure 
136. The test data (+) was made up of a blind set of n= 18 to the corresponding training 
data (O) n = 57. Model classification accuracy is given in Table 15. Sensitivity and 
Specificity of DFA ATR-FTIR classification of 1321N1, SVGP12 and U87MG at 95 and 90% 
Confidence intervals. 
Permanova 
 There is a Significance difference between the three groups, 1321N1, SVGP12 and 
U87MG based on Model C, 3 PCs using Permanova (Manhattan), (F2, 6=7.109, R2 = 0.487, 
P=<0.001, Permutations = 10 000). 
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Figure 137.  Discriminant function analysis plot of Model C, Red= (1321N1), Blue= (SVGP12) and Black = 
(U87MG), Train data= O and Test data = +. 
Support Vector Machine (SVM) 
The noise reduced (60 PCs), second derivative and vector normalised data was classified 
using SVM, the model carried out a cross validation with the following optimal 
parameters yielding classification accuracy = 100% where, cost (C) = 2048, gamma (g) = 
512. A decision matrix generated in the output table was used to calculate sensitivities 
and specificities shown in Table 16.   
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APPENDIX C (Histopathology and 
Patient History)  
 
Patient Type   Diagnosis Gender DOB DODi DOD       AADi SIM DODi=Date Of Diagnosis 
374 Glioma GBM F 20/11/1975 17/07/2009 20/03/2010 33 8 AADi= Age At Diagnosis 
376 Other Lymphoma M 09/08/1959 21/07/2009 02/10/2009 49 2 SIM=Survival In Months 
377 Glioma GBM F 08/03/1965 22/07/2009 31/07/2010 44 12 A=Alive 
390 Glioma GBM M 03/09/1929 02/09/2009 03/12/2009 79 3 
 392 Meningioma Meningioma II F 20/09/1916 03/09/2009 22/07/2011 92 22 
 395 Meningioma Meningioma II F 16/02/1930 10/09/2009 Alive 79 A 
 396 Glioma GBM M 08/12/1940 10/09/2009 17/09/2010 68 12 
 404 Glioma GBM M 18/11/1943 01/10/2009 16/05/2010 65 7 
 406 Meningioma Meningioma I F 22/05/1932 02/10/2009 Alive 77 A 
 407 Meningioma Meningioma I F 11/07/1967 06/10/2009 Alive 42 A 
 408 Meningioma Meningioma I F 24/11/1940 08/10/2009 Alive 68 A 
 411 Glioma GBM M 27/09/1947 15/10/2009 13/03/2010 62 4 
 412 Glioma GBM M 28/12/1947 16/10/2009 10/03/2010 61 4 
 418 Other Glioneuronal with PNET component F 18/11/1960 21/10/2009 17/06/2010 48 7 
 420 Meningioma Meningioma I F 28/04/1928 22/10/2009 Alive 81 A 
 428 Glioma GBM F 21/12/1972 04/11/2009 16/10/2014 36 59 
 432 Other Fibromyxoid tumour M 09/05/1991 11/11/2009 Alive 18 A 
 435 Glioma GBM F 08/02/1940 19/11/2009 27/07/2010 69 8 
 436 Other Gliosarcoma F 07/07/1971 01/04/2009 29/03/2010 37 11 
 445 Glioma GBM M 02/07/1980 26/11/2009 19/01/2010 29 1 
 452 Glioma GBM with oligo component M 29/12/1956 14/12/2009 15/03/2011 52 15 
 453 Other Gliosarcoma M 04/06/1957 16/12/2009 19/02/2012 52 26 
 457 Meningioma Meningioma II M 27/05/1934 17/12/2009 Unknown 75 A 
 458 Glioma Astro III F 31/07/1938 17/12/2009 18/05/2011 71 17 
 460 Glioma Oligo III M 15/09/1980 18/12/2009 21/10/2011 29 22 
 470 Glioma GBM with oligo component M 31/08/1934 13/01/2010 01/04/2010 75 2 
 473 Glioma GBM M 13/08/1935 19/01/2010 06/03/2010 74 1 
 477 Meningioma Meningioma II F 05/08/1947 22/01/2010 30/08/2011 62 19 
 478 Meningioma Meningioma II F 13/02/1945 22/01/2010 Alive 64 A 
 481 Meningioma Meningioma I F 10/12/1957 04/02/2010 Alive 52 A 
 482 Other Lymphoma M 16/02/1964 04/02/2010 16/03/2010 45 1 
 484 Glioma GBM F 01/08/1938 05/02/2010 19/04/2010 71 2 
 500 Glioma GBM F 17/11/1937 23/03/2010 02/08/2010 72 4 
 502 Meningioma Meningioma I F 28/09/1962 25/03/2010 Alive 47 A 
 507 Meningioma Meningioma I F 08/04/1948 31/03/2010 Alive 61 A 
 508 Meningioma Meningioma I F 28/05/1956 01/04/2010 Alive 53 A 
 512 Glioma GBM M 05/11/1942 08/04/2010 05/10/2010 67 5 
 519 Meningioma Meningioma I F 18/08/1957 14/04/2010 Alive 52 A 
 522 Glioma GBM M 22/06/1936 18/03/2010 05/05/2010 73 1 
 524 Meningioma Meningioma I F 08/02/1959 20/04/2010 Unknown 51 A 
 527 Glioma Oligoastro III / GBM F 15/06/1950 23/04/2010 11/07/2010 59 2 
 533 Glioma GBM M 23/01/1943 11/05/2010 05/11/2010 67 5 
 535 Glioma GBM F 12/01/1948 17/05/2010 17/12/2010 62 7 
 537 Medulloblastoma Medulloblastoma F 25/08/1988 18/05/2010 12/04/2011 21 10 
 538 Medulloblastoma PNET with glial differentiation F 27/02/1982 19/05/2009 10/05/2011 27 23 
 542 Glioma GBM M 18/10/1940 21/05/2010 13/04/2011 69 10 
 544 Glioma GBM M 21/07/1941 25/05/2010 13/08/2011 68 14 
 547 Meningioma Meningioma I M 17/04/1971 26/05/2010 Alive 39 A 
 551 Meningioma Meningioma I F 20/02/1967 27/05/2010 Alive 43 A 
 625 Meningioma Meningioma I F 29/11/1958 12/08/2010 Alive 51 A 
 625 Normal brain Normal brain F 29/11/1958 12/08/2010 Alive 51 A 
 658 Meningioma Meningioma II M 27/06/1964 07/09/2010 Unknown 46 A 
 811 Meningioma Meningioma III F 05/08/1947 22/01/2010 30/08/2011 62 19 
 828 Other Schwannoma F 30/11/1976 13/09/2011 31/01/2014 34 28 
 1383 Other Lymphoma M 06/03/1949 24/10/2013 Alive 64 A 
 1616 Other Schwannoma F 05/01/1960 12/06/2014 Alive 54 A 
 548 Glioma GBM M 21/07/1941 25/05/2010 13/08/2011 68 14 
 549 Glioma GBM M 02/04/1943 25/05/2010 01/04/2014 67 46 
 550 Other Malignant glio-neuronal tumour with PNET component F 18/11/1960 21/10/2009 17/06/2010 48 7 
 1694 Glioma GBM F 02/05/1956 09/10/2014 Alive 58 A 
 1 Meningioma Meningioma I F 07/05/1966 20/05/2005 Alive 39 A 
 2 Glioma GBM F 28/10/1937 09/06/2005 17/01/2006 67 7 
 3 Glioma GBM F 22/09/1981 28/06/2005 11/11/2005 23 4 
 4 Glioma GBM M 08/12/1942 29/06/2005 13/06/2006 62 11 
 5 Glioma GBM F 29/10/1958 23/09/2005 18/10/2006 46 12 
 6 Glioma Ependymoma III F 05/04/1971 29/09/2005 06/11/2005 34 1 
 7 Meningioma Meningioma I M 14/04/1939 01/11/2005 Alive 66 A 
 8 Meningioma Meningioma I F 05/05/1967 28/12/2005 Alive 38 A 
 9 Glioma Oligoastrocytoma III F 16/04/1943 04/02/2006 21/07/2007 62 17 
 10 Glioma GBM F 13/06/1929 08/02/2006 31/03/2006 76 1 
 11 Glioma GBM M 20/11/1967 26/05/2006 31/07/2006 38 2 
 12 Glioma GBM M 13/08/1942 03/08/2006 18/01/2007 63 5 
 13 Glioma Oligoastrocytoma II F 12/02/1954 14/09/2006 01/03/2009 52 29 
 14 Glioma Oligoastrocytoma III M 23/07/1962 26/09/2006 Alive 44 A 
 15 Glioma Oligodendroglioma II M 27/07/1950 28/09/2006 13/12/2007 56 14 
 20 Glioma Astrocytoma II M 20/08/1980 09/11/2006 Alive 26 A 
 22 Glioma Oligodendroglioma (quiescent) M 15/12/1935 23/11/2006 24/02/2007 70 3 
 25 Glioma GBM M 21/04/1953 12/12/2006 31/01/2007 53 1 
 26 Glioma GBM M 24/12/1974 12/12/2006 08/06/2007 31 5 
 29 Glioma GBM F 18/02/1942 20/12/2006 12/06/2007 64 5 
 30 Glioma GBM F 04/06/1939 05/01/2007 22/03/2007 67 2 
 33 Glioma GBM M 25/11/1936 26/01/2007 23/07/2007 70 5 
 35 Other Schwannoma I M 21/02/1990 06/02/2007 Alive 16 A 
 36 Meningioma Meningioma I M 06/09/1947 07/02/2007 Alive 59 A 
 37 Meningioma Meningioma II F 19/10/1930 07/02/2007 Alive 76 A 
 38 Glioma Astrocytoma III M 16/11/1958 08/02/2007 27/06/2007 48 4 
 39 Glioma GBM M 15/07/1937 08/02/2007 05/06/2007 69 3 
 40 Glioma GBM M 09/03/1936 09/02/2007 28/04/2007 70 2 
 41 Glioma GBM M 09/06/1959 15/02/2007 05/07/2007 47 4 
 42 Glioma GBM F 03/03/1936 16/03/2007 23/04/2008 71 13 
 43 Glioma GBM M 20/09/1942 01/03/2007 31/08/2007 64 5 
 44 Glioma GBM F 30/06/1946 02/03/2007 11/07/2007 60 4 
 45 Glioma GBM M 02/08/1929 08/03/2008 30/08/2007 78 A 
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46 Glioma GBM M 21/05/1932 09/03/2007 15/08/2007 74 5 
 47 Glioma GBM F 22/11/1944 14/03/2007 03/06/2007 62 2 
 51 Glioma GBM F 02/03/1941 29/03/2007 27/05/2007 66 1 
 52 Glioma GBM M 19/01/1933 30/03/2007 24/06/2007 74 2 
 53 Other Xanthrocytoma III M 20/02/1975 03/04/2007 04/04/2008 32 12 
 54 Glioma GBM M 21/01/1930 03/04/2007 03/10/2007 77 6 
 56 Glioma GBM M 19/08/1944 17/04/2007 04/08/2008 62 15 
 57 Glioma GBM F 26/01/1967 18/04/2007 Unknown 40 A 
 58 Glioma GBM M 06/10/1946 20/04/2007 03/02/2009 60 21 
 59 Glioma GBM F 19/07/1943 23/04/2007 21/10/2007 63 5 
 60 Glioma GBM M 15/12/1936 26/04/2006 25/05/2007 69 12 
 61 Glioma Astrocytoma II M 12/10/1974 01/05/2007 Unknown 32 A 
 62 Glioma Ependymoma  II F 25/11/1972 02/05/2007 Alive 34 A 
 63 Glioma GBM M 16/06/1941 03/05/2007 05/08/2007 65 3 
 
 Glioma Astrocytoma II M 01/06/1981 11/05/2007 27/02/2014 25 81 
66 Glioma GBM M 17/06/1964 11/05/2007 12/07/2008 42 14 
67 Glioma Oligodendroglioma III F 15/06/1945 15/05/2007 23/07/2007 61 2 
68 Glioma Ganglioglioma IV F 29/11/1978 18/05/2007 09/06/2008 28 12 
69 Glioma GBM M 16/03/1935 23/05/2007 10/11/2007 72 5 
70 Glioma Oligoastrocytoma III M 07/07/1944 24/05/2007 27/08/2007 62 3 
71 Meningioma Meningioma III F 02/02/1937 20/06/2007 07/07/2008 70 12 
72 Glioma GBM M 31/08/1931 25/06/2007 05/10/2007 75 3 
73 Glioma GBM M 24/10/1931 29/06/2007 17/07/2007 75 0 
74 Glioma GBM M 27/06/1945 04/07/2007 14/12/2007 62 5 
75 Glioma GBM M 18/11/1935 04/07/2007 01/04/2008 71 8 
76 Glioma Oligoastrocytoma III F 29/01/1968 05/07/2007 19/12/2007 39 5 
79 Glioma GBM M 01/09/1932 11/07/2007 24/11/2007 74 4 
80 Glioma GBM M 05/02/1943 12/07/2007 14/10/2007 64 3 
81 Glioma GBM with oligo component F 15/04/1935 13/07/2007 08/09/2007 72 1 
82 Glioma GBM M 15/01/1929 26/07/2007 29/10/2007 78 3 
84 Meningioma Meningioma I M 08/12/1949 01/08/2007 Alive 57 A 
85 Glioma GBM M 18/04/1959 28/08/2007 16/01/2008 48 4 
86 Glioma Ependymoma II F 13/02/1981 29/08/2007 Alive 26 A 
88 Meningioma Meningioma I F 18/01/1950 07/09/2007 Alive 57 A 
89 Glioma GBM M 13/11/1946 12/09/2007 Alive 60 A 
90 Other Neurilemmoma F 04/06/1954 12/09/2007 Unknown 53 A 
91 Meningioma Meningioma I F 16/02/1951 14/09/2007 Unknown 56 A 
93 Meningioma Meningioma I M 27/11/1959 21/09/2007 Alive 47 A 
95 Meningioma Meningioma I F 31/05/1936 21/09/2007 Unknown 71 A 
96 Glioma GBM M 16/11/1961 02/10/2007 26/02/2008 45 4 
98 Glioma GBM F 15/03/1968 08/10/2007 11/12/2007 39 2 
99 Meningioma Meningioma I F 29/11/1951 10/10/2007 Alive 55 A 
100 Glioma GBM F 09/12/1944 10/10/2007 03/02/2008 62 3 
101 Glioma GBM F 10/01/1933 11/10/2007 11/05/2008 74 7 
102 Glioma GBM F 15/03/1968 08/10/2007 11/12/2007 39 2 
103 Glioma GBM F 03/09/1930 29/10/2007 24/02/2008 77 3 
104 Meningioma Meningioma I F 18/03/1940 31/12/2007 Unknown 67 A 
105 Glioma Infiltrating edge glioma F 03/02/1928 06/11/2007 10/12/2007 79 1 
106 Meningioma Meningioma I F 14/02/1965 07/11/2007 19/11/2007 42 0 
107 Glioma Oligodendroglioma III M 27/07/1950 28/09/2006 13/12/2007 56 14 
108 Meningioma Meningioma I F 28/04/1944 09/11/2007 Alive 63 A 
109 Glioma Quiescent tumour, prev ganglioglioma M 15/06/1971 09/11/2007 10/08/2009 36 21 
110 Glioma GBM M 11/05/1948 12/11/2007 22/08/2008 59 9 
111 Glioma Edge, prob astrocytoma F 18/01/1930 15/11/2007 10/01/2008 77 1 
112 Glioma GBM M 05/02/1936 22/11/2007 05/01/2008 71 1 
113 Glioma GBM M 12/06/1954 23/11/2007 07/01/2008 53 1 
116 Glioma GBM F 21/10/1941 04/12/2007 17/05/2009 66 17 
118 Meningioma Meningioma I F 19/05/1962 06/12/2007 Alive 45 A 
120 Glioma Oligoastrocytoma III M 22/01/1980 13/12/2007 27/06/2011 27 42 
121 Glioma GBM F 31/07/1946 19/03/2007 04/03/2008 60 11 
122 Glioma GBM M 19/02/1955 21/12/2007 22/08/2010 52 32 
125 Glioma GBM M 11/02/1952 24/12/2007 01/03/2009 55 14 
127 Glioma Probably High Grade M 20/06/1948 28/12/2007 23/05/2008 59 4 
128 Glioma GBM M 17/09/1942 31/12/2007 28/01/2009 65 12 
129 Glioma GBM M 03/05/1944 02/01/2008 20/03/2008 63 2 
131 Meningioma Meningioma I M 01/11/1948 16/01/2008 Alive 59 A 
133 Glioma GBM M 22/01/1923 25/01/2008 25/03/2008 85 2 
134 Glioma GBM M 30/08/1938 25/01/2008 09/03/2008 69 1 
139 Meningioma Meningioma I F 09/04/1951 04/02/2008 Alive 56 A 
140 Glioma GBM F 21/02/1943 04/02/2008 17/07/2008 64 5 
141 Other Lymphoma M 17/11/1942 06/02/2008 26/04/2008 65 2 
142 Glioma GBM M 08/06/1938 06/02/2008 31/03/2008 69 1 
143 Meningioma Meningioma II F 12/06/1940 08/02/2008 Alive 67 A 
144 Glioma GBM F 30/04/1936 08/02/2008 21/05/2008 71 3 
145 Meningioma Meningioma I F 11/04/1976 12/02/2008 Alive 31 A 
146 Glioma GBM M 22/08/1943 13/02/2008 20/09/2008 64 7 
147 Meningioma Meningioma I F 18/06/1948 13/02/2008 Unknown 59 A 
148 Meningioma Meningioma I F 17/02/1935 21/02/2008 Unknown 73 A 
149 Other Lymphoma F 05/07/1946 22/03/2008 Alive 61 A 
150 Glioma Gliosarcoma IV M 16/10/1928 22/02/2008 17/06/2008 79 3 
151 Meningioma Meningioma I M 09/06/1960 29/02/2008 Alive 47 A 
154 Meningioma Meningioma I F 31/10/1937 03/03/2008 Alive 70 A 
155 Other Lymphoma M 06/11/1932 04/03/2008 19/05/2008 75 2 
157 Meningioma Meningioma (no grade) F 21/08/1932 07/03/2008 10/03/2008 75 0 
158 Glioma Astrocytoma II M 04/09/1933 07/03/2008 23/07/2008 74 4 
159 Other Lymphoma M 05/01/1955 20/03/2008 Alive 53 A 
160 Glioma Astrocytoma II M 17/10/1972 25/03/2008 Alive 35 A 
161 Glioma GBM M 28/04/1953 28/03/2008 01/11/2009 54 19 
162 Meningioma Meningioma III F 22/01/1932 27/03/2008 31/07/2010 76 28 
163 Glioma GBM M 07/07/1923 01/04/2008 07/04/2008 84 0 
165 Glioma GBM M 28/09/1935 02/04/2008 14/05/2008 72 1 
166 Glioma GBM M 03/12/1976 02/04/2008 20/07/2008 31 3 
167 Glioma Infiltrating edge glioma F 04/12/1939 03/04/2008 26/03/2009 68 11 
170 Glioma Astrocytoma III F 21/06/1934 04/04/2008 Unknown 73 A 
173 Glioma Astrocytoma III M 16/12/1957 11/04/2008 25/09/2008 50 5 
174 Glioma Oligoastrocytoma III F 26/03/1966 14/04/2008 01/02/2012 42 45 
175 Glioma GBM F 22/04/1953 15/04/2008 28/07/2009 54 15 
176 Meningioma Meningioma I M 31/12/1939 16/04/2008 Alive 68 A 
177 Glioma GBM F 18/05/1958 04/04/2008 14/11/2008 49 7 
178 Glioma GBM F 14/10/1939 21/04/2008 02/07/2008 68 2 
179 Glioma Oligodendroglioma III F 16/05/1972 24/04/2008 15/07/2009 35 14 
180 Meningioma Meningioma I F 20/11/1972 25/04/2008 Unknown 35 A 
183 Glioma Oligoastrocytoma III F 11/05/1942 02/05/2008 23/05/2008 65 0 
185 Glioma GBM M 15/04/1975 08/05/2008 21/06/2008 33 1 
186 Glioma GBM F 01/01/1952 08/05/2008 21/08/2008 56 3 
187 Meningioma Meningioma I F 05/01/1933 09/05/2008 10/02/2009 75 9 
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188 Glioma Oligodendroglioma II F 29/12/1964 14/05/2008 Alive 43 A 
190 Meningioma Meningioma I M 19/10/1988 16/05/2008 Unknown 19 A 
192 Meningioma Meningioma I F 25/04/1935 22/05/2008 Unknown 73 A 
196 Glioma Astrocytoma III M 24/10/1941 27/12/2007 05/07/2008 66 6 
197 Glioma GBM M 10/08/1931 29/05/2008 16/08/2008 76 2 
198 Meningioma Meningioma II F 02/06/1935 02/06/2008 15/10/2008 73 4 
199 Glioma GBM F 10/04/1922 02/06/2008 23/07/2008 86 1 
200 Glioma GBM F 03/09/1954 03/06/2008 27/09/2008 53 3 
201 Meningioma Meningioma I F 19/04/1955 05/06/2008 Unknown 53 A 
202 Other Schwannoma I M 05/07/1948 09/06/2008 Unknown 59 A 
203 Glioma Astrocytoma II F 12/05/1966 09/06/2008 Alive 42 A 
204 Glioma GBM F 29/04/1954 10/06/2008 15/03/2009 54 9 
205 Meningioma Meningioma I F 11/05/1954 11/06/2008 Alive 54 A 
206 Glioma Probably high grade M 27/04/1959 11/06/2008 09/05/2009 49 10 
207 Glioma GBM M 21/01/1933 12/06/2008 27/10/2008 75 4 
208 Glioma GBM M 04/09/1933 07/03/2008 23/07/2008 74 4 
209 Glioma Probably GBM M 21/03/1932 16/06/2008 19/08/2008 76 2 
 
210 
Glioma Astrocytoma II F 16/01/1955 27/06/2008 Alive 53 A 
1 Glioma Astrocytoma III M 27/10/1935 02/07/2008 02/09/2008 72 2 
212 Glioma Astrocytoma II M 28/09/1958 03/07/2008 15/04/2012 49 45 
213 Glioma GBM M 27/01/1938 04/07/2008 30/09/2008 70 2 
216 Glioma Astrocytoma I F 07/02/1947 10/07/2008 Unknown 61 A 
217 Glioma Ganglioglioma I M 15/09/1991 17/07/2008 Alive 16 A 
218 Meningioma Meningioma (no grade) F 16/11/1964 18/07/2008 Unknown 43 A 
220 Meningioma Meningioma II M 25/10/1945 18/07/2008 Alive 62 A 
222 Meningioma Meningioma I F 22/04/1953 23/07/2008 Alive 55 A 
223 Medulloblastoma PNET IV M 28/11/1940 25/07/2008 09/11/2008 67 3 
224 Other Lymphoma F 28/02/1943 25/07/2008 Alive 65 A 
226 Meningioma Meningioma I F 28/03/1938 30/07/2008 16/08/2008 70 0 
227 Glioma Astrocytoma III F 21/09/1983 31/07/2008 Unknown 24 A 
228 Glioma GBM F 15/04/1935 31/07/2008 25/10/2008 73 2 
229 Glioma GBM M 19/11/1980 01/08/2008 03/03/2009 27 7 
231 Glioma GBM F 03/10/1942 05/08/2008 19/11/2008 65 3 
233 Glioma Astrocytoma II F 07/09/1930 07/08/2008 16/03/2009 77 7 
234 Meningioma Meningioma II M 23/12/1950 15/08/2008 Alive 57 A 
235 Other Germinoma, high grade M 16/04/1984 15/08/2008 Alive 24 
 236 Glioma GBM F 10/12/1929 29/08/2008 15/12/2008 78 3 
237 Glioma GBM M 20/08/1952 03/09/2008 20/03/2009 56 6 
238 Meningioma Meningioma I F 03/12/1957 04/09/2008 Alive 50 A 
239 Meningioma Meningioma I M 22/08/1953 05/09/2008 Alive 55 A 
241 Glioma GBM M 24/07/1962 10/09/2008 20/10/2008 46 1 
242 Glioma GBM F 25/12/1948 10/09/2008 16/01/2009 59 4 
245 Glioma GBM F 22/04/1953 15/04/2008 28/07/2009 54 15 
246 Glioma GBM M 15/07/1936 15/09/2008 04/10/2008 72 0 
249 Meningioma Meningioma I F 15/07/1949 24/09/2008 Alive 59 A 
250 Glioma GBM F 30/05/1936 24/09/2008 26/09/2008 72 0 
251 Glioma GBM M 25/07/1937 25/09/2008 14/04/2009 71 6 
254 Meningioma Meningioma I F 13/01/1943 03/10/2008 Unknown 65 A 
256 Glioma Oligodendroglioma III F 10/01/1948 07/10/2008 Alive 60 A 
258 Glioma GBM M 05/02/1934 08/10/2008 23/04/2010 74 18 
259 Glioma GBM M 11/05/1952 10/10/2008 15/11/2009 56 13 
262 Meningioma Meningioma I F 07/01/1932 24/10/2008 Alive 76 A 
264 Glioma Astrocytoma (no grade) M 30/06/1938 28/10/2008 13/06/2009 70 7 
266 Meningioma Meningioma II F 20/06/1932 31/10/2008 Unknown 76 A 
267 Glioma GBM F 17/08/1931 07/11/2008 12/02/2009 77 3 
268 Glioma GBM M 22/05/1947 07/11/2008 20/11/2008 61 0 
273 Meningioma Meningioma II F 05/01/1942 14/11/2008 Unknown 66 A 
276 Meningioma Meningioma I F 19/08/1958 21/11/2008 Alive 50 A 
277 Meningioma Meningioma I F 13/06/1967 28/11/2008 Unknown 41 A 
278 Glioma GBM M 21/12/1932 04/12/2008 07/02/2009 75 2 
280 Glioma GBM M 13/05/1942 10/12/2008 09/02/2009 66 1 
282 Glioma GBM M 14/04/1946 11/12/2008 20/10/2009 62 10 
283 Glioma GBM M 16/05/1938 18/12/2008 05/01/2010 70 12 
284 Meningioma Meningioma I M 18/02/1939 19/12/2008 Alive 69 A 
285 Meningioma Meningioma I F 17/06/1960 19/12/2008 Alive 48 A 
286 Meningioma Meningioma II F 22/09/1955 19/12/2008 Unknown 53 A 
288 Glioma GBM F 26/08/1954 23/12/2008 01/04/2010 54 15 
289 Glioma GBM M 29/05/1922 31/12/2008 14/01/2009 86 0 
290 Meningioma Meningioma II M 31/08/1950 31/12/2008 Unknown 58 A 
291 Meningioma Meningioma I F 17/07/1956 02/01/2009 Alive 52 A 
293 Meningioma Meningioma I F 06/07/1954 05/01/2009 Alive 54 A 
294 Meningioma Meningioma I M 16/06/1920 07/01/2009 27/02/2009 88 1 
296 Meningioma Meningioma II M 01/07/1968 08/01/2009 17/02/2010 40 13 
297 Meningioma Meningioma II M 13/07/1928 13/01/2009 24/04/2012 80 39 
299 Meningioma Meningioma I F 14/07/1922 15/01/2009 Unknown 86 A 
300 Meningioma Meningioma I M 13/11/1930 21/01/2009 30/11/2013 78 58 
302 Meningioma Meningioma I F 18/01/1950 26/01/2009 Unknown 59 A 
303 Meningioma Meningioma II F 20/02/1964 28/01/2009 Alive 44 A 
306 Glioma GBM M 03/02/1940 05/02/2009 07/09/2009 69 7 
307 Glioma Astrocytoma I M 10/02/1984 11/02/2009 Alive 25 A 
308 Glioma GBM M 23/08/1930 12/02/2009 13/04/2009 78 2 
311 Meningioma Meningioma I F 04/07/1956 20/02/2009 Alive 52 A 
312 Glioma GBM M 29/02/1952 24/02/2009 05/07/2009 56 4 
314 Meningioma Meningioma I F 10/10/1972 02/03/2009 Unknown 36 A 
315 Meningioma Meningioma I F 19/08/1958 04/03/2009 Alive 50 A 
316 Glioma GBM M 03/05/1932 05/03/2009 21/04/2009 76 1 
317 Glioma GBM M 09/03/1929 06/03/2009 17/01/2010 79 10 
319 Glioma GBM F 07/01/1939 10/03/2009 07/09/2009 70 5 
320 Glioma GBM M 08/10/1939 11/03/2009 22/05/2009 69 2 
322 Glioma GBM M 24/11/1944 16/03/2009 19/07/2009 64 4 
324 Glioma GBM F 17/09/1937 18/03/2009 21/07/2009 71 4 
325 Glioma Oligodendroglioma / Oligoastrocytoma III M 26/08/1944 20/03/2009 07/12/2011 64 32 
326 Glioma Oligodendroglioma II F 20/12/1952 20/03/2009 12/05/2012 56 37 
327 Glioma GBM with focal oligo features IV M 15/08/1937 27/03/2009 20/08/2009 71 4 
328 Glioma GBM F 07/07/1971 01/04/2009 29/03/2010 37 11 
330 Meningioma Meningioma I F 26/11/1950 03/04/2009 14/04/2014 58 60 
331 Glioma GBM F 26/08/1939 06/04/2009 29/09/2009 69 5 
332 Meningioma Meningioma I M 04/08/1948 15/04/2009 Unknown 60 A 
334 Glioma GBM F 26/03/1938 30/04/2009 29/05/2009 71 0 
335 Glioma GBM F 18/09/1944 30/04/2009 25/12/2011 64 31 
336 Glioma GBM M 20/10/1930 01/05/2009 04/07/2009 78 2 
337 Glioma High grade F 09/06/1958 01/05/2009 04/05/2010 50 12 
338 Glioma GBM M 29/12/1937 05/05/2009 08/06/2009 71 1 
339 Glioma Oligodendroglioma III F 17/12/1927 05/05/2009 07/09/2009 81 4 
340 Glioma GBM M 26/08/1946 06/05/2009 26/07/2009 62 2 
341 Glioma GBM M 14/10/1925 06/05/2009 27/10/2009 83 5 
342 Glioma GBM M 22/04/1924 08/05/2009 14/07/2009 85 2 
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344 Glioma GBM with focal oligo features IV M 04/07/1938 12/05/2009 04/12/2009 70 6 
345 Meningioma Meningioma I M 13/06/1953 14/05/2009 Alive 55 A 
349 Meningioma Meningioma I F 20/04/1954 21/05/2009 Alive 55 A 
351 Glioma GBM M 18/09/1932 22/05/2009 08/12/2009 76 6 
352 Glioma GBM M 26/05/1960 02/06/2009 14/06/2009 49 0 
353 Meningioma Meningioma I F 15/05/1933 04/06/2009 Alive 76 A 
354 Glioma GBM M 29/07/1959 05/06/2009 13/11/2009 49 5 
355 Meningioma Meningioma I M 26/03/1959 10/06/2009 Alive 50 A 
357 Glioma Gliosarcoma IV F 10/11/1942 17/06/2009 15/09/2009 66 2 
360 Glioma GBM F 06/05/1941 19/06/2009 19/10/2009 68 4 
361 Glioma GBM M 21/09/1954 25/06/2009 29/07/2010 54 13 
362 Glioma GBM M 23/11/1956 25/06/2009 23/08/2010 52 13 
363 Glioma GBM M 30/11/1946 25/06/2009 23/11/2009 62 4 
366 Glioma Astrocytoma III M 30/04/1975 03/07/2009 01/10/2009 34 2 
367 Glioma Astrocytoma II M 01/06/1952 07/07/2009 Alive 57 A 
368 Meningioma Meningioma II M 02/10/1942 09/07/2009 15/05/2011 66 22 
370 Glioma Gliosarcoma IV F 30/07/1943 13/07/2009 29/08/2009 65 1 
383 Meningioma Meningioma II F 11/09/1951 06/08/2009 Alive 57 A 
399 Meningioma Meningioma I M 24/02/1948 16/09/2009 Unknown 61 A 
 
401 Meningioma Meningioma I F 19/05/1961 22/09/2009 Unknown 48 A 
454 Meningioma Meningioma I M 11/01/1950 17/12/2009 Alive 59 A 
461 Meningioma Meningioma I F 13/04/1937 21/12/2009 Unknown 72 A 
475 Meningioma Meningioma - no grade F 21/04/1993 19/01/2010 Alive 16 A 
479 Meningioma Meningioma I F 16/12/1943 27/01/2010 Alive 66 A 
496 Meningioma Meningioma I F 08/08/1951 04/03/2010 Alive 58 A 
525 Meningioma Meningioma I F 27/02/1953 21/04/2010 Alive 57 A 
528 Meningioma Meningioma I F 19/12/1951 29/04/2010 Alive 58 A 
243 Medulloblastoma Medulloblastoma IV M 27/04/1988 11/09/2008 16/07/2013 20 58 
269 Medulloblastoma Glial & PNET features, high grade F 04/07/1943 11/11/2008 19/12/2008 65 1 
275 Medulloblastoma Medulloblastoma IV M 23/08/1991 20/11/2008 18/09/2012 17 45 
348 Medulloblastoma PNET with glial differentiation IV F 27/02/1982 19/05/2009 10/05/2011 27 23 
359 Medulloblastoma Medulloblastoma IV M 14/09/1990 19/06/2009 Unknown 18 A 
387 Medulloblastoma PNET IV M 03/09/1960 20/08/2009 11/08/2014 48 59 
950 Medulloblastoma Medulloblastoma IV M 27/04/1988 11/09/2008 16/07/2013 20 58 
1079 Medulloblastoma Medulloblastoma IV F 15/12/1964 04/01/2013 Alive 48 A 
1118 Medulloblastoma PNET IV M 13/11/1967 20/03/2013 Unknown 45 A 
1313 Medulloblastoma Medulloblastoma IV F 14/12/1970 05/07/2013 Alive 42 A 
83 Normal brain Normal brain M 08/12/1949 01/08/2007 Alive 57 A 
132 Normal brain Normal brain F 24/06/1943 18/01/2008 Unknown 64 A 
136 Normal brain Normal brain F 25/09/1956 31/01/2008 Alive 51 A 
225 Normal brain Normal brain F 05/08/1981 25/07/2008 Alive 26 A 
540 Normal brain Normal brain F 14/02/1960 20/05/2010 06/10/2014 50 52 
486 Normal brain Normal brain M 19/04/1938 11/02/2010 20/05/2010 71 3 
444 Normal brain Normal brain M 30/01/1978 26/11/2009 Alive 31 A 
596 Normal brain Normal brain M 02/02/1950 20/07/2010 27/08/2010 60 1 
678 Normal brain Normal brain F 13/11/1961 04/10/2010 Alive 48 A 
713 Normal brain Normal brain F 01/08/1971 22/12/2010 08/04/2011 39 3 
772 Normal brain Normal brain M 21/09/1972 20/05/2011 Alive 38 A 
1039 Normal brain Normal brain F 26/06/1969 08/11/2012 Alive 43 A 
1085 Normal brain Normal brain M 21/04/1949 17/01/2013 Alive 63 A 
1157 Normal brain Normal brain M 21/11/1991 02/05/2013 Alive 21 A 
1544 Normal brain Normal brain M 27/04/1944 07/03/2014 Alive 69 A 
1759 Normal brain Normal brain M 05/03/1934 16/01/2015 Alive 80 A 
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APPENDIX D (WHO Grading of 
Tumours) 
 
WHO Grading of Tumours of the Central Nervous System (CNS).  
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APPENDIX E (Pre-WHO Grading of 
Tumours) 
 
Pre-WHO Grading of Tumours of the Central Nervous System (CNS).  
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APPENDIX F (Main Unit Specifications)                                         
 
Main unit specifications: 
Measurement wavenumber range: 7,800 to 360 cm-1 
Display wavenumber range: 7,900 to 0 cm-1 
Wavenumber accuracy: Within ± 0.01 cm-1 (theoretical value) 
Resolution: 0.9, 2, 4, 8, 16 cm-1 
Optical system: Single beam 
Sample chamber: 175 mm (W) × 255 mm (D) × 170 mm (H) 
Sample chamber light path: Centre focus, light axis 70 mm high 
Interferometer: 45°incident Michelson interferometer Corner cube, sealed structure 
Interferometer drive:  Mechanical bearing, electromagnetic drive 
Interferometer drive speed:  AUTO, 2.0, 4.0 mm/sec 
AUTO DLATGS 2.0 mm/sec. 
MCT (optional) 4.0 mm/sec. 
Beam splitter:  Wide bandwidth type, KBr 
Light source: Ceramic 
Detector:  DLATGS 
(Optional) W-MCT, M-MCT, N-MCT 
Signal-to-noise ratio: 15,000: 1 (4 cm-1 at near 2,200 cm-1) 
Gain switching: AUTO 
1, 2, 4, 8, 16, 32, 64, 128, 256, 512 times 
100%T line flatness: Within 100 ± 1.0%T 
(4,000 to 700 cm-1, continuous repetitive measurement) 
Dimensions (main unit only): 590 (W) × 550 (D) × 257 (H) mm 
Weight (main unit only): 42.0 kg 
Data processing Unit specifications: 
CPU:  32-bit processor 
Arithmetic operation: 32-bit processing 
Spectrum display: 15" colour CRT display 
Data processing functions: 
A. Measurement 
Parameter setting, sample name input, preview 
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B. Correction 
Baseline correction, smoothing, elimination of unwanted peaks, deconvolution, FFT filter, data 
interpolation and cutting 
C. Arithmetic operations, derivation, KK conversion 
D. Peak processing, peak find, peak height, peak area, FWHM 
E. Difference spectrum 
F. Vertical axis conversion KM conversion, ABS ⇔ %T 
G. IR option ATR correction, IF ⇔ spectrum 
H. Curve fitting 
I. Other Comment edit 
Recorder (optional):  Ink jet printer, laser printer, XY plotter 
Optional accessories:  ATR-300/H Attenuated Total Reflection 
RF-81S Infrared Reflection Attachment 
PL-81 Wire-grid type Polarizer 
PR-510 Infrared Polarization Accessory 
IRT-30 Infrared Microscope 
Infrared cells and other options 
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Appendix G (Sample Preparations 
Protocols)  
 
Cell Culture 
Protocol for Cell Culture 
A culture of cells when plated at 3 x 105 cells per dish in a medium with 10% blood serum will 
grow for a few days and then cease growth at about 106 cells3. Growth will cease because the 
cells would have reached saturation density. These cells will remain viable with no growth until 
fresh media is introduced into the culture. Cells in the saturated culture are quiescent and can 
maintain themselves in a viable state for a long time. Through experimental work, mixtures of 
purified proteins have been successfully substituted for serum to allow the long term growth of 
certain cell lines. Defined medium, with growth factors and hormones is used with a number of 
cell lines. This media has known components and no serum and varies from cell line to cell line. 
The components of a defined medium gives a good idea of the role of serum, with protein 
hormones and growth factors being the important constituents [111].    
Cell culturing requires strict control of the environment in which the experiment is carried out. 
Strict aseptic techniques should be followed and any materials that are contaminated as well as 
any materials with which they may have come into contact must be disposed of immediately 
[224]. There should be traceability of materials and reagents. A record of the manufacturer, 
catalog number, lot number, date received, date expired and any other pertinent information 
for all materials and reagents used should be kept. Expansion of cell line should be recorded by 
recording the subculture and growth expansion activities, such as passage number, % 
confluence, % viability, cell morphology and population doubling levels (PDLs). PDLs should be 
calculated using the equation [173]; 
𝑃𝐷𝐿 = 𝑋 + 3.322 (log𝑌 − log 𝐼) 
Where   X = Initial PDL 
  I = Cell inoculum (number of cells plated in the flask) 
  Y = final cell yield (number of cells at the end of the growth period) 
The volume of the medium is based on the flask size as outlined in Table 27 below. 
 
                                                          
3 The description of cell culture stated here does not apply to all cells. 
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Table 27. Recommended medium volume used in the culturing of U87MG cells  
Flask Size Medium Volume Range 
12.5 cm2 (T-12.5) 3 mL to 6 mL 
25 cm2 (T-25) 5 mL to 13 mL 
75 cm2 (T-75) 10 mL to 38 mL 
150 cm2 (T-150) 30 mL to 75 mL 
175 cm2 (T-175) 35 mL to 88 mL 
225 cm2 (T-225) 45 mL to 113 mL 
 
Safety precaution taken using U87MG cells require the use of approved Biological Safety Level 
2 (BSL-2) facilities and procedures. Some of the procedures include; 
 Wearing appropriate Personal Protective Equipment (PPE), such as isolation gown, lab 
coat with sleeve protectors, face shield and gloves. 
 Use of safety precautions for working with liquid nitrogen, nitrogen vapour, and 
cryogenically cooled fixtures. 
 Use of liquid nitrogen freezers and liquid nitrogen tanks only in areas with adequate 
ventilation. Liquid nitrogen reduces the concentration of oxygen and can cause 
suffocation. 
 Wearing latex gloves over insulating gloves to prevent liquid nitrogen from soaking in 
and being held next to skin. Liquid nitrogen is extremely cold and will cause burns and 
frostbites. Metal inventory racks, tank components, and liquid nitrogen transfer hoses 
exposed to liquid nitrogen or nitrogen vapour quickly cool to cryogenic temperatures 
and can cause burns and frostbites. 
 Wearing a full face mask when thawing and retrieving vials from liquid nitrogen freezer. 
On warming, rapid evaporation of the nitrogen within the confines of cryovials can cause 
an aerosol or explosion of the cryovial and contents. 
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U87MG 
The U87MG cell line was derived from a malignant glioma on a female patient by explant 
technique. The cell line is reported to produce a malignant tumour consistent with a 
glioblastoma in nude mice. This cell line is characterised as a WHO grade IV tumour.  
Culture Initiation 
 Cryoprotectant (DMSO) is removed by centrifugation. 
 Seeding density used is about 4 x 104 viable cells/cm2 or one vial of U87MG cells into 
one T-25 flask containing 10 mL of complete growth medium EMEM + 10 % (v/v) FBS 
Complete growth medium 
 The complete growth medium (EMEM  + 10 % (v/v) FBS) is used to expand U87MG 
 The complete growth medium is pre-warmed before use by placing into a water bath 
set between 35 to 37 ⁰C for 15 to 30 min. 
 After 30 min the complete growth medium is moved to room temperature until use. 
 Complete growth medium should be stored at 2 to 8 ⁰C when not in use. 
Growth profile 
 U87MG Population Doubling Time (PDT) is approximately 34 h 
Cell Growth 
 The growth temperature for U87MG is 37 ⁰C ± 1 ⁰C, 5 % ± 1 % CO2 in air atmosphere 
Special Growth Requirements 
 Subculture U87MG cells at 75 to 85 % confluence or when cell density reaches an 
average of 2 x 105 viable cells/cm2 
Subculture Medium 
 0.25 % (w/v) trypsin-0.53 mM EDTA  
 Subculturing reagents should be pre-warmed before use by placing in water bath set at 
35-37 ⁰C for 15 to 30 min. 
  Subsculture medium should be moved to room temperature after 30 min until use and 
stored at 2 to 8 ⁰C when not in use.  
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Subculture Method 
 Attached U87MG cells are subcultured using 0.25 % (w/v) trypsin-0.53 mM EDTA 
 The enzymatic action of trypsin-EDTA is stopped by adding complete growth medium to 
the detached cells. 
 A split ratio of 1:4 to 1:5 or a seeding density of 4.0 x 104 to 5.0 x 104 viable cells/cm2 is 
used when Subculturing U87MG cells  
Viable Cells/mL/Cryovial 
 Target number of viable cells/mL/Cryovial is 2 x 106 and the acceptable range is 1.0 x 106 
cells/mL to 2.0 x 106 cells/mL 
Cryopreservation Medium 
 Complete growth medium (EMEM + 10 % (v/v) FBS) containing 5 % (v/v) DMSO 
Reagents for expansion, subculturing and cryopreservation of U87MG cells include, complete 
growth medium made up of Eagle’s Minimum Essential Medium (EMEM) and 10 % (v/v) Fetal 
Bovine Serum (FBS), subculturing reagents made up of Trypsin-EDTA (0.25 % (w/v) Trypsin/0.53 
mM EDTA) and Dulbecco’s Phosphate Buffered Saline (DPBS); modified without calcium chloride 
and without magnesium chloride, cryopreservation medium made up of EMEM, 10 % (v/v) FBS 
and 5 % (v/v) Dimethyl Sulfoxide (DMSO). 
Preparation of complete growth medium 
The complete growth medium is prepared by aseptically combining,  
1. 56 mL FBS to a 500 mL bottle of basal medium EMEM.  
2. Mixing gently by swirling. 
Thawing and Propagation of Cells 
Materials 
 Complete growth medium 
 Water bath 
 T-25 cm2 polystyrene flask 
 15 mL polypropylene conical centrifuge tube 
 Plastic pipettes (1 mL, 10 mL, 25 mL) 
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Thawing cells 
1. Place complete growth medium in a water bath set at 35 to 37 ⁰C. 
2. Label T-25 flask to be used with;  
a) Name of cell line 
b) Passage number  
c) Date  
d) Initials of technician 
3. Wearing a full face shield, retrieve a vial of frozen cells from the vapour phase of the 
liquid nitrogen freezer. 
4. Thaw the vial by gentle agitation in a water bath set at 35 to 37 ⁰C. To reduce the 
possibility of contamination, keep the O-ring and cap out of the water. Thawing should 
be rapid (2-3 min) just long enough for most of the ice to melt. 
5. Remove vial from water bath and process immediately. 
6. Remove excess water from the vial by wiping with sterile gauze saturated with 70 % 
ethanol. 
7. Transfer the vial to a BSL-2 laminar-flow hood. 
Propagating cells 
Method: 
1. Add 9 mL of complete growth medium to a 15 mL conical centrifuge tube. 
2. Wipe the outer surface of the vial with sterile gauze wetted with 70 % ethanol. 
3. Using sterile gauze, carefully remove the cap from vial. 
4. With a 1 mL pipette transfer slowly the completely thawed content of the vial (1 mL cell 
suspension) to the 15 mL conical centrifuge tube containing 9 mL of complete growth 
medium. Gently re-suspend cells by pipetting up and down.  
5. Centrifuge at 125 xg at room temperature for 8 to 10 min. 
6. Carefully aspirate the medium, leaving the pellet undisturbed. 
7. Using a 10 mL pipette, add 10 mL of complete growth medium. 
8. Re-suspend pellet by gentle pipetting up and down. 
9. Using a 1 mL pipette, remove 1 mL of cell suspension for cell count and viability. Cell 
counts are performed using either an automated counter (such as Innovatis Cedex 
System; Beckman-Coulter ViCell System) or a haemocytometer.  
10. Record total cell count and viability.  
11. Plate cells in pre-labelled T-25 cm2 flask at about 4  x 104 viable cells/cm2 
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12. Transfer flask to a 37 ⁰C ± 1 ⁰C in 5 % CO2 incubator if using flasks with vented caps (for 
non-vented caps stream 5 % CO2 in the headspace of flask. 
13. Observe culture daily by eye and under an inverted microscope to ensure culture is free 
of contamination and culture has not reached confluence. Monitor, visually, the pH of 
the medium daily. If the medium goes from red through orange to yellow, change the 
medium. 
14. Note: Cultures at high cell density exhaust the medium faster than those at low cell 
density as is evident from the change in pH. A drop in pH is usually accompanied by an 
increase in cell density, which is an indicator to subculture the cells. Cells may stop 
growing when the pH is between pH 7 to pH 6 and loose viability between pH 6.5 and 
pH 6.  
15. If fluid is needed, aseptically aspire the complete growth medium from the flask and 
discard. Add an equivalent volume of fresh complete growth medium to the flask. 
Alternatively, perform a fluid addition by adding fresh complete growth medium to the 
flask without removing the existing medium. Record fluid change or fluid addition.  
16. If subculturing of cells is needed, continue to subculture when cells are 75-85 % 
confluent. U87MG cells may pile up and form cluster when allowed to become over 
confluent. 
Subculturing Cells 
   Reagents and Materials  
 0.25 % (w/v) Trypsin-0.53 mM EDTA 
 DPBS 
 Complete growth medium 
 Plastic pipettes (1, 10 and 25 mL) 
 T-75 cm2, T-225 cm2 polystyrene flasks 
Method: 
1. Aseptically remove medium from flask 
2. Add 5 mL of sterile Ca2+ -and Mg2+ - free DPBS to the side of the flask opposite the cells 
so as to avoid dislodging the cells 
3. Rinse the cells with DPBS (rocking the flask gently) and discard 
4. Add 2 mL of 0.25 (w/v) Trypsin-0.53 mM EDTA solution to the flask 
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5. Incubate the flask at 37 ⁰C ± 1 ⁰C until cells round up. Observe cells under an inverted 
microscope every 5 min. When the flask is tilted, the attached cells should slide down 
the surface. This usually occurs after 5 to 10 min of incubation.  
6. Neutralise the Trypsin-EDTA/cell suspension by adding an equal volume of complete 
growth medium to the flask. Disperse the cells by pipetting, gently, over the surface of 
the monolayer. Pipette the cell suspension up and down with the tip of the pipette 
resting on the bottom corner or edge until a single cell suspension is obtained. Care 
should be taken to avoid the formation of a foam. 
7. Using a 1 mL pipette, remove 1 mL of cell suspension for a total cell count and viability. 
8. Record total cell count and viability 
9. At this stage cells are ready to be seeded on substrates appropriate for vibrational 
spectroscopy such as CaF2 
10. Add appropriate volume of fresh complete growth medium and transfer cell suspension 
into new labelled flask/petri dish (with substrate)  at a seeding density of 4.0 x 104 to 5.0 
x 104 viable cells/ cm2 or a split ratio of 1:4 to 1:5 
 Split ratio =  
𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑜𝑟𝑖𝑔𝑖𝑛𝑎𝑙 𝑐𝑒𝑙𝑙 𝑠𝑢𝑠𝑝𝑒𝑛𝑠𝑖𝑜𝑛/𝑚𝐿
𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑟𝑒𝑞𝑢𝑖𝑟𝑒𝑑 𝑐𝑒𝑙𝑙 𝑠𝑢𝑠𝑝𝑒𝑛𝑠𝑖𝑜𝑛/𝑚𝐿
 
11. Label new flask/petri dish (with substrate) with the a) name of cell line, b) passage 
number, c) date and d) initials of technician.   
1321N1 
The 1321N1 cell line is a human astrocytoma cell line classified as a WHO grade II tumour. This 
cell line was isolated in 1972 as a sub clone of the cell line 118N1 which in turn was isolated from 
the parent line U-118MG [72].   
Culture Initiation 
 Cryoprotectant (DMSO) is removed by centrifugation. 
 Seeding density used is about 4 x 104 viable cells/cm2 or one vial of 1321N1 cells into 
one T-25 flask containing 10 mL of complete growth medium DMEM + 10 % (v/v) FBS + 
2 mM L-glutamine 
Complete growth medium 
 The complete growth medium (DMEM + 10 % (v/v) FBS + 2 mM L-glutamine) is used to 
expand 1321N1 
 The complete growth medium is pre-warmed before use by placing into a water bath 
set between 35 to 37 ⁰C for 15 to 30 min. 
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 After 30 min the complete growth medium is moved to room temperature until use. 
 Complete growth medium should be stored at 2 to 8 ⁰C when not in use. 
  
Growth profile 
 1321N1 Population Doubling Time (PDT) is approximately 22 h 
Cell Growth 
 The growth temperature for 1321N1 is 37 ⁰C ± 1 ⁰C, 5 % ± 1 % CO2 in air atmosphere 
Special Growth Requirements 
 Subculture 1321N1 cells at 70 to 80 % confluence or when cell density reaches an 
average of 2 x 104 viable cells/cm2 or 1:2 to 1:6 split ratio. 
Subculture Medium 
 0.25 % (w/v) trypsin-0.53 mM EDTA  
 DMEM + 10 % (v/v) FBS + 2 mM L-glutamine 
 Subculturing reagents should be pre-warmed before use by placing in water bath set at 
35-37 ⁰C for 15 to 30 min. 
  Subsculture medium should be moved to room temperature after 30 min until use and 
stored at 2 to 8 ⁰C when not in use.  
Subculture Method 
 Attached 1321N1 cells are subcultured using 0.25 % (w/v) trypsin-0.53 mM EDTA 
 The enzymatic action of trypsin-EDTA is stopped by adding complete growth medium to 
the detached cells. 
 A split ratio of 1:2 to 1:6 or a seeding density of 2-4 x 10 000 viable cells/cm2 is used 
when Subculturing 1321N1 cells  
Viable Cells/mL/Cryovial 
 Target number of viable cells/mL/Cryovial is 2 x 106 and the acceptable range is 1.0 x 106 
cells/mL to 2.0 x 106 cells/mL 
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Cryopreservation Medium 
 Complete growth medium (DMEM + 10 % (v/v) FBS + 2 mM L-glutamine) containing 5 % 
(v/v) DMSO 
Reagents for expansion, subculturing and cryopreservation of 1321N1 cells include, complete 
growth medium made up of Dulbecco’s Minimum Essential Medium (DMEM), 10 % (v/v) Fetal 
Bovine Serum (FBS) and 2 mM L-glutamine, subculturing reagents made up of Trypsin-EDTA 
(0.25 % (w/v) Trypsin/0.53 mM EDTA) and Dulbecco’s Phosphate Buffered Saline (DPBS); 
modified without calcium chloride and without magnesium chloride, cryopreservation medium 
made up of DMEM, 10 % (v/v) FBS and 5 % (v/v) Dimethyl Sulfoxide (DMSO). 
Preparation of complete growth medium 
The complete growth medium is prepared by aseptically combining,  
3. 50 mL of 10 % FBS, 5 mL of 2 mM L-glutamine to a 500 mL bottle of basal medium DMEM.  
4. Mixing gently by swirling.  
Thawing and Propagation of Cells 
Materials 
 Complete growth medium 
 Water bath 
 T-25 cm2 polystyrene flask 
 15 mL polypropylene conical centrifuge tube 
 Plastic pipettes (1 mL, 10 mL, 25 mL) 
Thawing cells 
8. Place complete growth medium in a water bath set at 35 to 37 ⁰C. 
9. Label T-25 flask to be used with;  
a) Name of cell line 
b) Passage number  
c) Date  
d) Initials of technician 
10. Wearing a full face shield, retrieve a vial of frozen cells from the vapour phase of the 
liquid nitrogen freezer. 
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11. Thaw the vial by gentle agitation in a water bath set at 35 to 37 ⁰C. To reduce the 
possibility of contamination, keep the O-ring and cap out of the water. Thawing should 
be rapid (2-3 min) just long enough for most of the ice to melt. 
12. Remove vial from water bath and process immediately. 
13. Remove excess water from the vial by wiping with sterile gauze saturated with 70 % 
ethanol. 
14. Transfer the vial to a BSL-2 laminar-flow hood. 
Propagating cells 
Method: 
17. Add 9 mL of complete growth medium to a 15 mL conical centrifuge tube. 
18. Wipe the outer surface of the vial with sterile gauze wetted with 70 % ethanol. 
19. Using sterile gauze, carefully remove the cap from vial. 
20. With a 1 mL pipette transfer slowly the completely thawed content of the vial (1 mL cell 
suspension) to the 15 mL conical centrifuge tube containing 9 mL of complete growth 
medium. Gently re-suspend cells by pipetting up and down.  
21. Centrifuge at 125 xg at room temperature for 8 to 10 min. 
22. Carefully aspirate the medium, leaving the pellet undisturbed. 
23. Using a 10 mL pipette, add 10 mL of complete growth medium. 
24. Re-suspend pellet by gentle pipetting up and down. 
25. Using a 1 mL pipette, remove 1 mL of cell suspension for cell count and viability. Cell 
counts are performed using either an automated counter (such as Innovatis Cedex 
System; Beckman-Coulter ViCell System) or a haemocytometer.  
26. Record total cell count and viability.  
27. Plate cells in pre-labelled T-25 cm2 flask at about 4  x 104 viable cells/cm2 
28. Transfer flask to a 37 ⁰C ± 1 ⁰C in 5 % CO2 incubator if using flasks with vented caps (for 
non-vented caps stream 5 % CO2 in the headspace of flask. 
29. Observe culture daily by eye and under an inverted microscope to ensure culture is free 
of contamination and culture has not reached confluence. Monitor, visually, the pH of 
the medium daily. If the medium goes from red through orange to yellow, change the 
medium. 
30. Note: Cultures at high cell density exhaust the medium faster than those at low cell 
density as is evident from the change in pH. A drop in pH is usually accompanied by an 
increase in cell density, which is an indicator to subculture the cells. Cells may stop 
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growing when the pH is between pH 7 to pH 6 and loose viability between pH 6.5 and 
pH 6.  
31. If fluid is needed, aseptically aspire the complete growth medium from the flask and 
discard. Add an equivalent volume of fresh complete growth medium to the flask. 
Alternatively, perform a fluid addition by adding fresh complete growth medium to the 
flask without removing the existing medium. Record fluid change or fluid addition.  
32. If subculturing of cells is needed, continue to subculture when cells are 70-80 % 
confluent. 1321N1 cells may pile up and form cluster when allowed to become over 
confluent. 
Subculturing Cells 
   Reagents and Materials  
 0.25 % (w/v) Trypsin-0.53 mM EDTA 
 DPBS 
 Complete growth medium (DMEM) 
 Plastic pipettes (1, 10 and 25 mL) 
 T-75 cm2, T-225 cm2 polystyrene flasks 
Method: 
12. Aseptically remove medium from flask 
13. Add 5 mL of sterile Ca2+ -and Mg2+ - free DPBS to the side of the flask opposite the cells 
so as to avoid dislodging the cells 
14. Rinse the cells with DPBS (rocking the flask gently) and discard 
15. Add 2 mL of 0.25 (w/v) Trypsin-0.53 mM EDTA solution to the flask 
16. Incubate the flask at 37 ⁰C ± 1 ⁰C until cells round up. Observe cells under an inverted 
microscope every 5 min. When the flask is tilted, the attached cells should slide down 
the surface. This usually occurs after 5 to 10 min of incubation.  
17. Neutralise the Trypsin-EDTA/cell suspension by adding an equal volume of complete 
growth medium to the flask. Disperse the cells by pipetting, gently, over the surface of 
the monolayer. Pipette the cell suspension up and down with the tip of the pipette 
resting on the bottom corner or edge until a single cell suspension is obtained. Care 
should be taken to avoid the formation of a foam. 
18. Using a 1 mL pipette, remove 1 mL of cell suspension for a total cell count and viability. 
19. Record total cell count and viability 
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20. At this stage cells are ready to be seeded on substrates appropriate for vibrational 
spectroscopy such as CaF2 
21. Add appropriate volume of fresh complete growth medium and transfer cell suspension 
into new labelled flask/petri dish (with substrate)  at a seeding density of 2-4 x 10 000 
viable cells/ cm2 or a split ratio of 1:2 to 1:6 
 Split ratio =  
𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑜𝑟𝑖𝑔𝑖𝑛𝑎𝑙 𝑐𝑒𝑙𝑙 𝑠𝑢𝑠𝑝𝑒𝑛𝑠𝑖𝑜𝑛/𝑚𝐿
𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑟𝑒𝑞𝑢𝑖𝑟𝑒𝑑 𝑐𝑒𝑙𝑙 𝑠𝑢𝑠𝑝𝑒𝑛𝑠𝑖𝑜𝑛/𝑚𝐿
 
22. Label new flask/petri dish (with substrate) with the a) name of cell line, b) passage 
number, c) date and d) initials of technician.   
SVGP12 
The SVGP12 cell line was established by transfecting cultured human fetal glial cells from brain 
material discarded from 8 to 12 week old embryos with DNA from an origin-mutant of Simian 
vacuolating virus (SV40). Genes expressed are SV40 T protein and glial fibrillary acidic protein 
(GFAP). SV40 is a polyomavirus that is found in both monkeys and humans. SV40 virus like other 
polyomaviruses is a DNA virus with the ability to cause tumours.  The base medium for this cell 
line EMEM and subculturing conditions are similar to U87MG.   
Cell Fixation 
A number of studies looked at the effects of chemical fixation of cells in spectroscopic studies to 
avoid potential confounding variables from autolytic processes initiated by cells during air-
drying [151, 173]. Fixation is used to quench autolysis, minimising leaching of biomolecular 
constituents, whilst at the same time using optimised dehydration protocols to bypass surface 
tension distortions and preserve the structural and functional chemistry of biomolecules for 
analysis.  
Substrate sterilisation method: 
1. CaF2 slides are dipped in 70 % ethanol for 40 min 
2. Slides are wiped down with lint free tissue and dipped into new clean bath of 70 % 
ethanol for 20 min 
3. Slides are wiped down with virkon and dipped into clean bath of 70 % ethanol for 15 
min in a BSL-2 flow hood  
4. Slides are picked up using forceps and allowed to dry in the flow hood before immersing 
in appropriate medium 
5. Slides dipped in petri-dish with appropriate medium for 10 min 
6. Slides immersed in new medium and left until placed in new petri-dish where cells are 
re-seeded according to the appropriate medium  
[CCXXXIX] 
 
Cell fixation method: 
1. Cells (U87MG, 1321N1 and SVGP12) are cultured directly onto CaF2 substrates 
2. At 80 % confluence the medium is removed 
3. Cells washed with 1 x PBS twice 
4. PBS is discarded 
5. Cells are fixed with 4 % formalin 
6. Cells are incubated at room temperature for 3-5 min 
7. Formalin is removed and cells washed with dH2O three times by gently shaking the dish 
in a circular motion for 5 min  
8. Cells are air dried and stored until analysis  
Brain Tissue 
Tissue surgically removed from the brain may undergo one or two commonly used methods of 
preservation, paraffin embedding and/or cryopreservation for long-term storage [85]. The 
choice of method used is usually based on the specific purpose of the resected tissue. Once 
tissue is received in pink transport medium in the neuropathology lab a neuropathologist 
examines it and divides it into that which will be required for paraffin and frozen section 
diagnosis.  
Formalin Fixed Paraffin Preservation (FFPP) 
Formalin fixation and paraffin preservation (FFPP) has been used traditionally for the 
preservation of biopsies in many biobanks. FFPP is currently the preferred source for histological 
examination of tissue sections [85]. Tissue is immersed in an aqueous formalin solution. 
Hydrated formalin which is methylene glycol, OH-CH-OH is a coagulative protein fixative which 
cross links primary and secondary amine groups of proteins [225], but preserves some lipids by 
reacting with unsaturated double bonds of hydrocarbon chains [226]. The tissue is dehydrated 
following formalin fixation, through a series of consecutive ethanol immersion in increasing 
grades up to 100 %. The displacement of water with ethanol preserves the secondary structure 
of proteins but denatures their tertiary structure. There are a few disadvantages that have been 
seen with formalin fixation as a preservative technique. Formalin and ethanol have been shown 
to induce coagulation of the globular proteins present in the cytoplasm. This can lead to loss of 
structural integrity of organelles such as mitochondria. Ethanol also precipitates lipid molecules 
that are not preserved in the primary fixation step [85]. However, the stabilisation of 
intercellular proteins by formalin and ethanol results in the localisation of associated glycogen. 
Following dehydration the alcohol is replaced by an organic solvent, such as HistoClear or xylene 
which is miscible with both alcohol and molten paraffin wax. Molten paraffin wax is allowed to 
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submerge and permeate the tissue. The infiltration of the wax into the intracellular spaces is 
made easy by the previous ethanol dehydration step that created pores in the plasma 
membrane of the cells. The tissue sample is then cooled at room temperature which allows the 
molten wax to solidify into a block. This process provides physical support of the tissue during 
sectioning which involves cutting of thin sections of tissue for histological assessment without 
deforming the cellular structure or architecture. The tissue is processed by a machine such as a 
CITADEL 200, these tissue processors have pre-programmed specific processing schedules with 
the majority of samples being processed on a 15 hour overnight schedule. Some tissues require 
longer processing to optimise the quality of the final tissue block. Each programme has been 
verified by Cellular Pathology. 
FFPP method: 
1. Brain biopsies are immersed for 12 hrs in 10 % formalin prior processing 
2. Processing steps see Table 28 
Table 28. Histological processing of human brain tissue using formalin fixation paraffin 
preservation (FFPP) method based on the Royal Preston Teaching Hospital protocol.  
Position/Step Reagent Immersion Period  
Hrs /Mins 
Period Entered 
Hrs /Mins 
Position 1 Formalin 2:00 2:00 
Position 2 Formalin  2:00 2:00 
Position 3 Alcohol 70 % 1:00 1:00 
Position 4 Alcohol 90 % 1:00 1:00 
Position 5 Alcohol 100 % 1:00 1:00 
Position 6 Alcohol 100 % 2:00 2:00 
Position 7 Alcohol 100 % 2:00 2:00 
Position 8 Xylene 1:00 1:00 
Position 9 Xylene 1:30 1:30 
Position 10 Xylene 1:30 1:30 
Wax Bath 1 (11) Wax 2:00 2:00 
Wax Bath 2 (12) Wax 3:00 3:00 
 
[CCXLI] 
 
                                            End of Cycle 
Total processing time = 20 hrs 
Full program time = 20 hrs 12 mins, allowing one minute for every change of position 
 
3. After processing as shown in table 3, sample is then immersed in molten wax 
4. Sample is then cooled at room temperature solidifying the wax and completing the 
embedding process. 
Snap-Freezing 
Snap-freezing of tissue is a generally preferred method of preservation in molecular based 
studies [85]. The technique does not require the use of organic solvents that cause degradation 
or loss of cellular components as previously discussed in formalin fixation. Frozen section of 
tissue are used to study enzymes and soluble lipids. The method is also used to conduct 
immunohistochemistry analysis since some antigens may be affected by extensive cross-linking 
chemical fixatives that denature their tertiary structure. During snap-freezing, water contained 
with the cells acts as the supporting medium. The process of snap-freezing of tissue is done in 
liquid nitrogen cooled isopentane (-170 ⁰C) to promote vitreous ice formation and to prevent 
ice crystal damage. Ice crystals can produce holes in the tissue and destroy cellular morphology 
and tissue architecture. The hardened tissue can then be embedded in mounting medium such 
optimal cutting temperature compound (OCT) for sectioning within a cryostat maintained at -17 
⁰C and then subsequently stained [85]. OCT is a viscous solution at room temperature which 
consists of a resin-polyvinyl alcohol, an antifungal agent, benzalkonium chloride and 
polyethylene glycol to lower the freezing temperature [101, 227]. Whilst this is an ideal method 
studies showed that snap-freezing can damage DNA fragments of greater than 300 bp but does 
not affect RNA [101].   
Snap-freezing method: 
Materials 
 Fresh tissue 
 1.5 mL conical microcentrifuge tubes 
 CoolRack M15.PF or M30-PF or CoolBox 30 system 
 Cryolabels or cryomarker 
 Crushed ice 
 Liquid nitrogen or dry ice 
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Snap freezing (liquid nitrogen) 
CoolRack Set-up Procedure 
1. Place 15 well CoolRack M15.PF directly in the CoolBox and fill with liquid nitrogen. The 
liquid nitrogen (LN2) level should be kept halfway up the side of the CoolRack module 
(approximately 2 cm) to maintain cryogenic temperature.  
2. CoolRack will cool to snap freezing temperature of -150 ⁰C in about 12 minutes, although 
to preserve LN2 and reduce time it takes to reach snap freezing temperature, the 
CoolRack may be pre-chilled in a refrigerator or freezer. 
3. With clean forceps, place the specimen to be frozen into empty tube, and then place 
tube in the CoolRack. 
4. The sample will quickly snap freeze and may be left in place while other samples are 
processed. 
5. If using the CoolBox, pour off the remaining LN2 fully seat the lid on the CoolBox and put 
the CoolBox into a -80 ⁰C freezer or dry ice. 
6. If storing samples in liquid nitrogen, it is recommended that the samples be placed in 
the vapour phase of liquid nitrogen to prevent possible LN2 aspiration into the tube and 
a possible explosion when the tube is returned to room temperature.  
7. All specimen should be recorded appropriately with Cryolabels or cryomarker 
 
Histology 
Histology is the study of minute structure of the tissue, which also includes cytology. The 
pathology of tissue is often investigated after histological processing in which sections of the 
tissue are cut at 3-4 µM, stained and assessed through a microscope. Histopathology, the 
microscopic diagnosis of stained tissue is the current gold standard which involves the 
assessment of tissue morphology. The technique has been shown to be subjective with 
differences in diagnostic results of similar samples to occur in as many as 43 % of specimens 
[111]. Vibrational spectroscopic analysis of tissue and cells has become known as spectral 
histopathology and cytopathology respectively. Tissue sections for this type of analysis are cut 
at 10 µM.  
Tissue Sectioning 
Tissue sections are cut using a microtome which poses a risk of laceration to fingers and hands.  
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Tissue sectioning on MirrIR slide methods: 
1. Place knife in holder on the microtome and check that the dial on the front of the 
microtome is set at 3 or 4 µM (histopathology) and 10 µM (spectral histopathology). 
2. Place cooled tissue block in the chuck, with the specimen facing the blade and the 
number facing towards the person cutting the section for small and medium blocks. The 
number should be facing upwards for large blocks. 
3. Advance the block slowly up to the blade, by using the front (course adjuster) handle. 
Once the block is touching the blade start to cut using the side handle. Turn the handle 
clockwise continuously with the right hand whilst lifting the sections from the blade with 
the forceps in the left hand. The sections must be lifted away horizontally from the 
blade. 
4. Once a ribbon of sections has been obtained, stop cutting and lock the side of the 
microtome. 
5. Place the sections on a preheated water bath (45 - 50 o c) to float out, allowing creases 
and bubbles to be removed. If the sections are creased, recut until a smooth section is 
obtained (sometimes the sections may require floating out on a glass slide coated in 
30% alcohol). Once the sections are floating drain the alcohol off and place the slide 
carefully in the water bath to allow the sections to float off onto the water). 
6. Once a section has been selected write the number of the block and the cutters initials 
on a glass slide. 
7. Slowly place the MirrIR slide in the water bath and guide the chosen section onto the 
slide surface with the forceps. 
8. Bring the slide out of the bath, tilting it slightly forwards to allow the section to adhere 
and water to drain off. 
9. Place the slide in a rack, and remove the block from the chuck. 
10. Wipe the surface of the water bath clean with a tissue. 
Microtome Maintenance and blade removal 
1. Remove the knife from the knife holder by loosening the lever at the side of the knife 
holder 
2. Remove the blade from the holder by sliding it along with a pair of forceps.  Never touch 
the cutting edge of the blade with fingers.  Discard the blade into the slot under the 
plastic blade dispenser or into a sharps-bin.  Do not put blades in the waste bin. 
3. Before inserting a new blade, wipe wax from the knife using a paper tissue or brush. 
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4. Take a new blade from the dispenser.   
5. Carefully slide the blade into the knife.  Make sure that the blade is fitted straight before 
tightening the lever again.   
6. The microtome should be serviced annually 
7. The microtome should be cleaned between each block to avoid contamination and 
crossover of material from one case to another with a soft brush to remove all waste 
wax, brushing away from the knife. The brake always be in the locked position. 
8. The microtome should be cleaned at the end of each session with the blade guard and 
brake in the locked position 
Dewaxing 
Tissue sections generally undergo a dewaxing process to allow histological staining for 
pathological examination. This process also reduces paraffin contributions in vibrational spectra, 
consequently returning the tissue to as much of an in vitro state as possible [85]. Studies by Ó 
Faolain et al. on the efficacy of dewaxing procedures on FFPP tissue on glass slides showed that 
some organic solvents such as xylene and HistoClear do not completely remove all of the paraffin 
wax [85]. This study shows that complete removal of paraffin residue on slides is possible with 
some adjustments to the dewaxing protocol by using xylene and increasing the bath times from 
5 min to 10 min. All steps are carried out in fume hood with control slides. 
Dewaxing slides for spectroscopy method: 
1. Xylene x 2 (10 min baths)  
2. Absolute ethanol 100 % (5 min baths) 
3. Ethanol 95 % (5 min baths) 
4. Ethanol 70 % (5 min baths) 
5. Tap water wash (2 min) 
6. Allow to dry before spectral acquisition. 
Dewaxing slides for Haematoxylin and Eosin (H and E) method: 
1. Absolute ethanol 100 % (5 min baths) 
2. Ethanol 95 % (5 min baths) 
3. Ethanol 70 % (5 min baths) 
4. Water wash 
5. Harris’ Haematoxylin (5 min) 
6. Running tap water (20 secs) 
7. Acid alcohol 0.3 % (2 min) 
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8. Tap water (2 min) or until tissue section turns blue 
9. Eosin ( 2 min) 
10. Tap water (20 secs) running tap water in a sink  
11. Dehydrate, clear and mount 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix H (Raman Classic Theory 
Electrodynamics) 
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 Raman Classic Theory of Electrodynamics 
Raman 
The theory of Raman scattering can be explained through the classical electrodynamic argument 
based on the vibrational modulation of the molecular polarizability. An induced molecular dipole 
moment is generated when light interacts with a molecule. This interaction of the molecule with 
light produces a dipole moment that generates an oscillating dipole moment which emits 
radiation or light scattering. The basis of this induced dipole moment is the polarizability, as a 
function of the nuclear coordinates or the vibrations of the molecule. The effect of the 
polarizability ellipsoid and their association with the chemical bonds can be shown 
mathematically and can help us understand how certain vibrational modes can be Raman active 
or inactive. 
𝐸𝑙𝑒𝑐𝑡𝑟𝑖𝑐 𝑑𝑖𝑝𝑜𝑙𝑒 𝑚𝑜𝑚𝑒𝑛𝑡 𝑜𝑓 𝑎 𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑒 𝑖𝑛𝑑𝑢𝑐𝑒𝑑 𝑏𝑦 𝑙𝑖𝑔ℎ𝑡:  
?⃗?   =  ?̃??⃗?    (15) 
Where ?⃗?  is the induced dipole moment which is the product of ?̃? the polarizability tensor and 
?⃗?  the incident electric field.  Molecular polarizability refers to the ease with which the electron 
density distribution can be distorted by an electric field. The induced dipole moment and the 
electric field are both vectors whilst ?̃? the polarizability is a tensor.  
The induced dipole moment is a vector with the XYZ axis and the electric field with its XYZ axis 
as well as alpha the tensor which is a three by three tensor can be represented as shown in (16).  
   𝑃𝑥
   𝑃𝑦
   𝑃𝑧
= {
𝜶𝒙𝒙
𝜶𝒚𝒙
𝜶𝒛𝒙
  𝛼𝑥𝑦  
𝛼𝑦𝑦
𝛼𝑧𝑦
𝜶𝒙𝒛
 𝜶𝒚𝒚
𝜶𝒛𝒛
{
𝐸𝑥
𝐸𝑦
𝐸𝑧
  (16) 
In classical electrodynamics an oscillating electrical field induces an oscillating dipole moment. 
Equation (13) shows that the incident electric field is an oscillating electric field at a frequency 
nu at that incident light. This is with reference to visible light, UV, near infrared etc. Incident 
radiation is at a much higher energy and much higher frequency of the vibrational motions of 
the molecule. If we now incorporate this varying electric field to the dipole moment we come 
up with equation (18). 
𝐸 = 𝐸ₒ𝐶𝑜𝑠(2𝜋𝑣𝑡)   (17) 
𝑃 =  𝛼𝐸ₒ𝐶𝑜𝑠(2𝜋𝑣𝑡)  (18) 
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When monochromatic light, such as a laser continuously interacts with a molecule it is 
continually inducing a dipole moment at a frequency of that incident radiation. This causes the 
oscillating dipole moment to emit radiation as shown in Figure 138. The scattering occurs in 
different directions, such as back scattering ~180° and right angle scattering 90°.  
 
Figure 138. Schematic diagram showing the interaction of laser light with a molecule and the 
induction of a dipole moment at a frequency of that incident light causing light to scatter as 
shown ~180 ℃ (back scattering) or 90 ℃ (right angle scattering) 
The polarizability of the molecule including vibrational displacements can be described as a 
Taylor expansion that includes the static polarizability as shown in (14) in addition to a 
component taking into account small vibrational displacements. This would be the derivative of 
polarizability with respect to Q shown in (15) for a molecule not in motion. 
 
So the derivative of 𝛼 by Q is going to vary sinusoidal by a frequency associated by that vibration 
shown by (16).    
𝑄 = 𝑄ₒcos (2𝜋𝑣𝑣𝑖𝑏𝑡)    (20) 
Here 𝑄ₒ is the maximum value of Q. So when this is put together our Taylor expansion becomes 
(21) limited to static linear polarizability and the vibrational modulation. 
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𝛼 =  𝛼ₒ +
𝜕𝛼
𝜕𝑄
𝑄ₒcos (2𝜋𝑣𝑣𝑖𝑏𝑡)  (21) 
Incorporating the polarizability from the static and the vibrational components to the original 
expression (15) of the induced dipole moment results in (22).  
𝑃 = 𝛼ₒ𝐸ₒ cos(2𝜋𝑣𝑡) +
𝜕𝛼
𝜕𝑄
𝑄ₒ𝐸ₒ(cos(2𝜋𝑣𝑡))(cos(2𝜋𝑣𝑣𝑖𝑏𝑡))  (22) 
The expression (22) shows the scattering that will occur at the frequency of the incident 
radiation at a given time and incident radiation frequency with vibrational radiation frequency 
of the molecule and vibrational modulation of the polarizability. If we use a trigonometric 
identity which is the cosine of an angle by the second angle is equal to half the cosine of the first 
angle subtract the second angle plus the cosine of the first angle plus the second angle shown 
by the expression (19).  
𝑐𝑜𝑠𝐴 × 𝑐𝑜𝑠𝐵 =
1
2
{cos(𝐴 − 𝐵) + cos (𝐴 + 𝐵)}  (23) 
Expression (23) can now be applied to (22) to the two cosines shown by (24) which is an 
expression of light scattering from oscillating molecular dipole moment. 
Polarizability tensor is symmetric and can be transformed to new coordinate system of  
𝑋′, 𝑌′𝑎𝑛𝑑 𝑍′ such that only the diagonal elements 𝛼𝑥′𝑥′, 𝛼𝑦′𝑦′ 𝑎𝑛𝑑 𝛼𝑧′𝑧′ are nonzero. The 
polarizability ellipsoid can be graphically represented in this new coordinate system.  
 
The conventional mathematical description of the Raman polarizability ellipsoid is given as 
follows; 
𝑋′2
[
1
√𝛼𝑥′𝑥′
]
2 +
𝑌′2
[
1
√𝛼𝑦′𝑦′
]
2 +
𝑍′2
[
1
√𝛼𝑧′𝑧′
]
2 (25) 
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Since X2 +Y2+Z2 are not equal to 1 we do not get a sphere but instead an ellipsoid. The three 
components (denominators) in (25) constitute the length of the polarizability ellipsoid semi axes. 
They are the reciprocal values of the polarizability.  
 
Figure 139. Schematic of the generic shape of an ellipsoid shown in expression (25). The larger 
the value of α, the smaller the length of the polarizability axis. The polarizability along X and Y 
are greater than Z axis. This is based on their length because the reciprocal values are shorter. 
The effect of polarizability can be shown in the polarizability ellipsoids of small molecule 
vibrations.  
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Figure 140. Schematic of the polarizability ellipsoid of small molecules based on different 
vibrational modes. 
In an Isotropic molecule the scattered radiation of the induced dipole moment is similar to the 
incident radiation. This is different for an anisotropic molecule because when light is scattered 
it can have cross polarization components as seen in Figure 141. The polarization of the induced 
dipole moment need not be parallel to that of the incident radiation for anisotropic molecules. 
 
Figure 141. Schematic diagram of polarization of induced dipole moment light scattering of 
isotropic molecule and anisotropic molecule. 
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Figure 142. Schematic diagram showing the polarizability ellipsoid of H2O vibrational modes 
and Raman activity. 
 
Changes to the size, shape and orientation of the polarizability ellipsoid contribute to whether 
or not a molecule is going to be Raman active. The strength of the Raman scattering dependence 
on the magnitude of Raman polarizability tensor. This largely depends on the collection 
polarizability which is the orientation in which the light is being collected. If α is low the Raman 
active mode will yield a weak or strong signal depending upon the magnitude of the nonzero 
Raman tensor element.  
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Appendix I (Raman Tentative 
Assignment of Vibrational Models) 
 
Raman Tentative Assignment of vibrational modes 
Table 29. Tentative assignment of the major vibrational modes of Raman spectroscopy based on [140] for Model A 
and C based on principal component loadings. 
Direction 
 
Model Wavenumber 
cm-1 
Proposed bimolecular assignment 
 
 
PCA 1 loadings   
+ve A 904 Stretching (C-C) protein backbone α 
(proline/glycogen), collagen 
+ve A 938 Stretching (C-C) protein backbone α 
(proline/glycogen), collagen 
+ve A 999 Glucose-1-phosphate and 
symmetric ring breathing mode of 
phenylalanine 
+ve A 1043 Protein 
+ve A 1130 Stretching (C-C) of lipids from trans-
segments and stretching (C-N) of 
proteins  
+ve A 1448 Protein and Lipids (CH2 
deformations) 
+ve A 1461 Protein and Lipids 
+ve A 1554 Protein and Lipids 
+ve A 1604 Protein and Lipids 
-ve A 996 Nucleic acids 
-ve A 1167 Bending (C-H) tyrosine 
-ve A 1200 Amide III 
-ve A 1223 Amide III 
-ve A 1240 Amide III 
-ve A 1328 Lipids 
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-ve A 1364 Lipids 
-ve A 1448 C-H deformations 
-ve A 1461 C-H deformations 
-ve A 1480 Nuclei Acids 
-ve A 1554 Nuclei Acids 
-ve A 1569 Nuclei Acids 
-ve A 1604 Phe, Tyr 
-ve A 1642 Amide I 
PCA 2 loadings  
-ve A 996 Nucleic Acids 
-ve A 1043 Protein 
-ve A 1120 Nucleic Acids 
-ve A 1200 Nucleic acids and proteins 
-ve A 1328 Lipids 
-ve A 1367 Lipids 
-ve A 1554 Nuclei Acids 
-ve A 1651 Phe,Tyr 
-ve A 965 Nucleic Acids 
-ve A 1345 Lipids 
-ve A 1451 Lipids and proteins 
-ve A 1515 Lipids and proteins 
-ve A 1607 Phe,Tyr 
-ve A 1628 Phe,Tyr 
-ve A 1698 Amide I 
-ve A 1736 Lipids and proteins 
 
PCA 1 Loadings 
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+ve C 985 Glucose-1-phosphate and 
symmetric ring breathing mode of 
phenylalanine 
+ve C 1020 Phe 
+ve C 1328 Lipids 
+ve C 1361 Lipids 
+ve C 1480 Protein and Lipids 
+ve C 1569 Protein and Lipids 
+ve C 1645 Protein and Lipids 
-ve C 975 Nucleic Acids 
-ve C 1006 Phe 
-ve C 1043 Phe 
-ve C 1345 Lipids 
-ve C 1461 Lipids and proteins 
-ve C 1554 Nuclei Acids 
 
PCA 2 Loadings 
 
 
+ve C 928 Stretching (C-C) protein backbone α 
(proline/glycogen), collagen 
+ve C 996 Phospholipids, glucose-1-phosphate 
+ve C 1480 Protein and Lipids 
+ve C 1550 Protein and Lipids 
+ve C 1601 Protein and Lipids 
+ve C 1645 Amide I , both α-helix and β sheet 
structure 
-ve C 1538 Nucleic Acids 
-ve C 1585 Nuclei Acids 
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Appendix J (IR Tentative Assignment 
of vibrational modes) 
 
Table 30. Major spectral peaks used to discriminate the cell lines and proposed biomolecular assignments for model 
C loadings 1 and 3 (Spectral assignments taken from [101].  
Direction Wavenumber (cm-1) Proposed biomolecular assignment 
 
 
+ve 1030 Nucleic acids and polysaccharides 
+ve 1085 DNA symmetric PO2- vibrations of phosphodiester 
group 
+ve 1092 Nucleic acids and polysaccharides 
+ve 1123 Nucleic acids and polysaccharides 
+ve 1239 Asymetric PO2- vibrations of phosphodiester group 
+ve 1398 Lipid and proteins 
+ve 1601 Proteins (C=O stretching vibrations) 
+ve 1628 Proteins (C=O stretching vibrations) 
+ve 1638 Proteins (C=O stretching vibrations) 
+ve 1656 Amide 1 (C=O stretching vibrations) 
+ve 1682 Proteins (C=O stretching vibrations) 
+ve 1696 Proteins (C=O stretching vibrations) 
+ve 1713 Lipid esters (C=O stretching vibrations) 
+ve 1724 Lipid esters (C=O stretching vibrations) 
-ve 1008 Nucleic Acids and Polysaccharides 
-ve 1022 Nucleic Acids and Polysaccharides 
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-ve 1031 Nucleic Acids and Polysaccharides 
-ve 1088 Nucleic Acids and Polysaccharides 
-ve 1452 Lipids and proteins 
-ve 1468 Lipids and proteins 
-ve 1478 Lipids and proteins 
-ve 1502 Proteins (C=O stretching vibrations) 
-ve 1513 Proteins (C=O stretching vibrations) 
-ve 1611 Proteins (C=O stretching vibrations) 
-ve 1628 Proteins (C=O stretching vibrations) 
-ve 1640 Proteins (C=O stretching vibrations) 
-ve 1658 Proteins (C=O stretching vibrations) 
-ve 1710 Lipid esters 
-ve 1721 Lipid esters 
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